Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer

ABSTRACT

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof: formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

BACKGROUND OF THE INVENTION

Cancer is one of the most significant health conditions facing individuals in both developed and developing countries. It has been reported that in the United States alone, one in three people will be afflicted with cancer during their lifetime. Moreover, typically more than half of patients diagnosed with cancer eventually die as a result of the disease. Although significant progress has been made in the early detection and treatment of certain cancers, other cancers have been more difficult to detect and/or treat.

Furthermore, genetic alterations of cancer cells often affect genes that are important for cell cycle control, proliferation, differentiation and/or signal transduction. Oncogenic activation of MAPK pathway is a signature feature of many human cancers, including melanoma and non-small cell lung cancer (NSCLC). Activated oncogenes can be pharmacologically inhibited using small molecules or antibodies. However, the clinical anti-tumor effect of receptor tyrosine kinase (RTK) inhibitors and other kinase inhibitors is not durable. Resistance to these inhibitors usually develops. More specifically the clinical anti-tumor effect of EGFR inhibitors (EGFRi) is not durable. Resistance to EGFR inhibitors usually develops within 9 to 19 months depending on the therapeutic agent and clinical setting. Therefore it is desirable to develop a mode of cancer treatment that would prevent drug resistance in cancer patients.

Phenotypic, signalling, transcriptional, and metabolic plasticity as well as the acquisition of novel genetic alterations have been found to be a driving factor in the development of resistance to cancer treatment including molecularly targeted inhibitors and immunotherapies. There is a need to avoid development of resistance to treatment.

Thus, an objective of the present invention is to provide novel compounds which are able to treat cancer or to prevent the development of resistance. Furthermore, it is an objective of the present invention to provide improved treatment options for cancer patients using the compounds of the invention alone or in combination therapy.

BRIEF SUMMARY OF THE INVENTION

The present inventors have surprisingly found that compounds of the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, have activity against cancer.

Thus, in a first aspect, the present invention provides a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

-   -   wherein     -   R¹ is selected from halogen and -(optionally substituted         hydrocarbon group which contains from 1 to 20 carbon atoms and         optionally 1 to 15 heteroatoms selected from O, N and S);     -   R²¹ is selected from hydrogen, -(optionally substituted C₁₋₆         alkyl) which may contain one to three oxygen atoms between         carbon atoms, and -(optionally substituted C₃₋₆ cycloalkyl);     -   R³ is selected from -(optionally substituted heterocyclyl),         -(optionally substituted carbocyclyl), -(optionally substituted         C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and         -(optionally substituted C₁₋₆ alkylene)-(optionally substituted         carbocyclyl);

each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH;

-   -   R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —(C₁₋₆-alkyl         substituted with one or more F); wherein R³ and any R³¹ can be         optionally linked; and     -   E is either absent or is selected from —CH₂—, —CHR^(x)—, —CR^(x)         ₂—, —NH—, —NR^(x)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is         selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and         —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—;     -   R^(6x) is -halogen, —OH, ═O, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆         alkyl substituted with one or more OH, monocyclic aryl         optionally substituted with one or more R^(xb), monocyclic         heteroaryl optionally substituted with one or more R^(xb),         monocyclic cycloalkyl optionally substituted with one or more         R^(xb), monocyclic heterocycloalkyl optionally substituted with         one or more R^(xb), monocyclic cycloalkenyl optionally         substituted with one or more R^(xb), monocyclic         heterocycloalkenyl optionally substituted with one or more         R^(xb), wherein said R^(xb) is independently selected from         -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl         substituted with one or two OH;

wherein Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups at ring A can be optionally linked and/or any R^(x) group at ring A can be optionally linked with R²¹; and/or wherein Ring A may be further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein Ring B is an -(optionally substituted heterocycle) or -(optionally substituted carbocycle); each R^(x) is independently selected from -halogen, —OH, —O-(optionally substituted C₁₋₆ alkyl), —NH-(optionally substituted C₁₋₆ alkyl), —N(optionally substituted C₁₋₆ alkyl)₂, ═O, -(optionally substituted C₁₋₆ alkyl), -(optionally substituted carbocyclyl), -(optionally substituted heterocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), and —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), and

wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C₁₋₆ cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C₁₋₆ alkylene is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and wherein the optional substituent of the optionally substituted C₁₋₆ alkyl and of the optionally substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked.

The type of cancer that can be treated with the compounds and compositions of the present invention is not specifically limited and can be selected from non-melanoma skin cancer, esophagogastric adenocarcinoma, glioblastoma, bladder cancer, bladder urothelial carcinoma, esophagogastric cancer, melanoma, non-small cell lung cancer, endometrial cancer, cervical adenocarcinoma, esophageal squamous cell carcinoma, breast cancer, head and neck squamous cell carcinoma, germ cell tumor, small cell lung cancer, ovarian cancer, soft tissue sarcoma, hepatocellular carcinoma, colorectal adenocarcinoma, cervical squamous cell carcinoma, cholangiocarcinoma, prostate cancer, upper tract urothelial carcinoma, diffuse glioma, colorectal cancer, ampullary carcinoma, adrenocortical carcinoma, head and neck cancer, renal clear cell carcinoma, hepatobiliary cancer, glioma, non-Hodgkin lymphoma, mesothelioma, salivary gland cancer, renal non-clear cell carcinoma, miscellaneous neuroepithelial tumor, pheochromocytoma, thymic tumor, multiple myeloma, renal cell carcinoma, bone cancer, pancreatic cancer, leukemia, peripheral nervous system tumors, thyroid cancer, B-lymphoblast leukemia, monoclonal B-cell lymphocytosis, lymphoma, hairy cell leukemia, acute myeloid leukemia, Wilms tumor, in particular multiple myeloma, acute myeloid leukemia, melanoma and non-small cell lung cancer.

Further aspects and embodiments of the present invention will be become apparent as this description continues.

DESCRIPTION OF FIGURES

FIG. 1 . The initial Fo-Fc difference electron density map of the model (contoured at 4.0 σ) resulting from refinement of the initial model prior to modelling of the compound with REFMAC5, in the determination of the crystal structure of the bromodomain of human CREBBP in complex with compound 00004.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. The herein described and disclosed embodiments, preferred embodiments and very preferred embodiments should apply to all aspects and other embodiments, preferred embodiments and very preferred embodiments irrespective of whether is specifically again referred to or its repetition is avoided for the sake of conciseness.

The articles “a” and “an”, as used herein, refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. The term “or”, as used herein, should be understood to mean “and/or”, unless the context clearly indicates otherwise.

The term “preferably” is used to describe features or embodiments which are not required in the present invention but may lead to improved technical effects and are thus desirable but not essential.

The term “linked” in the expression “optionally linked” as used herein refers to a linked group which is obtained from two substituents by theoretically abstracting one hydrogen radical from each substituent and forming a single bond between the two radicals thus formed in the two substituents. This may be illustrated as follows:

Although this explanation uses two aryl groups as an illustration, the meaning of the term “linked” is obviously not limited to such groups.

The term “hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S” refers to any group having 1 to 20 carbon atoms and optionally 1 to 15 (preferably 1 to 10, more preferably 1 to 8) heteroatoms selected from O, N and S which preferably contains at least one ring. The “hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S” is not limited in any way, provided that it is a group containing 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S. E.g., if the hydrocarbon group is an aliphatic group, it may include one or more of the heteroatoms in the main chain or in one or more side chains. The term is also meant to include bicyclic, tricyclic and polycyclic versions thereof. If more than one ring is present, they can be separate from each other or be annelated. Examples of bicyclic hydrocarbon groups include fused bicyclic hydrocarbon groups such as naphthalene as well as linked hydrocarbon groups such as biphenyl, bridged bicyclic hydrocarbon groups such as 1,4-diazabicyclo[2.2.2]octane and spiro-type hydrogen groups. The ring(s) can be either carbocyclic or heterocyclic and can be saturated, unsaturated or aromatic. The carbon atoms and heteroatoms can either all be present in the one or more rings or some of the carbon atoms and/or heteroatoms can be present outside of the ring, e.g., in a linker group (such as —(CH₂)_(p)— with p=1 to 6). Examples of these groups include -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

As used herein, the term “-(optionally substituted C₁₋₆ alkyl) which may contain one to three oxygen atoms between carbon atoms” preferably refers to a group in which one or more direct C—C bonds in the C₁₋₆ alkyl group are replaced by a C—O—C moiety. Examples thereof are —CH₂—CH₂—O—CH₃, —CH₂—CH₂—O—CH₂—CH₃, —CH₂—CH₂—O—CH₂—CH₂—O—CH₃ and —CH₂—CH₂—O—CH₂—CH₂—O—CH₂—CH₃.

As used herein, the term “alkyl” refers to a monovalent saturated acyclic (i.e., non-cyclic) hydrocarbon group which may be linear or branched. Accordingly, an “alkyl” group does not comprise any carbon-to-carbon double bond or any carbon-to-carbon triple bond. A “C₁₋₆ alkyl” denotes an alkyl group having 1 to 6 carbon atoms. Preferred exemplary alkyl groups are methyl, ethyl, propyl (e.g., n-propyl or isopropyl), or butyl (e.g., n-butyl, isobutyl, sec-butyl, or tert-butyl). Unless defined otherwise, the term “alkyl” preferably refers to C₁₋₄ alkyl, more preferably to methyl or ethyl, and even more preferably to methyl.

As used herein, the term “alkylene” refers to an alkanediyl group, i.e. a divalent saturated acyclic hydrocarbon group which may be linear or branched. A “C₁₋₆ alkylene” denotes an alkylene group having 1 to 6 carbon atoms, and the term “C₀₋₃ alkylene” indicates that a covalent bond (corresponding to the option “C₀ alkylene”) or a C₁₋₃ alkylene is present. Preferred exemplary alkylene groups are methylene (—CH₂—), ethylene (e.g., —CH₂—CH₂— or —CH(—CH₃)—), propylene (e.g., —CH₂—CH₂—CH₂—, —CH(—CH₂—CH₃)—, —CH₂—CH(—CH₃)—, or —CH(—CH₃)—CH₂—), or butylene (e.g., —CH₂—CH₂—CH₂—CH₂—). Unless defined otherwise, the term “alkylene” preferably refers to C₁₋₄ alkylene (including, in particular, linear C₁₋₄ alkylene), more preferably to methylene or ethylene, and even more preferably to methylene.

As used herein, the term “carbocyclyl” refers to a hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings), wherein said ring group may be saturated, partially unsaturated (i.e., unsaturated but not aromatic) or aromatic. Unless defined otherwise, “carbocyclyl” preferably refers to aryl, cycloalkyl or cycloalkenyl. The number of carbon atoms in the carbocyclyl group is not particularly limited and is preferably 3 to 14, more preferably 3 to 7.

As used herein, the term “heterocyclyl” refers to a ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings), wherein said ring group comprises one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group), and further wherein said ring group may be saturated, partially unsaturated (i.e., unsaturated but not aromatic) or aromatic. Unless defined otherwise, “heterocyclyl” preferably refers to heteroaryl, heterocycloalkyl or heterocycloalkenyl. The number of carbon atoms in the carbocyclyl group is not particularly limited and is preferably 5 to 14, preferably 5 to 10.

As used herein, the term “aryl” refers to an aromatic hydrocarbon ring group, including monocyclic aromatic rings as well as bridged ring and/or fused ring systems containing at least one aromatic ring (e.g., ring systems composed of two or three fused rings, wherein at least one of these fused rings is aromatic; or bridged ring systems composed of two or three rings, wherein at least one of these bridged rings is aromatic). “Aryl” may, e.g., refer to phenyl, naphthyl, dialinyl (i.e., 1,2-dihydronaphthyl), tetralinyl (i.e., 1,2,3,4-tetrahydronaphthyl), anthracenyl, or phenanthrenyl. Unless defined otherwise, an “aryl” preferably has 5 to 14 ring atoms, more preferably 5 to 10 ring atoms, and most preferably refers to phenyl.

As used herein, the term “heteroaryl” refers to an aromatic ring group, including monocyclic aromatic rings as well as bridged ring and/or fused ring systems containing at least one aromatic ring (e.g., ring systems composed of two or three fused rings, wherein at least one of these fused rings is aromatic; or bridged ring systems composed of two or three rings, wherein at least one of these bridged rings is aromatic), wherein said aromatic ring group comprises one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, and further wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group). “Heteroaryl” may, e.g., refer to thienyl (i.e., thiophenyl), benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl (i.e., furanyl), benzofuranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl, pyrrolyl (e.g., 2H-pyrrolyl), imidazolyl, pyrazolyl, pyridyl (i.e., pyridinyl; e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl (e.g., 3H-indolyl), indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl (e.g., [1,10]phenanthrolinyl, [1,7]phenanthrolinyl, or [4,7]phenanthrolinyl), phenazinyl, thiazolyl, isothiazolyl, phenothiazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, isothiadiazolyl, isoxazolyl, furazanyl, phenoxazinyl, pyrazolo[1,5-a]pyrimidinyl (e.g., pyrazolo[1,5-a]pyrimidin-3-yl), 1,2-benzoisoxazol-3-yl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, 1H-tetrazolyl, 2H-tetrazolyl, coumarinyl, or chromonyl. Unless defined otherwise, a “heteroaryl” preferably refers to a 5 to 14 membered (more preferably 5 to 10 membered) monocyclic ring or fused ring system comprising one or more (e.g., one, two, three or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; even more preferably, a “heteroaryl” refers to a 5 or 6 membered monocyclic ring comprising one or more (e.g., one, two or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.

As used herein, the term “cycloalkyl” refers to a saturated hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings). “Cycloalkyl” may, e.g., refer to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl. Unless defined otherwise, “cycloalkyl” preferably refers to a C₃₋₁₄ cycloalkyl, and more preferably refers to a C₃₋₇ cycloalkyl. A particularly preferred “cycloalkyl” is a monocyclic saturated hydrocarbon ring having 3 to 7 ring members.

As used herein, the term “heterocycloalkyl” refers to a saturated ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said ring group contains one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, and the remaining ring atoms are carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, and further wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group). “Heterocycloalkyl” may, e.g., refer to oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, morpholinyl (e.g., morpholin-4-yl), pyrazolidinyl, tetrahydrothienyl, octahydroquinolinyl, octahydroisoquinolinyl, oxazolidinyl, isoxazolidinyl, azepanyl, diazepanyl, oxazepanyl or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl. Unless defined otherwise, “heterocycloalkyl” preferably refers to a 3 to 14 membered saturated ring group, which is a monocyclic ring or a fused ring system (e.g., a fused ring system composed of two fused rings), wherein said ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized; more preferably, “heterocycloalkyl” refers to a 5 to 7 membered saturated monocyclic ring group containing one or more (e.g., one, two, or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, and wherein one or more carbon ring atoms are optionally oxidized.

As used herein, the term “cycloalkenyl” refers to an unsaturated alicyclic (non-aromatic) hydrocarbon ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said hydrocarbon ring group comprises one or more (e.g., one or two) carbon-to-carbon double bonds and does not comprise any carbon-to-carbon triple bond. “Cycloalkenyl” may, e.g., refer to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, or cycloheptadienyl. Unless defined otherwise, “cycloalkenyl” preferably refers to a C₃₋₁₄ cycloalkenyl, and more preferably refers to a C₃₋₇ cycloalkenyl. A particularly preferred “cycloalkenyl” is a monocyclic unsaturated alicyclic hydrocarbon ring having 3 to 7 ring members and containing one or more (e.g., one or two; preferably one) carbon-to-carbon double bonds.

As used herein, the term “heterocycloalkenyl” refers to an unsaturated alicyclic (non-aromatic) ring group, including monocyclic rings as well as bridged ring, spiro ring and/or fused ring systems (which may be composed, e.g., of two or three rings; such as, e.g., a fused ring system composed of two or three fused rings), wherein said ring group contains one or more (such as, e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, and the remaining ring atoms and carbon atoms, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) may optionally be oxidized, wherein one or more carbon ring atoms may optionally be oxidized (i.e., to form an oxo group), and further wherein said ring group comprises at least one double bond between adjacent ring atoms and does not comprise any triple bond between adjacent ring atoms. “Heterocycloalkenyl” may, e.g., refer to 1,2,3,6-tetrahydropyridinyl. Unless defined otherwise, “heterocycloalkenyl” preferably refers to a 3 to 14 membered unsaturated alicyclic ring group, which is a monocyclic ring or a fused ring system (e.g., a fused ring system composed of two fused rings), wherein said ring group contains one or more (e.g., one, two, three, or four) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein said ring group comprises at least one double bond between adjacent ring atoms and does not comprise any triple bond between adjacent ring atoms; more preferably, “heterocycloalkenyl” refers to a 5 to 7 membered monocyclic unsaturated non-aromatic ring group containing one or more (e.g., one, two, or three) ring heteroatoms independently selected from O, S and N, wherein one or more S ring atoms (if present) and/or one or more N ring atoms (if present) are optionally oxidized, wherein one or more carbon ring atoms are optionally oxidized, and wherein said ring group comprises at least one double bond between adjacent ring atoms and does not comprise any triple bond between adjacent ring atoms.

As used herein, the term “halogen” refers to fluoro (—F), chloro (—Cl), bromo (—Br), or iodo (−).

As used herein, the term “haloalkyl” refers to an alkyl group substituted with one or more (preferably 1 to 6, more preferably 1 to 3) halogen atoms which are selected independently from fluoro, chloro, bromo and iodo, and are preferably all fluoro atoms. It will be understood that the maximum number of halogen atoms is limited by the number of available attachment sites and, thus, depends on the number of carbon atoms comprised in the alkyl moiety of the haloalkyl group. “Haloalkyl” may, e.g., refer to —CF₃, —CHF₂, —CH₂F, —CF₂—CH₃, —CH₂—CF₃, —CH₂—CHF₂, —CH₂—CF₂—CH₃, —CH₂—CF₂—CF₃, or —CH(CF₃)₂. Very preferred “haloalkyl” as substituents for the inventive compounds are —CF₃, —CHF₂, and —CH₂—CF₃, and again further preferred are —CF₃ and —CHF₂.

Various groups are referred to as being “optionally substituted” in this specification. Generally, these groups may carry one or more substituents, such as, e.g., one, two, three or four substituents. It will be understood that the maximum number of substituents is limited by the number of attachment sites available on the substituted moiety. Unless defined otherwise, the “optionally substituted” groups referred to in this specification carry preferably not more than two substituents and may, in particular, carry only one substituent. Moreover, unless defined otherwise, it is preferred that the optional substituents are absent, i.e. that the corresponding groups are unsubstituted.

As used herein, the terms “optional”, “optionally” and “may” denote that the indicated feature may be present but can also be absent. Whenever the term “optional”, “optionally” or “may” is used, the present invention specifically relates to both possibilities, i.e., that the corresponding feature is present or, alternatively, that the corresponding feature is absent. For example, the expression “X is optionally substituted with Y” (or “X may be substituted with Y”) means that X is either substituted with Y or is unsubstituted. Likewise, if a component of a composition is indicated to be “optional”, the invention specifically relates to both possibilities, i.e., that the corresponding component is present (contained in the composition) or that the corresponding component is absent from the composition.

A skilled person will appreciate that the substituent groups comprised in the compounds of formula (I) may be attached to the remainder of the respective compound via a number of different positions of the corresponding specific substituent group. Unless defined otherwise, the preferred attachment positions for the various specific substituent groups are as illustrated in the examples.

As used herein, the term “about” preferably refers to +10% of the indicated numerical value, more preferably to ±5% of the indicated numerical value, and in particular to the exact numerical value indicated.

The scope of the invention embraces all pharmaceutically acceptable salt forms of the compounds of formula (I) which may be formed, e.g., by protonation of an atom carrying an electron lone pair which is susceptible to protonation, such as an amino group, with an inorganic or organic acid, or as a salt of an acid group (such as a carboxylic acid group) with a physiologically acceptable cation. Exemplary base addition salts comprise, for example: alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; zinc salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine salts, meglumine salts, ethylenediamine salts, or choline salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benzathine salts, benethamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts or tetrabutylammonium salts; and basic amino acid salts such as arginine salts, lysine salts, or histidine salts. Exemplary acid addition salts comprise, for example: mineral acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate salts (such as, e.g., sulfate or hydrogensulfate salts), nitrate salts, phosphate salts (such as, e.g., phosphate, hydrogenphosphate, or dihydrogenphosphate salts), carbonate salts, hydrogencarbonate salts, perchlorate salts, borate salts, or thiocyanate salts; organic acid salts such as acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, cyclopentanepropionate, decanoate, undecanoate, oleate, stearate, lactate, maleate, oxalate, fumarate, tartrate, malate, citrate, succinate, adipate, gluconate, glycolate, nicotinate, benzoate, salicylate, ascorbate, pamoate (embonate), camphorate, glucoheptanoate, or pivalate salts; sulfonate salts such as methanesulfonate (mesylate), ethanesulfonate (esylate), 2-hydroxyethanesulfonate (isethionate), benzenesulfonate (besylate), p-toluenesulfonate (tosylate), 2-naphthalenesulfonate (napsylate), 3-phenylsulfonate, or camphorsulfonate salts; glycerophosphate salts; and acidic amino acid salts such as aspartate or glutamate salts. Preferred pharmaceutically acceptable salts of the compounds of formula (I) include a hydrochloride salt, a hydrobromide salt, a mesylate salt, a sulfate salt, a tartrate salt, a fumarate salt, an acetate salt, a citrate salt, and a phosphate salt. A particularly preferred pharmaceutically acceptable salt of the compound of formula (I) is a hydrochloride salt. Accordingly, it is preferred that the compound of formula (I), including any one of the specific compounds of formula (I) described herein, is in the form of a hydrochloride salt, a hydrobromide salt, a mesylate salt, a sulfate salt, a tartrate salt, a fumarate salt, an acetate salt, a citrate salt, or a phosphate salt, and it is particularly preferred that the compound of formula (I) is in the form of a hydrochloride salt.

A “solvate” refers to an association or complex of one or more solvent molecules and the compound of formula (I). Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide (DMSO), ethyl acetate, acetic acid, acetonitril, and ethanolamine. The term “hydrate” refers to the complex where the solvent molecule is water. It is to be understood that such solvates of the compounds of the formula (I) also include solvates of pharmaceutically acceptable salts of the compounds of the formula (I).

A “cocrystal” refers to a crystalline structure that contains at least two different compounds that are solid in their pure form under ambient conditions. Cocrystals are made from neutral molecular species, and all species remain neutral after crystallization; further, typically and preferably, they are crystalline homogeneous phase materials where two or more building compounds are present in a defined stoichiometric ratio. See hereto Wang Y and Chen A, 2013; and Springuel G R, et al., 2012; and U.S. Pat. No. 6,570,036.

Furthermore, the compounds of formula (I) may exist in the form of different isomers, in particular stereoisomers (including, e.g., geometric isomers (or cis/trans isomers), enantiomers and diastereomers) or tautomers. All such isomers of the compounds of formula (I) are contemplated as being part of the present invention, either in admixture or in pure or substantially pure form. As for stereoisomers, the invention embraces the isolated optical isomers of the compounds according to the invention as well as any mixtures thereof (including, in particular, racemic mixtures/racemates). The racemates can be resolved by physical methods, such as, e.g., fractional crystallization, separation or crystallization of diastereomeric derivatives, or separation by chiral column chromatography. The individual optical isomers can also be obtained from the racemates via salt formation with an optically active acid followed by crystallization. The present invention further encompasses any tautomers of the compounds provided herein.

The scope of the invention also embraces compounds of formula (I), in which one or more atoms are replaced by a specific isotope of the corresponding atom. For example, the invention encompasses compounds of formula (I), in which one or more hydrogen atoms (or, e.g., all hydrogen atoms) are replaced by deuterium atoms (i.e., ²H; also referred to as “D”). Accordingly, the invention also embraces compounds of formula (I) which are enriched in deuterium. Naturally occurring hydrogen is an isotopic mixture comprising about 99.98 mol-% hydrogen-1 (¹H) and about 0.0156 mol-% deuterium (²H or D). The content of deuterium in one or more hydrogen positions in the compounds of formula (I) can be increased using deuteration techniques known in the art. For example, a compound of formula (I) or a reactant or precursor to be used in the synthesis of the compound of formula (I) can be subjected to an H/D exchange reaction using, e.g., heavy water (D₂O). Further suitable deuteration techniques are described in: Atzrodt J et al., Bioorg Med Chem, 20(18), 5658-5667, 2012; William J S et al., Journal of Labelled Compounds and Radiopharmaceuticals, 53(11-12), 635-644, 2010; Modvig A et al., J Org Chem, 79, 5861-5868, 2014. The content of deuterium can be determined, e.g., using mass spectrometry or NMR spectroscopy. Unless specifically indicated otherwise, it is preferred that the compound of formula (I) is not enriched in deuterium. Accordingly, the presence of naturally occurring hydrogen atoms or ¹H hydrogen atoms in the compounds of formula (I) is preferred.

The present invention also embraces compounds of formula (I), in which one or more atoms are replaced by a positron-emitting isotope of the corresponding atom, such as, e.g., ¹⁸F ¹¹C, ¹³N, ¹⁵O, ⁷⁶Br, ⁷⁷Br, ¹²⁰I and/or ¹²⁴I. Such compounds can be used as tracers or imaging probes in positron emission tomography (PET). The invention thus includes (i) compounds of formula (I), in which one or more fluorine atoms (or, e.g., all fluorine atoms) are replaced by ¹⁸F atoms, (ii) compounds of formula (I), in which one or more carbon atoms (or, e.g., all carbon atoms) are replaced by ¹¹C atoms, (iii) compounds of formula (I), in which one or more nitrogen atoms (or, e.g., all nitrogen atoms) are replaced by ¹³N atoms, (iv) compounds of formula (I), in which one or more oxygen atoms (or, e.g., all oxygen atoms) are replaced by ¹⁵O atoms, (v) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine atoms) are replaced by ⁷⁶Br atoms, (vi) compounds of formula (I), in which one or more bromine atoms (or, e.g., all bromine atoms) are replaced by ⁷⁷Br atoms, (vii) compounds of formula (I), in which one or more iodine atoms (or, e.g., all iodine atoms) are replaced by ¹²⁰I atoms, and (viii) compounds of formula (I), in which one or more iodine atoms (or, e.g., all iodine atoms) are replaced by ¹²⁴I atoms. In general, it is preferred that none of the atoms in the compounds of formula (I) are replaced by specific isotopes.

In a first aspect, the present invention provides a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein R¹ is selected from halogen and -(optionally substituted hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S); R²¹ is selected from hydrogen, -(optionally substituted C₁₋₆ alkyl) which may contain one to three oxygen atoms between carbon atoms, and -(optionally substituted C₃₋₆ cycloalkyl); R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl); each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH; R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —(C₁₋₆-alkyl substituted with one or more F); wherein R³ and any R³¹ can be optionally linked; and E is either absent or is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—; R^(6x) is -halogen, —OH, ═O, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl substituted with one or more OH, monocyclic aryl optionally substituted with one or more R^(xb), monocyclic heteroaryl optionally substituted with one or more R^(xb), monocyclic cycloalkyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkyl optionally substituted with one or more R^(xb), monocyclic cycloalkenyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkenyl optionally substituted with one or more R^(xb), wherein said R^(xb) is independently selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl substituted with one or two OH; wherein Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups at ring A can be optionally linked and/or any R^(x) group at ring A can be optionally linked with R²¹; and/or wherein Ring A may be further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein Ring B is an -(optionally substituted heterocycle) or -(optionally substituted carbocycle); each R^(x) is independently selected from -halogen, —OH, —O-(optionally substituted C₁₋₆ alkyl), —NH-(optionally substituted C₁₋₆ alkyl), —N(optionally substituted C₁₋₆ alkyl)₂, ═O, -(optionally substituted C₁₋₆ alkyl), -(optionally substituted carbocyclyl), -(optionally substituted heterocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), and —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), and wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C₃₋₆ cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C₁₋₆ alkylene is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and wherein the optional substituent of the optionally substituted C₁₋₆ alkyl and of the optionally substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked.

In a preferred embodiment, at least one of said X¹, X² and X³ is N. In a further preferred embodiment, at least one of said X² and X³ is N. In a further preferred embodiment, X² is N. In another preferred embodiment, X² and X³ are both N. Thus, in a further preferred embodiment, the compound of formula (I) is a compound of formula (Ia)

In a further preferred embodiment, X¹ is nitrogen or CH, and X² and X³ are both N. In a further very preferred embodiment, X¹ is CH and X² and X³ are both N. Thus, in a further preferred embodiment, the compound of formula (I) is a compound of formula (Ib)

R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —(C₁₋₆-alkyl substituted with one or more F); wherein R³ and any R³¹ can be optionally linked. When R³ and an R³¹ are linked, a cyclic group, such as a 3 to 8-membered ring containing 1 to 8 carbon atoms and optionally 1 to 4 heteroatoms selected from N, O and S may be formed. These cyclic groups typically include the carbon or nitrogen to which R³¹ is bound as one ring member. Examples of such a cyclic group are cyclopentane, cyclohexane, pyrrolidine, piperidine and morpholine rings. In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₄-alkyl, and —C₁₋₂-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₂-alkyl, and —C₁-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen and methyl. In a further very preferred embodiment, said R³¹ is -hydrogen.

Thus, in a further preferred embodiment, the compound of formula (I) is a compound of formula (II)

In a further preferred embodiment, the compound of formula (I) is a compound of formula (IIa)

In again a further preferred embodiment, the compound of formula (I) is a compound of formula (IIb)

In a further preferred embodiment, E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. Still more preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—. Even more preferably, E is CH₂. Thus, in a further preferred embodiment, the compound of formula (I) is a compound of formula (III)

In a further preferred embodiment, the compound of formula (I) is a compound of formula (IIIa)

In again a further preferred embodiment, the compound of formula (I) is a compound of formula (IIIb)

In a further very preferred embodiment, the compound of formula (I) is a compound of formula (IV)

In a further preferred embodiment, the compound of formula (I) is a compound of formula (IVa)

In again a further preferred embodiment, the compound of formula (I) is a compound of formula (IVb)

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₁₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is methyl.

In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or more OH. In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl and C₁₋₂ haloalkyl. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl and C₁ haloalkyl. In a further preferred embodiment, R^(6x) is selected from methyl, ethyl, CHF₂ and CF₃. In a further preferred embodiment, R^(6x) is CHF₂. In a further preferred embodiment, R^(6x) is CF₃. In a further preferred embodiment, R^(6x) is ethyl. In a further very preferred embodiment, R^(6x) is methyl.

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1. In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

Ring A may be further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein preferably Ring B is an optionally substituted aromatic monocyclic ring such as -(optionally substituted aryl) or -(optionally substituted heteroaryl) ring. Examples of Ring B include benzene, furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine, pyrrole, imidazole, pyrazole, isoxazole, isothiazole, oxazole, thiazole, oxadiazole, thiadiazole, triazole, tetrazole, each of which is optionally substituted. The optional substituent of Ring B is the same as the optional substituent of the -(optionally substituted heterocycle) or -(optionally substituted carbocycle), preferably said optional substituent of Ring B is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl.

In another preferred embodiment, said Ring B is an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, or optionally substituted heterocycloalkenyl, wherein said optional substituent of said cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl, wherein said optional substituent of said cycloalkyl or said heterocycloalkyl, is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted monocyclic cycloalkyl or an optionally substituted monocyclic heterocycloalkyl, wherein said optional substituent of said monocyclic cycloalkyl or said monocyclic heterocycloalkyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₆ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₆ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₆ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₆ alkyl optionally substituted with one or more R^(xa), C₁₋₆ haloalkyl, —(C₁₋₃ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₃ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₃ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₃ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃.

In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further aspect and embodiment, the present invention provides a compound of formula (I), preferably a compound of formula (Ia), and further preferably a compound of formula (Ib), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein R¹ is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl), and wherein said, preferably one or two, optional substituent of said heteroaryl or said phenyl is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked; R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is methyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl. each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably at least one of said X² and X³ is N; again further preferably X² and X³ are both N, and still further preferably X² and X³ are both N, and X¹ is CH; R³¹ is selected from -hydrogen, —C₁₋₄-alkyl, and —C₁₋₂-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₂-alkyl, and —C₁-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen and methyl. In a further preferred embodiment, said R³¹ is -hydrogen; and E is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹, wherein L¹ is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—. In a further preferred embodiment, said E is —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂— and —CHCH₃—. In a further preferred embodiment E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. Preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—. Even more preferably, E is CH₂; R^(6x) is selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or more OH. In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. H. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl and C₁₋₂ haloalkyl. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl and C haloalkyl. In a further preferred embodiment, R^(6x) is selected from methyl, ethyl, CHF₂ and CF₃. In a further preferred embodiment, R^(6x) is CHF₂. In a further preferred embodiment, R^(6x) is CF₃. In a further preferred embodiment, R^(6x) is ethyl. In a further very preferred embodiment, R^(6x) is methyl; wherein Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A can be optionally linked and/or any R^(x) group at ring A can be optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2, or alternatively preferably 0 or 1. In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A; and/or wherein Ring A may be further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein Ring B is is an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, or optionally substituted heterocycloalkenyl, wherein said optional substituent of said cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl; each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH, and wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C₃₋₆ cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C₁₋₆ alkylene is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and wherein the optional substituent of the optionally substituted C₁₋₆ alkyl and of the optionally substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked. In a further preferred embodiment, both X² and X³ are nitrogen. In a further preferred embodiment, X¹ is CH.

In a preferred embodiment, said compound of formula (I) is a compound selected from a compound of formula (II), (IIa), (IIb), (III), (IIIa), (IIIb), (IV), (Iva) and (IVb). In a preferred embodiment, said compound of formula (I) is a compound of formula (II). In a preferred embodiment, said compound of formula (I) is a compound of formula (IIa). In a preferred embodiment, said compound of formula (I) is a compound of formula (IIb). In a preferred embodiment, said compound of formula (I) is a compound of formula (III). In a preferred embodiment, said compound of formula (I) is a compound of formula (IIIa). In a preferred embodiment, said compound of formula (I) is a compound of formula and (IIIb). In a preferred embodiment, said compound of formula (I) is a compound of formula (IV). In a preferred embodiment, said compound of formula (I) is a compound of formula (IVa). In a preferred embodiment, said compound of formula (I) is a compound of formula and (IVb).

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

In a further preferred embodiment, said Ring B is an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl, wherein said optional substituent of said cycloalkyl or said heterocycloalkyl, is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted monocyclic cycloalkyl or an optionally substituted monocyclic heterocycloalkyl, wherein said optional substituent of said monocyclic cycloalkyl or said monocyclic heterocycloalkyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂ alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

In a further preferred embodiment, R¹ is selected from -(optionally substituted heteroaryl) and -(optionally substituted phenyl), wherein said heteroaryl is a 5 or 6 membered monocyclic ring or 8 to 12, alternatively 10 to 12 but preferably 8 to 10, membered fused ring system comprising one or more ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms are optionally oxidized, and wherein said, preferably one or two, optional substituent of said heteroaryl or said phenyl is independently selected from —C₁₋₆ alkyl, C₁₋₆ haloalkyl, -halogen, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —OR*; and carbocyclyl and heterocyclyl, each independently optionally substituted with, preferably one or two, halogen or C₁₋₄ alkyl; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —C(O)—C₁₋₆ alkyl, —C(O)—C₁₋₆ haloalkyl, —NH—C(O)—C₁₋₆ alkyl, —NH—C(O)—C₁₋₆ haloalkyl and —C(O)—NH—C₁₋₆ alkyl, —C(O)—NH—C₁₋₆ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl.

In a further preferred embodiment, R¹ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl. In a further preferred embodiment, R¹ is 3-pyridyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃.

In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

The present inventors have further surprisingly found that the enantiomers of the compounds of the present invention as depicted in formula (V) are significantly more active than the other enantiomers or diastereomers of the said compounds. Thus, in a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (V), preferably of formula (Va) and further preferably of formula (Vb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein R¹ is selected from halogen and -(optionally substituted hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S); R²¹ is selected from hydrogen, -(optionally substituted C₁₋₆ alkyl) which may contain one to three oxygen atoms between carbon atoms, and -(optionally substituted C₃₋₆ cycloalkyl); R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl); each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH; R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —(C₁₋₆-alkyl substituted with one or more F); wherein R³ and any R³¹ can be optionally linked; and E is either absent or is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—; R^(6x) is -halogen, —OH, ═O, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl substituted with one or more OH, monocyclic aryl optionally substituted with one or more R^(xb), monocyclic heteroaryl optionally substituted with one or more R^(xb), monocyclic cycloalkyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkyl optionally substituted with one or more R^(xb), monocyclic cycloalkenyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkenyl optionally substituted with one or more R^(xb), wherein said R^(xb) is independently selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl substituted with one or two OH; wherein Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups at ring A can be optionally linked and/or any R^(x) group at ring A can be optionally linked with R²; and/or wherein Ring A may be further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein Ring B is an -(optionally substituted heterocycle) or -(optionally substituted carbocycle); each R^(x) is independently selected from -halogen, —OH, —O-(optionally substituted C₁₋₆ alkyl), —NH-(optionally substituted C₁₋₆ alkyl), —N(optionally substituted C₁₋₆ alkyl)₂, ═O, -(optionally substituted C₁₋₆ alkyl), -(optionally substituted carbocyclyl), -(optionally substituted heterocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), and —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), and wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C₃₋₆ cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C₁₋₆ alkylene is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and wherein the optional substituent of the optionally substituted C₁₋₆ alkyl and of the optionally substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked. In a further preferred embodiment, both X² and X³ are nitrogen. In a further preferred embodiment, X¹ is CH.

In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₄-alkyl, and —C₁₋₂-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₂-alkyl, and —C₁-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen and methyl. In a further preferred embodiment, said R³¹ is -hydrogen.

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is methyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl.

It is to be understood that Ring A may be further substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2, or alternatively preferably 0 or 1. In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a further preferred embodiment, said E is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹, wherein L¹ is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—. In a further preferred embodiment, said E is —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂— and —CHCH₃—. In a further preferred embodiment E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. Preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—. Even more preferably, E is CH₂;

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa)—N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(x), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(x)a, wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₁₋₆₃ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

It is to be understood that said Ring A may further be substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein, in a preferred embodiment, said Ring B is an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, or optionally substituted heterocycloalkenyl, wherein said optional substituent of said cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl, wherein said optional substituent of said cycloalkyl or said heterocycloalkyl, is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted monocyclic cycloalkyl or an optionally substituted monocyclic heterocycloalkyl, wherein said optional substituent of said monocyclic cycloalkyl or said monocyclic heterocycloalkyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl.

In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or more OH. In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. H. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl and C₁₋₂ haloalkyl. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl and C₁ haloalkyl. In a further preferred embodiment, R^(6x) is CHF₂. In a further preferred embodiment, R^(6x) is CF₃. In a further preferred embodiment, R^(6x) is ethyl. In a further very preferred embodiment, R^(6x) is methyl.

In a further preferred embodiment, R¹ is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

In a further preferred embodiment, R¹ is selected from -(optionally substituted heteroaryl) and -(optionally substituted aryl), and wherein said, preferably one or two, optional substituent of said heteroaryl or said aryl, preferably phenyl, is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked.

In a further preferred embodiment, R¹ is selected from -(optionally substituted heteroaryl) and -(optionally substituted phenyl), wherein said heteroaryl is a 5 or 6 membered monocyclic ring or 10 to 12 membered fused ring system comprising one or more ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms are optionally oxidized, and wherein said, preferably one or two, optional substituent of said heteroaryl or said phenyl is independently selected from —C₁₋₆ alkyl, C₁₋₆ haloalkyl, -halogen, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —OR*; and carbocyclyl and heterocyclyl, each independently optionally substituted with, preferably one or two, halogen or C₁₋₄ alkyl; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —C(O)—C₁₋₆ alkyl, —C(O)—C₁₋₆ haloalkyl, —NH—C(O)—C₁₋₆ alkyl, —NH—C(O)—C₁₋₆ haloalkyl and —C(O)—NH—C₁₋₆ alkyl, —C(O)—NH—C₁₋₆ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl.

In a further preferred embodiment, R¹ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl. In a further preferred embodiment, R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄ alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a for (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₃alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₃alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl). Preferably, R³ is -(optionally substituted carbocyclyl). More preferably, R³ is phenyl which is optionally substituted with one or more groups selected from halogen, —(C₁₋₆ alkyl which is optionally substituted with one or more F) and —O—(C₁₋₆ alkyl which is optionally substituted with one or more F). Further preferred are compounds in which R³ is pyridinyl which may have the same substituents as the optionally substituted heterocyclyl. In other preferred compounds, R³ is quinazoline or cinnoline, each of which may have the same substituents as the optionally substituted heterocyclyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A³¹), wherein A³¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N; A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; A³¹ is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂ alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

In a very preferred embodiment, said compound of formula (V) is a compound selected from a compound of formula (VI), (VIa) and (IVb). In a very preferred embodiment, said compound of formula (V) is a compound of formula (VI). In a very preferred embodiment, said compound of formula (V) is a compound of formula (VIa). In a very preferred embodiment, said compound of formula (V) is a compound of formula and (VIb).

Thus, in a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (VI), preferably of formula (VIa), and further preferably of formula (VIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein R¹ is selected from halogen and -(optionally substituted hydrocarbon group which contains from 1 to 20 carbon atoms and optionally 1 to 15 heteroatoms selected from O, N and S); R²¹ is selected from hydrogen, -(optionally substituted C₁₋₆ alkyl) which may contain one to three oxygen atoms between carbon atoms, and -(optionally substituted C₃₋₆ cycloalkyl); R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl); each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH; R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —(C₁₋₆-alkyl substituted with one or more F); wherein R³ and any R³¹ can be optionally linked; and E is either absent or is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—; wherein Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups at ring A can be optionally linked and/or any R^(x) group at ring A can be optionally linked with R²; and/or wherein Ring A may be further substituted with one group R^(x) so as to form together with said methyl substitution group of Ring A a bicyclic moiety having the following partial structure:

wherein Ring B is an -(optionally substituted heterocycle) or -(optionally substituted carbocycle); each R^(x) is independently selected from -halogen, —OH, —O-(optionally substituted C₁₋₆ alkyl), —NH-(optionally substituted C₁₋₆ alkyl), —N(optionally substituted C₁₋₆ alkyl)₂, ═O, -(optionally substituted C₁₋₆ alkyl), -(optionally substituted carbocyclyl), -(optionally substituted heterocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl), and —O-(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl), and wherein the optional substituent of the optionally substituted hydrocarbon group, optionally substituted C₃₋₆ cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocycle, optionally substituted carbocyclyl, optionally substituted carbocycle and optionally substituted C₁₋₆ alkylene is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked, and wherein the optional substituent of the optionally substituted C₁₋₆ alkyl and of the optionally substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom can be optionally linked. In a further preferred embodiment, both X² and X³ are nitrogen. In a further preferred embodiment, X¹ is CH.

In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₄-alkyl, and —C₁₋₂-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen, —C₁₋₂-alkyl, and —C₁-fluoroalkyl. In a further preferred embodiment, said R³¹ is selected from -hydrogen and methyl. In a further preferred embodiment, said R³¹ is -hydrogen.

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH;

In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl.

In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl.

In a further preferred embodiment, said R²¹ is methyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl.

It is to be understood that Ring A may be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2, or alternatively preferably 0 or 1. In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1.

In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a further preferred embodiment, said E is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹, wherein L¹ is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂—, —CHCH₃—, —C(CH₃)₂—. In a further preferred embodiment, said E is —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHCH₃—, —NH—, —N(CH₃)—, and —O— and L² is selected from —CH₂— and —CHCH₃—. In a further preferred embodiment E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. Preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—. Even more preferably, E is CH₂.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —C, —F, and —OH.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —C, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa) monocyclic heterocyclyl optionally substituted with one or more R^(x)a, wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(x) C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

It is to be understood that said Ring A may further be substituted with one group R^(x) so as to form together with said methyl substitution group of Ring A a bicyclic moiety having the following partial structure:

wherein, in a preferred embodiment, said Ring B is an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, or optionally substituted heterocycloalkenyl, wherein said optional substituent of said cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted cycloalkyl or an optionally substituted heterocycloalkyl, wherein said optional substituent of said cycloalkyl or said heterocycloalkyl, is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl. In a further preferred embodiment, said Ring B is an optionally substituted monocyclic cycloalkyl or an optionally substituted monocyclic heterocycloalkyl, wherein said optional substituent of said monocyclic cycloalkyl or said monocyclic heterocycloalkyl is independently selected from —C₁₋₄ alkyl, —C₁₋₂ haloalkyl, -halogen, -oxo, —NR*R*, —OR*; wherein each R* is independently selected from H and C₁₋₄ alkyl.

In a further preferred embodiment, R¹— is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

In a further preferred embodiment, R¹— is selected from -(optionally substituted heteroaryl) and -(optionally substituted aryl), and wherein said, preferably one or two, optional substituent of said heteroaryl or said aryl, preferably phenyl is independently selected from —(C₁₋₆ alkyl which is optionally substituted with one or more halogen), -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl which is optionally substituted with halogen, heterocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl, and carbocyclyl which is optionally substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom can be optionally linked.

In a further preferred embodiment, R¹ is selected from -(optionally substituted heteroaryl) and -(optionally substituted phenyl), wherein said heteroaryl is a 5 or 6 membered monocyclic ring or 10 to 12 membered fused ring system comprising one or more ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms are optionally oxidized, and wherein said, preferably one or two, optional substituent of said heteroaryl or said phenyl is independently selected from —C₁₋₆ alkyl, C₁₋₆ haloalkyl, -halogen, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —OR*; and carbocyclyl and heterocyclyl, each independently optionally substituted with, preferably one or two, halogen or C₁₋₄ alkyl; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —C(O)—C₁₋₆ alkyl, —C(O)—C₁₋₆ haloalkyl, —NH—C(O)—C₁₋₆ alkyl, —NH—C(O)—C₁₋₆ haloalkyl and —C(O)—NH—C₁₋₆ alkyl, —C(O)—NH—C₁₋₆ haloalkyl.

In a further preferred embodiment, R¹ is phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl.

In a further preferred embodiment, R¹ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from halogen, —OH, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₂ haloalkyl), —C(O)—C₁₋₃ alkyl, —C(O)—C₁₋₂ haloalkyl, —NH—C(O)—C₁₋₃ alkyl, —NH—C(O)—C₁₋₂ haloalkyl and —C(O)—NH—C₁₋₃ alkyl, —C(O)—NH—C₁₋₂ haloalkyl. In a further preferred embodiment, R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄ alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄ alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₂ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₂ alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl). Preferably, R³ is -(optionally substituted carbocyclyl). More preferably, R³ is phenyl which is optionally substituted with one or more groups selected from halogen, —(C₁₋₆ alkyl which is optionally substituted with one or more F) and —O—(C₁₋₆ alkyl which is optionally substituted with one or more F). Further preferred are compounds in which R³ is pyridinyl which may have the same substituents as the optionally substituted heterocyclyl. In other preferred compounds, R³ is quinazoline or cinnoline, each of which may have the same substituents as the optionally substituted heterocyclyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂ alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂ alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A⁴¹), wherein A³¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N; A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; A³¹ is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

In a very preferred embodiment, said compound of formula (VI) is a compound selected from a compound of formula (VII), (VIIa), (VIIb), (VIII), (VIIIa), (IIIb), (IX), (IXa) and (IXb). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (VII). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (VIIa).

In a very preferred embodiment, said compound of formula (VI) is a compound of formula and (VIIb). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (VIII). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (VIIIa). In a very preferred embodiment, said compound of formula (VI) is a compound of formula and (VIIIb). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (IX). In a very preferred embodiment, said compound of formula (VI) is a compound of formula (IXa). In a very preferred embodiment, said compound of formula (VI) is a compound of formula and (IXb).

Thus, in a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (VII), preferably of formula (VIIa) and further preferably of formula (VIIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

and in a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (VIII), preferably of formula (VIIIa) and further preferably of formula (VIIIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

and in again a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (IX), preferably of formula (IXa) and further preferably of formula (IXb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein

R¹ is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₂ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₂ alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is ethyl. In a further very preferred embodiment, said R²¹ is methyl.

R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl). Preferably, R³ is -(optionally substituted carbocyclyl). More preferably, R³ is phenyl which is optionally substituted with one or more groups selected from halogen, —(C₁₋₆ alkyl which is optionally substituted with one or more F) and —O—(C₁₋₆ alkyl which is optionally substituted with one or more F). Further preferred are compounds in which R³ is pyridinyl which may have the same substituents as the optionally substituted heterocyclyl. In other preferred compounds, R³ is quinazoline or cinnoline, each of which may have the same substituents as the optionally substituted heterocyclyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂ alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A³¹), wherein A³¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N;

A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

A³¹ is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂ alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃ alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

Each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH.

E is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—. In a further preferred embodiment, said E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. Preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—. In a very preferred embodiment, E is CH₂.

R^(6x) is -halogen, —OH, ═O, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl substituted with one or more OH, monocyclic aryl optionally substituted with one or more R^(xb), monocyclic heteroaryl optionally substituted with one or more R^(xb), monocyclic cycloalkyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkyl optionally substituted with one or more R^(xb), monocyclic cycloalkenyl optionally substituted with one or more R^(xb), monocyclic heterocycloalkenyl optionally substituted with one or more R^(xb), wherein said R^(xb) is independently selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl substituted with one or two OH;

In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or more OH. In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. H. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl and C₁₋₂ haloalkyl. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl and C, haloalkyl. In a further preferred embodiment, R^(6x) is CHF₂. In a further preferred embodiment, R^(6x) is CF₃. In a further preferred embodiment, R^(6x) is ethyl. In a further very preferred embodiment, R^(6x) is methyl.

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1.

In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is methyl.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

In a further very preferred aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (IXb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂ alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂ alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₂ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₂ alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is ethyl. In a further very preferred embodiment, said R²¹ is methyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂ alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A³¹), wherein A⁴¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N;

A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴³ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

A³¹ is independently ‘selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

R^(6x) is selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or more OH. In a further preferred embodiment, R^(6x) is selected from -halogen, —OH, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₁₋₃ alkyl substituted with one or two OH. H. In a further preferred embodiment, R^(6x) is selected from C₁₋₃ alkyl and C₁₋₂ haloalkyl. In a further preferred embodiment, R^(6x) is selected from C₁₋₂ alkyl and C₁ haloalkyl. In a further preferred embodiment, R^(6x) is CHF₂. In a further preferred embodiment, R^(6x) is CF₃. In a further preferred embodiment, R^(6x) is ethyl. In a further very preferred embodiment, R^(6x) is methyl.

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1.

In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is methyl.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

In a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (X), preferably of formula (Xa), and further preferably of formula (Xb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

and in a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (XI), preferably of formula (XIa), and further preferably of formula (XIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

and in again a further aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (XII), preferably of formula (XIIa), and further preferably of formula (XIIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein

R¹ is selected from -(optionally substituted heterocyclyl) and -(optionally substituted carbocyclyl).

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₂ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₂ alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is ethyl. In a further very preferred embodiment, said R²¹ is methyl.

R³ is selected from -(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl), -(optionally substituted C₁₋₆ alkylene)-(optionally substituted heterocyclyl) and -(optionally substituted C₁₋₆ alkylene)-(optionally substituted carbocyclyl). Preferably, R³ is -(optionally substituted carbocyclyl). More preferably, R³ is phenyl which is optionally substituted with one or more groups selected from halogen, —(C₁₋₆ alkyl which is optionally substituted with one or more F) and —O—(C₁₋₆ alkyl which is optionally substituted with one or more F). Further preferred are compounds in which R³ is pyridinyl which may have the same substituents as the optionally substituted heterocyclyl. In other preferred compounds, R³ is quinazoline or cinnoline, each of which may have the same substituents as the optionally substituted heterocyclyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl); A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A⁴¹), wherein A³¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N;

A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, 1-2 haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, 1-2 haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴³ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, 1-2 haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

A³¹ is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

Each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein preferably at least one of said X¹, X² and X³ is N, wherein further preferably at least one of said X² and X³ is N; and wherein again further preferably X² and X³ are both N, and wherein still further preferably X² and X³ are both N, and X¹ is CH.

E is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—. In a further preferred embodiment, said E is selected from —CH₂—, —NH—, —O—, —CH₂—O—, —O—CH₂—, —CH₂—NH—, —NH—CH₂— and —CH₂—CH₂—. Preferably, E is selected from CH₂—, —O—, —CH₂—O—, —O—CH₂— and —CH₂—CH₂—. More preferably, E is selected from CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—.

In a very preferred embodiment, E is CH₂.

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1.

In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is methyl.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

In a further very preferred aspect and embodiment, the present invention provides a compound of formula (I), wherein said compound of formula (I) is a compound of formula (XIIb), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₄alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, preferably 1 to 5, ring heteroatoms independently selected from O, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising one or more, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from —F, —Cl, —C₁₋₃ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C alkyl), —O—(C₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5- or 6-membered monocyclic heteroaryl comprising one or two heteroatoms independently selected from S and N and a 8-10 membered bicyclic heteroaryl comprising 1 to 5, preferably 1 to 4, ring nitrogen heteroatoms, wherein one or two, preferably one, carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized, and wherein said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, —O—(C₁₋₂alkylene)-C(O)N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂ alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl, wherein the phenyl, thiophenyl, pyrrolyl, pyrazolyl, azaindolyl, azaindazolyl, pyrazinyl, pyridyl or pyrimidinyl is optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₂ alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from a 5-membered monocyclic heteroaryl comprising one or two heteroatoms selected from S and N, wherein said 5-membered monocyclic heteroaryl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, each monocyclic heterocyclyl optionally substituted with one or two, preferably one, substituents independently selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂alkyl), —O—(C₁₋₂ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R¹ is selected from thiophenyl, pyrrolyl and pyrazolyl, preferably thiophenyl and pyrrolyl, wherein said thiophenyl, pyrrolyl and pyrazolyl is independently optionally substituted with methyl or ethyl, or R¹ is selected from a formula (A) and (B)

wherein

Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is selected from a formula (A) and (B)

wherein Y¹ is NH, N(C₁₋₃alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₃alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —OCHF₂, —OCHF₃, —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH, N(C₁₋₂ alkyl), N(C₁₋₂ alkylene)-O—(C₁₋₂ alkyl) or CH₂, and Y² is N or CH, and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (B)

wherein Y¹ is NH or N(C₁₋₂ alkyl), preferably Y¹ is NH or N(CH₃), and Y² is CH, wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N or CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is CH, and A¹ is selected from hydrogen, —C₁₋₂ alkyl, —CHF₂, —CF₃, —O—(C₁₋₂ alkyl), —O—(C₁₋₂alkylene)-OR*, —OCHF₂, —OCHF₃, —OH, ═O, and a 4-6 membered monocyclic heterocyclyl comprising 1 or 2 heteroatoms selected from O and N, wherein said monocyclic heterocyclyl is optionally substituted with one or two, preferably one, substituents selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —O—(C₁₋₂ alkyl), —O—(C₁₋₂ haloalkyl), —OH, —O—(C₁₋₂alkylene)-OR*, —O—(C₁₋₂alkylene)-N(R^(oo))₂ and ═O; wherein each R* is independently selected from H, C₁₋₂ alkyl, C₁₋₂ haloalkyl, and wherein each R^(oo) is independently selected from H, C₁₋₂ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl, preferably selected from morpholine, piperidine and piperazine; and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R¹ is of a formula (A)

wherein B¹ is CH and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 3-pyridyl.

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is selected from hydrogen and —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R¹ is of a formula (A)

wherein

B¹ is N, and A¹ is hydrogen, and wherein the arrow denotes the bond in the compounds of formula (I). Thus, in a further very preferred embodiment, said R¹ is 2-pyrazinyl.

R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²², wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is ethyl. In a further very preferred embodiment, said R²¹ is methyl.

In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—C₁₋₆ alkyl, and —O—C₁₋₆ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from halogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —O—C₁₋₂ alkyl, and —O—C₁₋₃ haloalkyl. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —C₁₋₂ alkyl, C₁ haloalkyl, —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one or more, preferably one or two, substituents selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or 3-pyridyl or 4-pyridyl, each of which is optionally substituted with one substituent selected from —F, —Cl, —CH₃ and —OCH₃.

In a further preferred embodiment, R³ is phenyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted at the meta position of said phenyl, 3-pyridyl or 4-pyridyl with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl or phenyl substituted at the meta position with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 3-pyridyl or 3-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is 4-pyridyl or 4-pyridyl substituted at the meta position (5 position) with one substituent selected from —F, —Cl, —CH₃ and —OCH₃. In a further preferred embodiment, R³ is phenyl. In a further preferred embodiment, R³ is 3-pyridyl. In a further preferred embodiment, R³ is 4-pyridyl.

In a further preferred embodiment, said R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more, typically 1 to 5, preferably 1 to 4, ring heteroatoms independently selected from O, B, S and N, wherein one or two carbon ring atoms of said monocyclic heteroaryl or said bicyclic heteroaryl are optionally oxidized typically and preferably leading to a C═O functionality, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently optionally substituted with one or more, typically and preferably with 1 to 5, further preferably with 1 to 4, and again further preferably with 1 to 3 substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —(C₁₋₆ alkylene)-OR*, —(C₁₋₆ alkylene)-NR*R*, —O—(C₁₋₆ alkylene)-OR*, —O—(C₁₋₆ alkylene)-NR*R*, —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, —SO₂R*, —SO₂OR*, —SO₂ NR*R* and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.

In a further preferred embodiment, said R³ is selected from formula (C), formula (D), formula (E), formula (F) and formula (G)

wherein

B³¹ is N, CH or C(A³¹), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl), wherein A³¹ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂ alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, B³² is N, CH or C(A³²), wherein A³² is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

B³³ is N, CH or C(A³³), wherein A³³ is selected from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

ZZZA² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-OH, —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

and wherein

Y³¹ is N, CH or C(A⁴¹), wherein A³¹ is selected from methyl and ethyl; Y³² is N, CH or C(A³²), wherein A³² is selected from methyl and ethyl; Y³³ is N, CH or C(A³³), wherein A³³ is selected from methyl and ethyl; and wherein B³⁴ is N;

A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3D) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁴ is N, NH, N(A⁴⁴), C(O), CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, NH, N(A⁴⁵), C(O), CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from methyl and ethyl; Y⁴⁶ is N, NH, N(A⁴⁶), O, C(O), CH or C(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴, Y⁴⁵ and Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

Y⁴⁷ is N, NH, N(A⁴⁷), C(O), CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴³ is N, NH, N(A⁴⁸), C(O), CH or C(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, NH, N(A⁴⁹), O, C(O), CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷, Y⁴⁸ and Y⁴⁹ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH;

and wherein

G¹, G², G³, G⁴ is independently selected from N, CH, C(O), NH or N(C₁₋₂ alkyl); and wherein the arrow denotes the bond in the compounds of formula (I).

In a further preferred embodiment, said R³ is selected from the following formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A² is independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl;

A³¹ is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), —OH, —NHC(O)(C₁₋₂alkyl);

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, phenyl, and/or wherein each monocyclic heterocyclyl is independently optionally substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and phenyl;

In a further preferred embodiment, A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂ alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³⁵ is independently selected for each formula from —C₁₋₂ alkyl; and wherein the arrow denotes the bond in the compounds of formula (I).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² and A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl); and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic heterocyclyl independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F; and wherein

A³² is independently selected for each formula from —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 3 heteroatoms selected from O and N, each monocyclic heterocyclyl independently optionally substituted with one or two substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from hydrogen, —C₁₋₃alkyl, —C₁₋₂haloalkyl, —F, —Cl, —O(C₁₋₃alkyl), —OH, —NHC(O)(C₁₋₂alkyl), —NHC(O)—C₁₋₂alkylene-O(C₁₋₂alkyl), —NHC(O)(cyclopropyl), —NHC(O)(phenyl), and 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, tetrahydropyranyl, cyclopropyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —CI, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or more, preferably one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₃ alkyl, C₁₋₃ haloalkyl and phenyl; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl).

In a further very preferred embodiment, said R³ is selected from the formulas

wherein

A² is independently selected for each formula from a 4-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O and N, wherein said 4-6 membered monocyclic heterocyclyl is selected from the group consisting of azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, morpholinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, triazolyl and tetrazolyl, and wherein each monocyclic heterocyclyl is independently optionally substituted with one or two, substituents independently selected from halogen, cyclopropyl, tetrahydropyranyl, —C₁₋₃ alkyl, C₁₋₃ haloalkyl, —O—(C₁₋₃ alkyl), —O—(C₁₋₃ haloalkyl), —OH, ═O, —C₁₋₃alkylene-O—(C₁₋₃ alkyl) and —C₁₋₃alkylene-OH; and wherein

A³² are independently selected for each formula from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), and wherein preferably A³² are independently selected for each formula from hydrogen, —CH₃, —CHF₂, —CF₃, —F, —Cl, —OCH₃.

In a further preferred embodiment, said R³ is selected from formulas

wherein

Y⁴⁴ is N, CH or C(A⁴⁴), wherein A⁴⁴ is independently selected from methyl and ethyl; Y⁴⁵ is N, CH or C(A⁴⁵), wherein A⁴⁵ is independently selected from msethyl and ethyl; Y⁴⁶ is NH, N(A⁴⁶), O, C(O), CH₂ or CH(A⁴⁶), wherein A⁴⁶ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁴ and Y⁴⁵ is N or Y⁴⁶ is NH, N(CH₃) or N(C₂H₅); and wherein

A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —C, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3E) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, and further preferably A^(3E) is hydrogen;

and wherein

Y⁴⁷ is N, CH or C(A⁴⁷), wherein A⁴⁷ is independently selected from methyl and ethyl; Y⁴⁸ is NH, N(A⁴⁸), O, C(O), CH₂ or CH(A⁴⁸), wherein A⁴⁸ is independently selected from methyl and ethyl; Y⁴⁹ is N, CH or C(A⁴⁹), wherein A⁴⁹ is independently selected from methyl and ethyl; and wherein at least one of said Y⁴⁷ and Y⁴⁹ is N or Y⁴⁸ is NH, N(CH₃) or N(C₂H₅);

A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH, —NHC(O)(C₁₋₂alkyl), —C(O)NH(C₁₋₂alkyl), —C(O)N(C₁₋₂alkyl)₂, —NHC(O)(phenyl); In a further preferred embodiment, A^(3F) is selected from hydrogen, —C₁₋₂ alkyl, C₁₋₂ haloalkyl, —F, —Cl, —O(C₁₋₂alkyl), ═O, —OH; and further preferably A^(3F) is hydrogen.

In a further preferred embodiment, said R³ is selected from formulas

It is to be understood that Ring A may further be substituted with one or more groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹; the number of groups R^(x) in Ring A is 0, 1, 2, 3, or 4, preferably 0, 1, 2, or 3, further preferably 0, 1, or 2 or alternatively preferably 0 or 1.

In case that Ring A may be substituted with one or more groups R^(x) and one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

Thus, in a preferred embodiment, said Ring A is further substituted with 1, 2, 3 or 4 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1, 2 or 3 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 or 2 groups R^(x), wherein any two R^(x) groups, preferably adjacent R^(x) groups, at ring A are optionally linked and/or any R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is optionally linked with R²¹. In case that one of said R^(x) group at ring A is optionally linked with R²¹ then said one of said R^(x) group at ring A optionally linked with R²¹ is a substituent at the 2-position of Ring A.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹.

In a preferred embodiment, said Ring A is further substituted with 1 group R^(x), wherein said R^(x) group at ring A is not linked with R²¹. In a further preferred embodiment, said group R^(x) is —F, and wherein preferably said group R^(x) being —F is at the 3-position of Ring A, said position which connects said Ring A with the X¹, X², X³ ring system.

In a preferred embodiment, said Ring A is not further substituted. Thus, in a preferred embodiment, said Ring A is not further substituted with a group R^(x).

In a preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl optionally substituted with one or more OH, C₁₋₆ alkyl containing one to three oxygen atoms between carbon atoms, and C₃₋₆ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from halogen, preferably —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from hydrogen, C₁₋₂ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl optionally substituted with one or two OH, and C₃₋₄ cycloalkyl optionally substituted with one or more R²² wherein R²² is selected from —Cl, —F, and —OH. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl, C₁₋₂ haloalkyl and C₃₋₄ cycloalkyl. In a further preferred embodiment, said R²¹ is selected from C₁₋₂ alkyl and cyclopropyl. In a further preferred embodiment, said R²¹ is ethyl. In a further preferred embodiment, said R²¹ is cyclopropyl. In a further very preferred embodiment, said R²¹ is methyl.

In a preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₃ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₃ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₄ alkyl optionally substituted with one or more R^(xa), C₁₋₄ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted carbocyclyl), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(optionally substituted heterocyclyl), -(optionally substituted carbocyclyl) and -(optionally substituted heterocyclyl), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —O—(C₁₋₂ alkylene optionally substituted with one or more R^(xa))-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), monocyclic carbocyclyl optionally substituted with one or more R^(xa), monocyclic heterocyclyl optionally substituted with one or more R^(xa), wherein said R^(xa) is independently selected from halogen, preferably —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —NH—C₁₋₂ alkyl optionally substituted with one or more R^(xa), —N(C₁₋₂ alkyl optionally substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl optionally substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.

In a further preferred embodiment, each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl, —N(C₁₋₂ alkyl)₂, ═O, C₁₋₃ alkyl, C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl optionally substituted with one R^(xa)), —W-(monocyclic heterocyclyl optionally substituted with one R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —F, and —OH.

Specific examples and very preferred compounds and embodiments of the present invention are any of the compounds 00001 to 00168. Thus, in a very further preferred embodiment, said compound of formula (I) is a compound selected from any one of the compounds 00001 to 00168.

The present inventors have surprisingly found that the compounds of the present invention bind to p300 (also called EP300 or E1A binding protein p300) and CBP (also known as CREB-binding protein or CREBBP) which are two structurally very similar transcriptional co-activating proteins. Without wishing to be limited by theory, it is believed that this binding is a main reason for the activity of the compounds of the present invention as set out herein. It is furthermore believed that the compounds of the present invention bind to the bromodomains of p300 and CBP.

It is therefore preferred that the compounds of the present invention bind to the bromodomain of p300 and/or the bromodomain of CBP and are active with an EC50 of 10000 nM or less, preferably 2000 nM or less, more preferably 1000 nM or less, even more preferably 500 nM or less, still more preferably 200 nM or less, still more preferably 100 nM or less, still more preferably 50 nM or less, still more preferably 20 nM or less, still more preferably 10 nM or less.

The present invention furthermore relates to a pharmaceutical composition comprising a compound having the formula (I) as defined herein, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, and optionally one or more pharmaceutically acceptable excipient(s) and/or carrier(s).

In addition, the present invention provides the compound having the formula (I) as defined herein, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, wherein the compound is for use in the treatment, amelioration or prevention of cancer.

The present invention also relates to a method of treating or ameliorating cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof.

The present invention also relates to a method of treating or ameliorating cancer by preventing or delaying drug resistance, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof.

Furthermore, the present invention provides the use of the compound having the formula (I) as defined herein, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, for the manufacture of a medicament for the treatment or amelioration of cancer.

Furthermore, the present invention provides the use of the compound having the formula (I) as defined herein, optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, for the manufacture of a medicament for the treatment or amelioration of cancer by preventing or delaying drug resistance.

The type of cancer that can be treated with the compounds and compositions of the present invention is typically selected from non-melanoma skin cancer, esophagogastric adenocarcinoma, glioblastoma, bladder cancer, bladder urothelial carcinoma, esophagogastric cancer, melanoma, non-small cell lung cancer, endometrial cancer, cervical adenocarcinoma, esophageal squamous cell carcinoma, breast cancer, head and neck squamous cell carcinoma, germ cell tumor, small cell lung cancer, ovarian cancer, soft tissue sarcoma, hepatocellular carcinoma, colorectal adenocarcinoma, cervical squamous cell carcinoma, cholangiocarcinoma, prostate cancer, upper tract urothelial carcinoma, diffuse glioma, colorectal cancer, ampullary carcinoma, adrenocortical carcinoma, head and neck cancer, renal clear cell carcinoma, hepatobiliary cancer, glioma, non-Hodgkin lymphoma, mesothelioma, salivary gland cancer, renal non-clear cell carcinoma, miscellaneous neuroepithelial tumor, pheochromocytoma, thymic tumor, multiple myeloma, renal cell carcinoma, bone cancer, pancreatic cancer, leukemia, peripheral nervous system tumors, thyroid cancer, B-lymphoblast leukemia, monoclonal B-cell lymphocytosis, lymphoma, hairy cell leukemia, acute myeloid leukemia, Wilms tumor in particular melanoma and non-small cell lung cancer, in particular melanoma and non-small cell lung cancer. The above diseases typically exhibit a mutation incidence of more than 3% of RTKs (EGFR, ERBB2, ERBB3, ERBB4, PDGFA, PDGFB, PDGFRA, PDGFRB, KIT, FGF1, FGFR1, IGF1, IGFR, VEGFA, VEGFB, KDR) and/or MAPK pathway members (KRAS, HRAS, BRAF, RAF1, MAP3K1/2/3/4/5, MAP2K1/2/3/4/5, MAPK1/3/4/6/7/8/9/12/14, DAB, RASSF1, RAB25).

In a further embodiment, the tumor may be adrenocortical carcinoma, astrocytoma, basal cell carcinoma, carcinoid, cardiac, cholangiocarcinoma, chordoma, chronic myeloproliferative neoplasms, craniopharyngioma, ductal carcinoma in situ, ependymoma, intraocular melanoma, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gestational trophoblastic disease, glioma, histiocytosis, leukemia {e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, myelogenous leukemia, myeloid leukemia), lymphoma (e.g., Burkitt lymphoma [non-Hodgkin lymphoma], cutaneous T-cell lymphoma, Hodgkin lymphoma, mycosis fungoides, Sezary syndrome, AIDS-related lymphoma, follicular lymphoma, diffuse large B-cell lymphoma), melanoma, merkel cell carcinoma, mesothelioma, myeloma (e.g., multiple myeloma), myelodysplastic syndrome, papillomatosis, paraganglioma, pheochromacytoma, pleuropulmonary blastoma, retinoblastoma, sarcoma (e.g., Ewing sarcoma, Kaposi sarcoma, osteosarcoma, rhabdomyosarcoma, uterine sarcoma, vascular sarcoma), Wilms' tumor, and/or cancer of the adrenal cortex, anus, appendix, bile duct, bladder, bone, brain, breast, bronchus, central nervous system, cervix, colon, endometrium, esophagus, eye, fallopian tube, gall bladder, gastrointestinal tract, germ cell, head and neck, heart, intestine, kidney (e.g., Wilms' tumor), larynx, liver, lung (e.g., non-small cell lung cancer, small cell lung cancer), mouth, nasal cavity, oral cavity, ovary, pancreas, rectum, skin, stomach, testes, throat, thyroid, penis, pharynx, peritoneum, pituitary, prostate, rectum, salivary gland, ureter, urethra, uterus, vagina, vulva, or acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes, embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, head and neck cancer, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer (NSCLC), oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, s)movioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, or Wilms' tumor.

The tumour may also be a tumour which is dependent on androgen receptor (AR) signaling or which overexpresses c-Myc, or in cancers in which there is activation of CBP and/or p300 function. The cancers that can be treated include those which express AR or are otherwise associated with AR, those that harbour loss of function mutations in CBP or p300 and those which have activated CBP and/or p300. Cancers that may be treated include, but are not restricted to, prostate cancer, breast cancer, bladder cancer, lung cancer, lymphoma and leukaemia. The prostate cancer may be, for instance, castration-resistant prostate cancer (CRPC). The lung cancer may be, for instance, non-small cell lung cancer or small cell lung cancer.

The compounds provided herein may be administered as compounds per se or may be formulated as medicaments. The medicaments/pharmaceutical compositions may optionally comprise one or more pharmaceutically acceptable excipients, such as carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants, and/or solubility enhancers, or any combination thereof.

In particular, the pharmaceutical compositions may comprise one or more solubility enhancers, such as, e.g., poly(ethylene glycol), including poly(ethylene glycol) having a molecular weight in the range of about 200 to about 5,000 Da, ethylene glycol, propylene glycol, non-ionic surfactants, tyloxapol, polysorbate 80, macrogol-15-hydroxystearate, phospholipids, lecithin, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, cyclodextrins, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxyethyl-γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, sulfobutylether-γ-cyclodextrin, glucosyl-α-cyclodextrin, glucosyl-β-cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, carboxyalkyl thioethers, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, vinyl acetate copolymers, vinyl pyrrolidone, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or any combination thereof.

The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavoring agents, coloring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

The pharmaceutical compositions can be formulated by techniques known to the person skilled in the art, such as the techniques published in “Remington: The Science and Practice of Pharmacy”, Pharmaceutical Press, 22^(nd) edition. The pharmaceutical compositions can be formulated as dosage forms for oral, parenteral, such as intramuscular, intravenous, subcutaneous, intradermal, intraarterial, intracardial, rectal, nasal, topical, aerosol or vaginal administration. Dosage forms for oral administration include coated and uncoated tablets, soft gelatin capsules, hard gelatin capsules, lozenges, troches, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewing tablets and effervescent tablets. Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions and powders and granules for reconstitution. Emulsions are a preferred dosage form for parenteral administration. Dosage forms for rectal and vaginal administration include suppositories and ovula. Dosage forms for nasal administration can be administered via inhalation and insufflation, for example by a metered inhaler. Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems.

The compounds of formula (I) or the above described pharmaceutical compositions comprising a compound of formula (I) may be administered to a subject by any convenient route of administration, whether systemically/peripherally or at the site of desired action, including but not limited to one or more of: oral (e.g., as a tablet, capsule, or as an ingestible solution), topical (e.g., transdermal, intranasal, ocular, buccal, and sublingual), parenteral (e.g., using injection techniques or infusion techniques, and including, for example, by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, or intrasternal by, e.g., implant of a depot, for example, subcutaneously or intramuscularly), pulmonary (e.g., by inhalation or insufflation therapy using, e.g., an aerosol, e.g., through mouth or nose), gastrointestinal, intrauterine, intraocular, subcutaneous, ophthalmic (including intravitreal or intracameral), rectal, and vaginal.

If said compounds or pharmaceutical compositions are administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracardially, intracranially, intramuscularly or subcutaneously administering the compounds or pharmaceutical compositions, and/or by using infusion techniques. For parenteral administration, the compounds are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Said compounds or pharmaceutical compositions can also be administered orally in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavoring or coloring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

Alternatively, said compounds or pharmaceutical compositions can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch.

Said compounds or pharmaceutical compositions may also be administered by sustained release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.

Sustained-release matrices include, e.g., polylactides (see, e.g., U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly(2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP133988). Sustained-release pharmaceutical compositions also include liposomally entrapped compounds. Liposomes containing a compound of the present invention can be prepared by methods known in the art, such as, e.g., the methods described in any one of: DE3218121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. (USA) 77:4030-4034 (1980); EP0052322; EP0036676; EP088046; EP0143949; EP0142641; JP 83-118008; U.S. Pat. Nos. 4,485,045; 4,544,545; and EP0102324.

Said compounds or pharmaceutical compositions may also be administered by the pulmonary route, rectal routes, or the ocular route. For ophthalmic use, they can be formulated as micronized suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

It is also envisaged to prepare dry powder formulations of the compounds of formula (I) for pulmonary administration, particularly inhalation. Such dry powders may be prepared by spray drying under conditions which result in a substantially amorphous glassy or a substantially crystalline bioactive powder. Accordingly, dry powders of the compounds of the present invention can be made according to the emulsification/spray drying process disclosed in WO 99/16419 or WO 01/85136. Spray drying of solution formulations of the compounds of the present invention can be carried out, e.g., as described generally in the “Spray Drying Handbook”, 5th ed., K. Masters, John Wiley & Sons, Inc., NY (1991), and in WO 97/41833 or WO 03/053411.

For topical application to the skin, said compounds or pharmaceutical compositions can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, 2-octyldodecanol, benzyl alcohol and water.

The present invention thus relates to the compounds or the pharmaceutical compositions provided herein, wherein the corresponding compound or pharmaceutical composition is to be administered by any one of: an oral route; topical route, including by transdermal, intranasal, ocular, buccal, or sublingual route; parenteral route using injection techniques or infusion techniques, including by subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, intrasternal, intraventricular, intraurethral, or intracranial route; pulmonary route, including by inhalation or insufflation therapy; gastrointestinal route; intrauterine route; intraocular route; subcutaneous route; ophthalmic route, including by intravitreal, or intracameral route; rectal route; or vaginal route. Particularly preferred routes of administration of the compounds or pharmaceutical compositions of the present invention are oral forms of administration.

Typically, a physician will determine the dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual subject may be varied and will depend upon a variety of factors including the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual subject undergoing therapy.

A proposed, yet non-limiting dose of the compounds according to the invention for administration to a human (of approximately 70 kg body weight) may be 0.05 to 2000 mg, preferably 0.1 mg to 1000 mg, of the active ingredient per unit dose. The unit dose may be administered, e.g., 1, 2, 3 or more times per day. The unit dose may also be administered 1 to 7 times per week, e.g., with one, two or more administration(s) per day. It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient/subject as well as the severity of the condition to be treated. The precise dose and also the route of administration will ultimately be at the discretion of the attendant physician.

The compounds of formula (I) can be used in combination with other therapeutic agents, including in particular other anticancer agents. When a compound of the invention is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. The combination of a compound of the present invention with a second therapeutic agent may comprise the administration of the second therapeutic agent simultaneously/concomitantly or sequentially/separately with the compound of the invention.

Preferably, the second therapeutic agent to be administered in combination with a compound of this invention is an anticancer drug. The anticancer drug to be administered in combination with a compound of formula (I) according to the present invention may, e.g., be a androgen receptor (AR) antagonists, a receptor tyrosine kinase (RTK) inhibitor, a MAP kinase inhibitor, a checkpoint kinase inhibitor, and/or, in general, an agent used in immunotherapy of cancer.

For example, many cancers are known to involve AR, BRAF, MEK, ERK and/or EGFR expression. Thus, within the present invention the second therapeutic agent to be administered in combination with a compound of this invention, may be an inhibitor of AR, BRAF, MEK, ERK and/or EGFR. In particular not limiting embodiments:

-   -   i) said andogren receptor antagonist is enzalutamide or the         complementary CYP17A1 (17 alpha-hydroxylase/C17,20 lyase)         inhibitor abiraterone     -   ii) said BRAFi is vemurafenib, dabrafenib, encorafenib, LGX818,         PLX4720, TAK-632, MLN2480, SB590885, XL281, BMS-908662, PLX3603,         R05185426, GSK2118436 or RAF265,     -   iii) said MEKi is AZD6244, trametinib, selumetinib, cobimetinib,         binimetinib, MEK162, R05126766, GDC-0623, PD 0325901, CI-1040,         PD-035901, hypothemycin or TAK-733,     -   iv) said ERKi is ulixertinib, corynoxeine, SCH772984, XMD8-92,         FR 180204, GDC-0994, ERK5-IN-1, DEL-22379, BIX 02189, ERK         inhibitor (CAS No. 1049738-54-6), ERK inhibitor III (CAS No.         331656-92-9), GDC-0994, honokiol, LY3214996, CC-90003, deltonin,         VRT752271, TIC10, astragaloside IV, XMD8-92, VX-11e, mogrol, or         VTX11e, and/or     -   v) said EGFRi is cetuximab, panitumumab, zalutumumab,         nimotuzumab, matuzumab, gefitinib, erlotinib, lapatinib,         neratinib, vandetanib, necitumumab, osimertinib, afatinib,         dacomitinib, AP26113, EGFR inhibitor (CAS No. 879127-07-8),         EGFR/ErbB-2/ErbB-4 Inhibitor (CAS No. 881001-19-0), EGFR/ErbB-2         Inhibitor (CAS No. 179248-61-4), EGFR inhibitor II (BIBX 1382,         CAS No. 196612-93-8), EGFR inhibitor III (CAS No. 733009-42-2),         EGFR/ErbB-2/ErbB-4 Inhibitor II (CAS No. 944341-54-2) or         PKCβII/EGFR Inhibitor (CAS No. 145915-60-2).

In particular embodiments of the invention, the second therapeutic agent administered in combination with a compound of the invention may be an immunotherapy agent, more particular immuno-oncology agent, such as, e.g. an agent targeting CD52, PD-L1, CTLA4, CD20, or PD-1. Agents that may be used in combination with a compound of the present invention include, for example, alemtuzumab, atezolizumab, ipilimumab, nivolumab, ofatumumab, pembrolizumab, rituximab.

The second therapeutic agent may also be selected from: a tumor angiogenesis inhibitor (for example, a protease inhibitor, an epidermal growth factor receptor kinase inhibitor, or a vascular endothelial growth factor receptor kinase inhibitor); a cytotoxic drug (for example, an antimetabolite, such as purine and pyrimidine analogue antimetabolites); an antimitotic agent (for example, a microtubule stabilizing drug or an antimitotic alkaloid); a platinum coordination complex; an anti-tumor antibiotic; an alkylating agent (for example, a nitrogen mustard or a nitrosourea); an endocrine agent (for example, an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analogue); or a compound that targets an enzyme or receptor that is overexpressed and/or otherwise involved in a specific metabolic pathway that is misregulated in the tumor cell (for example, ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors (such as serine, threonine and tyrosine kinase inhibitors (for example, Abelson protein tyrosine kinase)) and the various growth factors, their receptors and corresponding kinase inhibitors (such as epidermal growth factor receptor (EGFR) kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors)); methionine, aminopeptidase inhibitors, proteasome inhibitors, cyclooxygenase inhibitors (for example, cyclooxygenase-1 or cyclooxygenase-2 inhibitors), topoisomerase inhibitors (for example, topoisomerase I inhibitors or topoisomerase II inhibitors), and poly ADP ribose polymerase inhibitors (PARP inhibitors).

An alkylating agent which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a nitrogen mustard (such as cyclophosphamide, mechlorethamine (chlormethine), uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, or trofosfamide), a nitrosourea (such as carmustine, streptozocin, fotemustine, lomustine, nimustine, prednimustine, ranimustine, or semustine), an alkyl sulfonate (such as busulfan, mannosulfan, or treosulfan), an aziridine (such as hexamethylmelamine (altretamine), triethylenemelamine, ThioTEPA (N,N′N′-triethylenethiophosphoramide), carboquone, or triaziquone), a hydrazine (such as procarbazine), a triazene (such as dacarbazine), or an imidazotetrazines (such as temozolomide).

A platinum coordination complex which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, or triplatin tetranitrate.

A cytotoxic drug which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, an antimetabolite, including folic acid analogue antimetabolites (such as aminopterin, methotrexate, pemetrexed, or raltitrexed), purine analogue antimetabolites (such as cladribine, clofarabine, fludarabine, 6-mercaptopurine (including its prodrug form azathioprine), pentostatin, or 6-thioguanine), and pyrimidine analogue antimetabolites (such as cytarabine, decitabine, 5-fluorouracil (including its prodrug forms capecitabine and tegafur), floxuridine, gemcitabine, enocitabine, or sapacitabine).

An antimitotic agent which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a taxane (such as docetaxel, larotaxel, ortataxel, paclitaxel/taxol, or tesetaxel), a Vinca alkaloid (such as vinblastine, vincristine, vinflunine, vindesine, or vinorelbine), an epothilone (such as epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, or epothilone F) or an epothilone B analogue (such as ixabepilone/azaepothilone B).

An anti-tumor antibiotic which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, an anthracycline (such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, or zorubicin), an anthracenedione (such as mitoxantrone, or pixantrone) or an anti-tumor antibiotic isolated from Streptomyces (such as actinomycin (including actinomycin D), bleomycin, mitomycin (including mitomycin C), or plicamycin).

A tyrosine kinase inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, afatinib, acalabrutinib, alectinib, apatinib, axitinib, bosutinib, cabozantinib, canertinib, crenolanib, cediranib, crizotinib, damnacanthal, dasatinib, dacomitinib, entospletinib, entrectinib, erlotinib, foretinib, fostamatinib, gilteritinib, glesatinib, gefitinib, ibrutinib, icotinib, imatinib, linafanib, lapatinib, lestaurtinib, motesanib, mubritinib, nintedanib, nilotinib, ONT-380, osimertinib, pazopanib, quizartinib, regorafenib, rociletinib, radotinib, savolitinib, sitravatinib, semaxanib, sorafenib, sunitinib, savolitinib, sitravatinig, tesevatinib, vatalanib, vemurafenib or vandetanib.

A topoisomerase-inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, a topoisomerase I inhibitor (such as irinotecan, topotecan, camptothecin, belotecan, rubitecan, or lamellarin D) or a topoisomerase II inhibitor (such as amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin).

A PARP inhibitor which can be used as an anticancer drug in combination with a compound of the present invention may be, for example, BMN-673, olaparib, rucaparib, veliparib, CEP 9722, MK 4827, BGB-290, or 3-aminobenzamide.

Further anticancer drugs may also be used in combination with a compound of the present invention. The anticancer drugs may comprise biological or chemical molecules, like TNF-related apoptosis-inducing ligand (TRAIL), tamoxifen, amsacrine, bexarotene, estramustine, irofulven, trabectedin, cetuximab, panitumumab, tositumomab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, alvocidib, seliciclib, aminolevulinic acid, methyl aminolevulinate, efaproxiral, porfimer sodium, talaporfin, temoporfin, verteporfin, alitretinoin, tretinoin, anagrelide, arsenic trioxide, atrasentan, bortezomib, carmofur, celecoxib, demecolcine, elesclomol, elsamitrucin, etoglucid, lonidamine, lucanthone, masoprocol, mitobronitol, mitoguazone, mitotane, oblimersen, omacetaxine, sitimagene, ceradenovec, tegafur, testolactone, tiazofurine, tipifarnib, vorinostat, or iniparib.

Also biological drugs, like antibodies, antibody fragments, antibody constructs (for example, single-chain constructs), and/or modified antibodies (like CDR-grafted antibodies, humanized antibodies, “full humanized” antibodies, etc.) directed against cancer or tumor markers/factors/cytokines involved in proliferative diseases can be employed in co-therapy approaches with the compounds of the invention. Antibodies may, for example, be immuno-oncology antibodies, such as ado-trastuzumab, alemtuzumab, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximab, capromab, cetuximab, ipilimumab, necitumumab, nivolumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab, trastuzumab, or rituximab.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation. The individual components of such combinations may be administered either sequentially or simultaneously/concomitantly in separate or combined pharmaceutical formulations by any convenient route. When administration is sequential, either the compound of the present invention (i.e., the compound of formula (I) or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof) or the second therapeutic agent may be administered first.

When administration is simultaneous, the combination may be administered either in the same pharmaceutical composition or in different pharmaceutical compositions. When combined in the same formulation, it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately, they may be provided in any convenient formulation.

The compounds of formula (I) can also be administered in combination with physical therapy, such as radiotherapy. Radiotherapy may commence before, after, or simultaneously with administration of the compounds of the invention. For example, radiotherapy may commence 1-10 minutes, 1-10 hours or 24-72 hours after administration of the compounds. Yet, these time frames are not to be construed as limiting. The subject is exposed to radiation, preferably gamma radiation, whereby the radiation may be provided in a single dose or in multiple doses that are administered over several hours, days and/or weeks. Gamma radiation may be delivered according to standard radiotherapeutic protocols using standard dosages and regimens.

The present invention thus relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, for use in the treatment or prevention of cancer, wherein the compound or the pharmaceutical composition is to be administered in combination with an anticancer drug and/or in combination with radiotherapy.

Yet, the compounds of formula (I) can also be used in monotherapy, particularly in the monotherapeutic treatment or prevention of cancer (i.e., without administering any other anticancer agents until the treatment with the compound(s) of formula (I) is terminated). Accordingly, the invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, or a pharmaceutical composition comprising any of the aforementioned entities in combination with a pharmaceutically acceptable excipient, for use in the monotherapeutic treatment or prevention of cancer.

The subject or patient, such as the subject in need of treatment or prevention, may be an animal (e.g., a non-human animal), a vertebrate animal, a mammal, a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), a murine (e.g., a mouse), a canine (e.g., a dog), a feline (e.g., a cat), a porcine (e.g., a pig), an equine (e.g., a horse), a primate, a simian (e.g., a monkey or ape), a monkey (e.g., a marmoset, a baboon), an ape (e.g., a gorilla, chimpanzee, orang-utan, gibbon), or a human. In the context of this invention, it is particularly envisaged that animals are to be treated which are economically, agronomically or scientifically important. Scientifically important organisms include, but are not limited to, mice, rats, and rabbits. Lower organisms such as, e.g., fruit flies like Drosophila melagonaster and nematodes like Caenorhabditis elegans may also be used in scientific approaches. Non-limiting examples of agronomically important animals are sheep, cattle and pigs, while, for example, cats and dogs may be considered as economically important animals. Preferably, the subject/patient is a mammal; more preferably, the subject/patient is a human or a non-human mammal (such as, e.g., a guinea pig, a hamster, a rat, a mouse, a rabbit, a dog, a cat, a horse, a monkey, an ape, a marmoset, a baboon, a gorilla, a chimpanzee, an orang-utan, a gibbon, a sheep, cattle, or a pig); most preferably, the subject/patient is a human.

The term “treatment” of a disorder or disease as used herein (e.g., “treatment” of cancer) is well known in the art. “Treatment” of a disorder or disease implies that a disorder or disease is suspected or has been diagnosed in a patient/subject. A patient/subject suspected of suffering from a disorder or disease typically shows specific clinical and/or pathological symptoms which a skilled person can easily attribute to a specific pathological condition (i.e., diagnose a disorder or disease).

The “treatment” of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease (e.g., no deterioration of symptoms) or a delay in the progression of the disorder or disease (in case the halt in progression is of a transient nature only). The “treatment” of a disorder or disease may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the subject/patient suffering from the disorder or disease. Accordingly, the “treatment” of a disorder or disease may also refer to an amelioration of the disorder or disease, which may, e.g., lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease. Such a partial or complete response may be followed by a relapse. It is to be understood that a subject/patient may experience a broad range of responses to a treatment (such as the exemplary responses as described herein above). The treatment of a disorder or disease may, inter alia, comprise curative treatment (preferably leading to a complete response and eventually to healing of the disorder or disease) and palliative treatment (including symptomatic relief).

The “amelioration” of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease.

The term “prevention” of a disorder or disease as used herein (e.g., “prevention” of cancer) is also well known in the art. For example, a patient/subject suspected of being prone to suffer from a disorder or disease may particularly benefit from a prevention of the disorder or disease. The subject/patient may have a susceptibility or predisposition for a disorder or disease, including but not limited to hereditary predisposition. Such a predisposition can be determined by standard methods or assays, using, e.g., genetic markers or phenotypic indicators. It is to be understood that a disorder or disease to be prevented in accordance with the present invention has not been diagnosed or cannot be diagnosed in the patient/subject (for example, the patient/subject does not show any clinical or pathological symptoms). Thus, the term “prevention” comprises the use of a compound of the present invention before any clinical and/or pathological symptoms are diagnosed or determined or can be diagnosed or determined by the attending physician.

It is to be understood that the present invention specifically relates to each and every combination of features and embodiments described herein, including any combination of general and/or preferred features/embodiments. In particular, the invention specifically relates to each combination of meanings (including general and/or preferred meanings) for the various groups and variables comprised in formula (I).

In this specification, a number of documents including patent applications and scientific literature are cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

The present invention may be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention.

Examples General Experimental Methods LCMS Methods:

Method A: Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315D, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800, ELSD Alltech 3300 gas flow 1.5 ml/min, gas temp: 40° C.; column: Waters XSelect™ 018, 30×2.1 mm, 3.5μ, Temp: 35° C., Flow: 1 mL/min, Gradient: t₀=5% A, t_(1.6min)=98% A, t_(3min)=98% A, Posttime: 1.3 min, Eluent A: 0.1% formic acid in acetonitrile, Eluent B: 0.1% formic acid in water). Method B: Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315D, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800, ELSD Alltech 3300 gas flow 1.5 ml/min, gas temp: 40° C.; column: Waters XSelect™ 018, 50×2.1 mm, 3.5μ, Temp: 35° C., Flow: 0.8 mL/min, Gradient: t₀=5% A, t_(3.5 min)=98% A, t₆ min=98% A, Posttime: 2 min; Eluent A: 0.1% formic acid in acetonitrile, Eluent B: 0.1% formic acid in water). Method C: Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315C, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800; column: Waters XSelect™ CSH C18, 30×2.1 mm, 3.5μ, Temp: 25° C., Flow: 1 mL/min, Gradient: to =5% A, t_(1.6min)=98% A, t_(3min)=98% A, Posttime: 1.3 min. Eluent A: 95% acetonitrile+5% 10 mM ammoniumbicarbonate in water in acetonitrile, Eluent B: 10 mM ammoniumbicarbonate in water (pH=9.5). Method D: Apparatus: Agilent 1260 Bin. Pump: G1312B, degasser; autosampler, ColCom, DAD: Agilent G1315C, 220-320 nm, MSD: Agilent LC/MSD G6130B ESI, pos/neg 100-800; column: Waters XSelect™ CSH C18, 50×2.1 mm, 3.5μ, Temp: 25° C., Flow: 0.8 mL/min, Gradient: t₀=5% A, t_(3.5 min)=98% A, t_(3min)=98% A, Posttime: 2 min, Eluent A: 95% acetonitrile+5% 10 mM ammoniumbicarbonate in water in acetonitrile, Eluent B: 10 mM ammoniumbicarbonate in water (pH=9.5).

UPLC Methods:

Method A: Apparatus: Agilent Infinity II; Bin. Pump: G7120A, Multisampler, VTC, DAD: Agilent G7117B, 220-320 nm, PDA: 210-320 nm, MSD: Agilent G6135B ESI, pos/neg 100-1000, ELSD G7102A: Evap 40° C., Neb 50° C., gasflow 1.6 ml/min, Column: Waters XSelect CSH C18, 50×2.1 mm, 2.5 μm Temp: 25° C., Flow: 0.6 mL/min, Gradient: t₀=5% B, t₂ min=98% B, t_(2.7 min)=98% B, Post time: 0.3 min, Eluent A: 10 mM ammonium bicarbonate in water (pH=9.5), Eluent B: acetonitrile. Method B: Apparatus: Agilent Infinity II; Bin. Pump: G7120A, Multisampler, VTC, DAD: Agilent G7117B, 220-320 nm, PDA: 210-320 nm, MSD: Agilent G6135B ESI, pos/neg 100-1000, ELSD G7102A: Evap 40° C., Neb 40° C., gasflow 1.6 ml/min, Column: Waters XSelect™ CSH C18, 50×2.1 mm, 2.5 μm Temp: 40° C., Flow: 0.6 mL/min, Gradient: t₀=5% B, t₂ min=98% B, t_(2.7 min)=98% B, Post time: 0.3 min, Eluent A: 0.1% formic acid in water, Eluent B: 0.1% formic acid in acetonitrile.

GCMS Methods:

Method A: Instrument: GC: Agilent 6890N G1530N and MS: MSD 5973 G2577A, EI-positive, Det.temp.: 280° C. Mass range: 50-550; Column: RXi-5MS 20 m, ID 180 μm, df 0.18 μm; Average velocity: 50 cm/s; Injection vol: 1 μl; Injector temp: 250° C.; Split ratio: 100/1; Carrier gas: He; Initial temp: 100° C.; Initial time: 1.5 min; Solvent delay: 1.0 min; Rate 75° C./min; Final temp 250° C.; Hold time 4.3 min.

Chiral LC:

Method A: (apparatus: Agilent 1260 Quart. Pump: G1311C, autosampler, ColCom, DAD: Agilent G4212B, 220-320 nm, column: Chiralcel® OD-H 250×4.6 mm, Temp: 25° C., Flow: 1 mL/min, Isocratic: 90/10, time: 30 min, Eluent A: heptane, Eluent B: ethanol).

Preparative Reversed Phase Chromatography:

Method A: Instrument type: Reveleris™ prep MPLC; Column: Phenomenex LUNA C18 (150×25 mm, 10p); Flow: 40 mL/min; Column temp: room temperature; Eluent A: 0.1% (v/v) formic acid in water, Eluent B: 0.1% (v/v) formic acid in acetonitrile; Gradient: t=0 min 5% B, t=1 min 5% B, t=2 min 30% B, t=17 min 70% B, t=18 min 100% B, t=23 min 100% B; Detection UV: 220/254 nm. Appropriate fractions combined and lyophilised. Method B: Instrument type: Reveleris™ prep MPLC; Column: Waters XSelect™ CSH C18 (145×25 mm, 10p); Flow: 40 mL/min; Column temp: room temperature; Eluent A: 10 mM ammoniumbicarbonate in water pH=9.0); Eluent B: 99% acetonitrile+1% 10 mM ammoniumbicarbonate in water; Gradient: t=0 min 5% B, t=1 min 5% B, t=2 min 30% B, t=17 min 70% B, t=18 min 100% B, t=23 min 100% B; Detection UV: 220/254 nm. Appropriate fractions combined and lyophilised.

Chiral (Preparative) SFC

Method A: (Column: SFC instrument modules: Waters Prep100q SFC System, PDA: Waters 2998, Fraction Collector: Waters 2767; Column: Phenomenex Lux Amylose-1 (250×20 mm, 5 μm), column temp: 35° C.; flow: 100 ml/min; ABPR: 170 bar; Eluent A: CO₂, Eluent B: 20 mM ammonia in methanol; isocratic 10% B, time: 30 min, detection: PDA (210-320 nm); fraction collection based on PDA). Method B: (Column: SFC instrument modules: Waters Prep100q SFC System, PDA: Waters 2998, Fraction Collector: Waters 2767; Column: Phenomenex Lux Cellulose-1 (250×20 mm, 5 μm), column temp: 35° C.; flow: 100 ml/min; ABPR: 170 bar; Eluent A: CO₂, Eluent B: 20 mM ammonia in methanol; isocratic 10% B, time: 30 min, detection: PDA (210-320 nm); fraction collection based on PDA). Method C: (Column: SFC instrument modules: Waters Prep100q SFC System, PDA: Waters 2998; Column: Chiralpak IC (100×4.6 mm, 5 μm), column temp: 35° C.; flow: 2.5 mL/min; ABPR: 170 bar; Eluent A: CO₂, Eluent B: methanol with 20 mM ammonia; t=0 min 5% B, t=5 min 50% B, t=6 min 50% B, detection: PDA (210-320 nm); fraction collection based on PDA).

Starting Materials

Standard reagents and solvents were obtained at highest commercial purity and used as such, specific reagents purchased are described below.

Compound name Supplier Purity CAS tert-butyl 3-cyanopiperidine-1- Combi- 97% 91419-53-3 carboxylate Blocks Raney ®-Nickel, 50% slurry Acros 50% 7440-02-0 in water Organics tetrakis(triphenyl- Sigma- 98% 14221-01-3 phosphine)palladium(0) Aldrich tris(dibenzyl- Sigma- 97% 51364-51-3 ideneacetone)dipalladium(0) Aldrich 1,1′- Sigma- — 72287-26-4 bis(diphenylphosphino)ferrocene- Aldrich palladium(II) dichloride Xphos Sigma- 97% 564483-18-7 Aldrich bis(triphenyl- Fluorochem 98% 13965-03-2 phosphine)palladium(II) dichloride 2-(tributylstannyl)-pyrimidine Sigma- 95% 153435-63-3 Aldrich 10% palladium on activated ACROS — 7440-05-3 carbon

Synthetic Procedures for Key Intermediates Intermediate 1: synthesis of 1-(5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one

To a solution of methyl 6-methylnicotinate (100 g, 662 mmol) in acetic acid (250 mL) in a 1 L steel autoclave, platinum (IV) oxide (0.5 g, 2.202 mmol) was added after which the reaction mixture was stirred under 10 bar hydrogen atmosphere at 60° C. Rapid hydrogen consumption was observed and the autoclave was refilled several times until hydrogen consumption stopped and the reduction was complete. The mixture was cooled to room temperature and filtrated over Celite. The filtrate was concentrated to afford methyl 6-methylpiperidine-3-carboxylate acetate as a mixture of diastereoisomers (143.8 g, 100%) that was used as such in the next step. GCMS (Method A): t_(R) 2.40 (80%) and 2.48 min (20%), MS (EI) 157.1 (M)⁺, 142.1 (M-Me)⁺. To a solution of methyl 6-methylpiperidine-3-carboxylate acetate (53 g, 244 mmol) in a mixture of water (500 mL) and dichloromethane (500 mL), sodium bicarbonate (82 g, 976 mmol) was added carefully (effervescence!!) after which acetic anhydride (29.9 g, 293 mmol) was added slowly. The reaction mixture was stirred at room temperature for 2 hours. The organic layer was separated, dried over sodium sulfate, filtered and concentrated in vacuo to afford methyl 1-acetyl-6-methylpiperidine-3-carboxylate (49 g, 100%) as a yellow oil. ¹H-NMR (400 MHz, Chloroform-d) mixture of diastereoisomers and rotamers δ 5.01-4.86 (m, 0.5H), 4.82-4.70 (m, 0.5H), 4.19-4.04 (m, 0.5H), 3.86-3.76 (m, 0.5H), 3.75-3.65 (m, 3H), 3.37-3.14 (m, 0.5H), 2.81-2.67 (m, 0.5H), 2.49-2.32 (m, 1H), 2.19-2.03 (m, 3H), 2.02-1.89 (m, 1H), 1.89-1.53 (m, 3H), 1.30-1.07 (m, 3H). A solution of methyl 1-acetyl-6-methylpiperidine-3-carboxylate (49 g, 246 mmol) in ammonia in methanol (7N, 500 mL, 3.5 mol) was stirred in a pressure vessel at 120° C. for 40 hours. The mixture was cooled to room temperature and concentrated to afford a light yellow solid. This solid was dissolved in dichloromethane and filtered over a plug of silica. The filtrate was concentrated to afford 1-acetyl-6-methylpiperidine-3-carboxamide as an off white solid that was used as such in the next step. ¹H-NMR (400 MHz, DMSO-d6) mixture of diastereoisomers and rotamers δ 12.32-11.66 (m, 1H), 11.53-10.91 (m, 1H), 4.44-4.21 (m, 1H), 4.06-3.81 (m, 1H), 3.60 (s, 3H), 3.14-2.92 (m, 1H), 2.60-2.52 (m, 1H), 1.92-1.74 (m, 2H), 1.63-1.48 (m, 2H), 1.12 (d, J=6.9 Hz, 3H). A solution of 1-acetyl-6-methylpiperidine-3-carboxamide (266 mmol) from the previous step in phosphorus oxychloride (500 mL, 5.37 mol) was stirred at room temperature for 16 hours. The reaction mixture was evaporated in vacuo affording a thick oil. This oil was co-evaporated twice with toluene and carefully partitioned between cold saturated sodium carbonate (effervescence!) and ethyl acetate. The organic layer was separated from the basic water layer, dried on sodium sulfate, filtered and concentrated in vacuo to afford the product as a thick oil that solidified upon standing. The crude was dissolved in dichloromethane and filtered over a plug of silica (eluted with 10% methanol in dichloromethane). This afforded 1-acetyl-6-methylpiperidine-3-carbonitrile (28 g, 63%) as an oil that solidified upon standing. ¹H-NMR (400 MHz, DMSO-d6) mixture of diastereoisomers and rotamers δ 5.16-4.92 (m, 0.5H), 4.88-4.75 (m, 0.5H), 4.47-4.27 (m, 0.5H), 4.15-3.99 (m, 0.5H), 3.74-3.63 (m, 0.3H), 3.59-3.46 (m, 0.3H), 3.31-3.07 (m, 1H), 3.07-2.93 (m, 0.4H), 2.91-2.77 (m, 0.4H), 2.64-2.57 (m, 1.2H), 2.56-2.48 (m, 1.4H), 2.31-1.64 (m, 4H), 1.49-1.39 (m, 1.5H), 1.39-1.28 (m, 1.5H); GCMS (Method A): t_(R) 3.78 (63%) and 3.89 min (378%), MS (EI) 166.1 (M)⁺. To a solution of 1-acetyl-6-methylpiperidine-3-carbonitrile (23 g, 138 mmol) in ethanol (300 ml), hydroxylamine solution (50% in water, 25.4 mL, 415 mmol) was added after which the reaction mixture was stirred at reflux for 16 hours. The reaction mixture was concentrated and co-evaporated with ethyl acetate three times to dryness to afford 1-acetyl-N-hydroxy-6-methylpiperidine-3-carboximidamide as a sticky solid. LCMS (Method A): t_(R) 0.13 min, 100%, MS (ESI) 200.2 (M+H)⁺. Assuming quantitative yield, the product was used as such in the next step. To a solution of 1-acetyl-N-hydroxy-6-methylpiperidine-3-carboximidamide (23 g, 138 mmol) from the previous step in ethanol (500 mL), acetic acid (23.79 mL, 416 mmol) and 50% Raney®-Nickel slurry in water (5 mL) were added after which the reaction mixture was stirred under hydrogen atmosphere for 2 days at 50° C. The mixture was filtered over Celite, washed with some ethanol and concentrated to afford 70 g of a thick oil. This was co-evaporated twice with ethyl acetate and extensively dried in vacuo to afford 1-acetyl-6-methylpiperidine-3-carboximidamide acetate (33 g, 98%) as a greenish yellow oil that was used as such in the next step. LCMS (Method A): t_(R) 0.14 min, 90%, MS (ESI) 184.1 (M+H)⁺. To a solution of sodium (18.14 g, 789 mmol) in dry methanol under nitrogen atmosphere (60 mL) 1-acetyl-6-methylpiperidine-3-carboximidamide acetate (32 g, 132 mmol) and dimethyl malonate (26.1 g, 197 mmol) were added, after which the reaction mixture was stirred at 50° C. for 16 hours. The reaction mixture was concentrated, taken up in water (300 mL), acidified to pH 4 using 6N hydrochloric acid and allowed to precipitate. The precipitate was filtered off to afford 1-(5-(4,6-dihydroxypyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one as a yellow solid (10.4 g, 31%) that was used as such in the next step. A suspension of 1-(5-(4,6-dihydroxypyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (10.4 g, 41.4 mmol) in phosphorus oxychloride (200 mL, 2146 mmol) was stirred at 50° C. The solids slowly dissolved after approximately 3 hours. After 5 hours, the reaction mixture was concentrated in vacuo and co-evaporated with toluene twice. The remaining oil was carefully quenched with ice and neutralised with saturated aqueous sodium bicarbonate and extracted with ethyl acetate (2×100 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to afford 1-(5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 1, 6.8 g, 57%) as a yellow oil that solidified upon standing. ¹H-NMR (400 MHz, Chloroform-d) -9/1 mixture of cis/trans isomers, mixture of rotamers δ 7.97-7.89 (m, 1H), 4.83-4.73 (m, 0.5H), 4.69-4.62 (m, 0.5H), 4.23-4.13 (m, 0.5H), 3.97-3.88 (m, 0.5H), 3.67-3.56 (m, 0.3H), 3.39-3.34 (m, 0.3H), 3.00-2.89 (m, 0.4H), 2.81-2.68 (m, 1H), 2.11-1.72 (m, 5.3H), 1.71-1.58 (m, 1.3H), 1.29-1.15 (m, 1.9H), 1.14-1.04 (m, 1.5H); LCMS (Method A): t_(R) 1.88 min, MS (ESI) 288.1 (M+H)⁺.

Intermediate 2: synthesis of 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one

To a solution of N-acetyl-D-leucine (1 kg, 5.77 mol) in ethanol (1.5 L) was added a solution of methyl 6-methylpiperidine-3-carboxylate (934 g, 2.38 mol, prepared under Intermediate 1) in ethyl acetate (3 L) and the mixture was heated to 40° C. The resulting solution was allowed to reach room temperature over 16 hours during which precipitation occurred. The precipitate was filtered off, washed with diethyl ether (500 mL) and air dried to afford crude methyl (3R,6S)-6-methylpiperidine-3-carboxylate acetyl-D-leucinate (287 g, 34%) as a white solid. The crude methyl (3R,6S)-6-methylpiperidine-3-carboxylate acetyl-D-leucinate (287 g, 869 mmol) was crystallised from a hot mixture of ethanol and ethyl acetate 1:2 (1 L). The precipitate was filtered off and the filtercake was triturated in a mixture of diethyl ether and n-pentane 1:1 (500 mL). The precipitate was filtered off and air dried to afford methyl (3R,6S)-6-methylpiperidine-3-carboxylate acetyl-D-leucinate (128 g, 44%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) δ 7.80 (d, J=8.2 Hz, 1H), 5.80-5.00 (broad s, 2H), 4.20-4.04 (m, 1H), 3.63 (s, 3H), 3.32-3.21 (m, 1H), 2.93-2.80 (m, 2H), 2.73-2.65 (m, 1H), 2.04-1.94 (m, 1H), 1.82 (s, 3H), 1.68-1.49 (m, 3H), 1.49-1.37 (m, 2H), 1.30-1.15 (m, 1H), 1.02 (d, J=6.4 Hz, 3H), 0.85 (m, 6H). To a solution of methyl (3R,6S)-6-methylpiperidine-3-carboxylate acetyl-D-leucinate (128 g, 387 mmol) in dichloromethane (1 L) was added a saturated sodium carbonate solution (1 L). The biphasic system was stirred vigorous for 10 minutes and the layers were separated. The organic layer was dried with sodium sulfate and filtered to afford a clear solution. Next, triethylamine (65 mL, 465 mmol) and acetic anhydride (44 mL, 465 mmol) were added and the mixture was stirred at room temperature for 1 hour. The mixture was washed with saturated sodium bicarbonate solution, dried over sodium sulfate and concentrated to afford methyl (3R,6S)-1-acetyl-6-methylpiperidine-3-carboxylate (93 g) as a light yellow solid. ¹H-NMR (400 MHz Chloroform-d) mixture of rotamers δ 5.02-4.87 (m, 0.5H), 4.84-4.68 (m, 0.5H), 4.18-4.05 (m, 0.5H), 3.89-3.77 (m, 0.5H), 3.71 (d, J=11.6 Hz, 3H), 3.31-3.18 (m, 0.5H), 2.79-2.67 (m, 0.5H), 2.51-2.31 (m, 1H), 2.11 (d, J=6.7 Hz, 3H), 2.01-1.90 (m, 1H), 1.88-1.55 (m, 3H), 1.33-1.21 (m, 1.5H), 1.20-1.06 (m, 1.5H). An autoclave was charged with methyl (3R,6S)-1-acetyl-6-methylpiperidine-3-carboxylate (93 g, 387 mmol) in 7N ammonia in methanol (600 mL, 4200 mmol) and was heated to 60° C. for 3 days. The mixture was concentrated to afford (3R,6S)-1-acetyl-6-methylpiperidine-3-carboxamide (102 g) as a pale yellow oil. Assuming quantitative yield, the product was used as such in the next step. ¹H-NMR (400 MHz, DMSO-d6), mixture of rotamers δ 7.38 (s, 1H), 6.89 (d, J=24.7 Hz, 1H), 4.76-4.59 (m, 0.5H), 4.39-4.24 (m, 0.5H), 4.16-4.01 (m, 0.5H), 3.72-3.51 (m, 0.5H), 3.14-2.99 (m, 0.5H), 2.68-2.51 (m, 0.5H), 2.30-2.12 (m, 0.5H), 2.11-1.92 (m, 3.5H), 1.78-1.38 (m, 4H), 1.23-1.11 (m, 1.5H), 1.09-0.94 (m, 1.5H); Chiral LC (Method A) t_(R)=12.35 min, >98% ee. To a solution of (3R,6S)-1-acetyl-6-methylpiperidine-3-carboxamide (50 g, 271 mmol) in dichloromethane (500 mL) was added triethyloxonium tetrafluoroborate (77 g, 407 mmol) portion wise and the mixture was stirred at room temperature for 4 hours. Slowly, 7N ammonia in methanol (200 ml, 9.15 mol) was added and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated to afford (3R,6S)-1-acetyl-6-methylpiperidine-3-carboximidamide (50 g) as a pink solid which was used as such in the next step. To a solution of 5.4M sodium methoxide in methanol (99 mL, 535 mmol) in methanol (200 mL) was added, (3R,6S)-1-acetyl-6-methylpiperidine-3-carboximidamide (49 g, 267 mmol) in methanol (400 mL) and dimethyl malonate (61.4 mL, 535 mmol). The mixture was heated to 50° C. and stirred for 24 hours. The mixture was acidified (pH -3) with concentrated hydrochloric acid and was concentrated to a smaller volume. The residue was filtered through silica (20% methanol in dichloromethane) and concentrated to afford an orange oil. The crude product was purified with silica column chromatography (0% to 20% methanol in dichloromethane) to afford 1-((2S,5R)-5-(4,6-dihydroxypyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (12 g, 17%) as a colorless gum. LCMS (Method C): t_(R) 0.17 min, 100%, MS (ESI) 252.1 (M+H)⁺. A solution of 1-((2S,5R)-5-(4,6-dihydroxypyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (12 g, 47.8 mmol) in phosphorus oxychloride (80 mL, 858 mmol) was stirred at 60° C. for 24 hours. The reaction mixture was concentrated and co-evaporated with toluene twice to afford a yellow oil. The oil was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate twice. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated to afford a yellow oil. The oil was purified with silica column chromatography (0% to 20% tetrahydrofuran in toluene) to afford 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 2, 1.5 g, 11%) as a colorless gum. ¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 7.95 (d, J=7.3 Hz, 1H), 4.85-4.72 (m, 1H), 4.69-4.62 (m, 1H), 4.23-4.13 (m, 1H), 4.07-3.98 (m, 1H), 3.97-3.88 (m, 1H), 3.00-2.89 (m, 1H), 2.81-2.67 (m, 1H), 2.09-1.72 (m, 7H), 1.71-1.58 (m, 2H), 1.25-1.14 (m, 3H), 1.12-1.05 (m, 2H); LCMS (Method B): t_(R) 3.34 min, MS (ESI) 288.0 (M+H)⁺; Chiral UPLC (Method: A) t_(R) 2.54 min, >95% ee and de.

Synthetic Procedures for Final Products Example 1: synthesis of 1-((2S,5R)-2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00001) and 1-((2R,5S)-2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00002)

To a solution of 3-amino-5-methylpyridine (0.751 g, 6.94 mmol) in tetrahydrofuran (20 mL) was added 1M lithium bis(trimethylsilyl)amide in tetrahydrofuran (6.94 mL, 6.94 mmol) and the mixture was stirred at room temperature for 10 minutes. Next, 1-(5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 1, 1 g, 3.47 mmol) in tetrahydrofuran (20 ml) was added and the mixture was stirred at room temperature for 2 hours. The mixture was poured into saturated ammonium chloride solution and was extracted with ethyl acetate twice.

The combined organic layers were washed with brine once, dried over sodium sulfate and concentrated to afford a yellow solid. The solid was purified with silica column chromatography (0% to 5% methanol in dichloromethane) to afford 1-(5-(4-chloro-6-((5-methylpyridin-3-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (788 mg, 60%) as a yellow foam.

LCMS (Method B): t_(R) 1.81 min, MS (ESI) 360.1 (M+H)⁺. Under nitrogen, 2-(tributylstannyl)pyrazine (103 mg, 0.28 mmol), 1-(5-(4-chloro-6-((5-methylpyridin-3-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (50 mg, 0.14 mmol) and bis(triphenylphosphine)palladium(II) dichloride (9.75 mg, 0.01 mmol) were dissolved in N,N-dimethylformamide (3 mL). The mixture was heated to 80° C. for 24 hours and cooled to room temperature. The mixture was eluted through a C18 plug using acetonitrile, the filtrate was purified with reversed phase chromatography (method B) and lyophilized to afford 1-(2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (22 mg, 37%) as a white solid. The obtained mixture of cis enantiomers was submitted for chiral preparative SFC (Method A) and lyophilized to afford both stereoisomers. 1-((2S,5R)-2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (5 mg, 22%)¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 10.03 (d, J=3.9 Hz, 1H), 9.55 (d, J=12.8 Hz, 1H), 8.81 (d, J=2.2 Hz, 2H), 8.76-8.60 (m, 1H), 8.24-8.00 (m, 2H), 7.66 (d, J=3.3 Hz, 1H), 4.90-4.72 (m, 1H), 4.28-4.17 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.5-3.41 (m, 0.5H), 3.01-2.84 (m, 1H), 2.84-2.69 (m, 0.5H), 2.33 (d, J=3.9 Hz, 3H), 2.12-1.92 (m, 5H), 1.92-1.78 (m, 0.5H), 1.78-1.60 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.17 min, MS (ESI) 404.1 (M+H)⁺; Chiral UPLC (Method: A): t_(R) 3.17 min, >95% ee and de. 1-((2R,5S)-2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (6 mg, 27%)¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 10.03 (d, J=3.9 Hz, 1H), 9.55 (d, J=12.8 Hz, 1H), 8.81 (d, J=2.2 Hz, 2H), 8.77-8.60 (m, 1H), 8.24-8.05 (m, 2H), 7.66 (d, J=3.2 Hz, 1H), 4.92-4.70 (m, 1H), 4.27-4.20 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.51-3.41 (m, 0.5H), 3.01-2.84 (m, 1H), 2.82-2.72 (m, 0.5H), 2.33 (d, J=3.9 Hz, 3H), 2.17-1.92 (m, 5H), 1.91-1.78 (m, 0.5H), 1.78-1.60 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.17 min, MS (ESI) 404.2 (M+H)⁺; Chiral UPLC (Method A): t_(R) 4.60 min, >95% ee and de.

The following compounds were prepared using procedures analogous to Example 1, using the appropriate starting materials and purified using reversed phase chromatography method A or B and preparative-SFC.

Compound Structure and compound # name Analytical data 00003

¹H-NMR (400 MHz, Chloroform-d) mixture of rotamers δ 8.74 (d, J = 16.9 Hz, 1H), 8.40 (dd, J = 7.9, 2.9 Hz, 1H), 7.90 (dt, J = 6.4, 2.1 Hz, 1H), 7.49- 7.35 (m, 1H), 7.34 -7.29 (m, 1H), 7.16 (dt, J = 7.9, 2.2 Hz, 1H), 7.04-6.95 (m, 2H), 6.89-6.81 (m, 1H), 5.15-5.05 (m, 0.5H), 4.96-4.85 (m, 0.5H), 4.25- 4.17 (m, 0.5H), 4.12-4.00 (m, 0.5H), 3.95 (d, J = 4.7 Hz, 3H), 3.61-3.50 (m, 0.5H), 3.15-3.06 (m, 0.5H), 2.98-2.88 (m, 1H), 2.17 (d, J = 7.8 Hz, 3H), 2.15- 1.99 (m, 2H), 1.92-1.69 (m, 2H), 1.39-1.34 (m, 1.5H), 1.28-1.23 (m, 1.5H); LCMS (Method D): t_(R) 3.42 min, MS (ESI) 436.2 (M + H)⁺; specific optical rotation [α]_(D) _(23.8) : 36.4 (c = 0.43, methanol). 00004

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 7.3 Hz, 1H), 8.81 (dd, J = 7.2, 1.8 Hz, 1H), 8.44 (t, J = 2.4 Hz, 1H), 8.03-7.88 (m, 2H), 7.43- 7.32 (m, 2H), 7.19 (d, J = 4.1 Hz, 1H), 6.98-6.71 (m, 1H), 4.92-4.78 (m, 0.5H), 4.78-4.62 (m, 0.5H), 4.28-4.17 (m, 0.5H), 4.15-3.99 (m, 0.5H), 3.93 (d, J = 1.2 Hz, 3H), 3.50-3.37 (m, 0.5H), 2.97-2.85 (m, 1H), 2.81-2.68 (m, 0.5H), 2.15-1.77 (m, 5.5H), 1.77-1.55 (m, 1.5H), 1.30-1.22 (m, 1.5H), 1.19- 1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.42 min, MS (ESI) 436.2 (M + H)⁺; [α]_(D) _(23.9) : −37.0 (c = 0.43, methanol). 00005

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.29 (s, 1H), 9.97 (d, J = 8.0 Hz, 1H), 8.65 (dd, J = 5.6, 1.8 Hz, 1H), 8.24 (d, J = 2.6 Hz, 1H), 7.97 (t, J = 12.6 Hz, 1H), 7.80-7.75 (m, 1H), 7.42-7.33 (m, 2H), 7.15-7.10 (d, J = 2.9 Hz, 1H), 6.88-6.80 (m, 1H), 4.88-4.79 (m, 0.5H), 4.77-4.68 (m, 0.5H), 4.27-4.17 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.50- 3.42 (m, 0.5H), 2.97-2.81 (m, 1H), 2.78-2.70 (m, 0.5H), 2.11-1.97 (m, 5H), 1.89-1.77 (m, 0.5H), 1.77-1.61 (m, 1.5H), 1.30-1.24 (m, 1.5H), 1.17- 1.13 (m, 1.5H); LCMS (Method D): t_(R) 2.99 min, MS (ESI) 422.1 (M + H)⁺, specific optical rotation [α]_(D) _(24.4) : −29.0 (c = 0.23, methanol) 00006

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.20 (d, J = 5.5 Hz, 1H), 9.24 (dd, J = 6.2, 2.3 Hz, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.45-8.38 (m, 3H), 7.79 (dt, J = 4.6, 2.5 Hz, 2H), 7.59 (dd, J = 8.0, 4.8 Hz, 1H), 7.27 (d, J = 3.1 Hz, 1H), 4.93-4.62 (m, 1H), 4.32-4.15 (m, 0.5H), 4.12-4.03 (m, 0.5H), 3.56- 3.41 (m, 0.5H), 3.00-2.85 (m, 1H), 2.82-2.71 (m, 0.5H), 2.18-1.93 (m, 5H), 1.92-1.78 (m, 0.5H), 1.78-1.58 (m, 1.5H), 1.30-1.26 (m, 1.5H), 1.18- 1.13 (m, 1.5H); LCMS (Method D): t_(R) 2.96 min, MS (ESI) 389.2 (M + H)⁺; Chiral SFC (Method A): t_(R) 3.33 min, >95% ee and de. 00007

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.20 (d, J = 5.5 Hz, 1H), 9.24 (dd, J = 6.2, 2.3 Hz, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.45-8.38 (m, 3H), 7.79 (dt, J = 4.6, 2.5 Hz, 2H), 7.59 (dd, J = 8.0, 4.8 Hz, 1H), 7.27 (d, J = 3.1 Hz, 1H), 4.93-4.62 (m, 1H), 4.32-4.15 (m, 0.5H), 4.12-4.03 (m, 0.5H), 3.56- 3.41 (m, 0.5H), 3.00-2.85 (m, 1H), 2.82-2.71 (m, 0.5H), 2.18-1.93 (m, 5H), 1.92-1.78 (m, 0.5H), 1.78-1.58 (m, 1.5H), 1.30-1.26 (m, 1.5H), 1.18- 1.13 (m, 1.5H); LCMS (Method D): t_(R) 2.96 min, MS (ESI) 389.2 (M + H)⁺; Chiral SFC (Method A): t_(R) 3.56 min, >95% ee and de. 00008

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.91 (d, J = 4.2 Hz, 1H), 9.22 (dd, J = 5.7, 2.3 Hz, 1H), 8.75-8.66 (m, 2H), 8.45-8.34 (m, 1H), 8.21- 8.13 (m, 1H), 8.09 (d, J = 2.5 Hz, 1H), 7.61-7.54 (m, 1H), 7.18 (d, J = 4.1 Hz, 1H), 4.88-4.69 (m, 1H), 4.27-4.16 (m, 0.5H), 4.09-3.97 (m, 0.5H), 3.44 (m, 0.5H), 2.96-2.82 (m, 1H), 2.79-2.68 (m, 0.5H), 2.33 (d, J = 3.6 Hz, 3H), 2.12-1.80 (m, 5H), 1.80- 1.76 (m, 0.5H), 1.75-1.64 (m, 1.5H), 1.29-1.25 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.13 min, MS (ESI) 403.3 (M + H)⁺; Chiral SFC (Method B): t_(R) 2.92 min, >95% ee and de. 00009

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.91 (d, J = 4.2 Hz, 1H), 9.22 (dd, J = 5.7, 2.3 Hz, 1H), 8.75-8.66 (m, 2H), 8.45-8.34 (m, 1H), 8.21- 8.13 (m, 1H), 8.09 (d, J = 2.5 Hz, 1H), 7.61-7.54 (m, 1H), 7.18 (d, J = 4.1 Hz, 1H), 4.88-4.69 (m, 1H), 4.27-4.16 (m, 0.5H), 4.09-3.97 (m, 0.5H), 3.44 (m, 0.5H), 2.96-2.82 (m, 1H), 2.79-2.68 (m, 0.5H), 2.33 (d, J = 3.6 Hz, 3H), 2.12-1.80 (m, 5H), 1.80- 1.76 (m, 0.5H), 1.75-1.64 (m, 1.5H), 1.29-1.25 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.13. min, MS (ESI) 403.2 (M + H)⁺; Chiral SFC (Method B): t_(R) 4.67 min, >95% ee and de. 00010

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 7.7 Hz, 1H), 9.21 (dd, J = 6.4, 2.3 Hz, 1H), 8.71 (d, J = 4.9 Hz, 1H), 8.46-8.30 (m, 1H), 7.97 (t, J = 12.2 Hz, 1H), 7.58 (dd, J = 8.0, 4.7 Hz, 1H), 7.38 (t, J = 6.4 Hz, 2H), 7.18 (d, J = 3.5 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 4.90-4.62 (m, 1H), 4.23- 4.15 (m, 0.5H), 4.09-4.00 (m, 0.5H), 3.48-3.40 (m, 0.5H), 2.96-2.83 (m, 1H), 2.80-2.68 (m, 0.5H), 2.10-1.89 (m, 5H), 1.88-1.76 (m, 0.5H), 1.76- 1.60 (m, 1.5H); LCMS (Method D): t_(R) 3.62 min, MS (ESI) 409.2 (M + H)⁺; Chiral SFC (Method B): t_(R) 3.64 min, >95% de. 00011

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.05 (d, J = 4.3 Hz, 1H), 9.55 (dd, J = 12.8, 1.2 Hz, 1H), 8.81 (d, J = 2.0 Hz, 2H), 8.70 (dd, J = 11.8, 2.4 Hz, 1H), 8.24-8.04 (m, 2H), 7.66 (d, J = 3.3 Hz, 1H), 4.86-4.72 (m, 1H), 4.25-4.18 (m, 0.5H), 4.10- 4.01 (m, 0.5H), 3.50-3.41 (m, 0.5H), 3.00-2.85 (m, 1H), 2.82-2.71 (m, 0.5H), 2.33 (d, J = 4.0 Hz, 3H), 2.13-1.95 (m, 5H), 1.91-1.79 (m, 0.5H), 1.77- 1.61 (m, 1.5H); LCMS (Method D): t_(R) 3.14 min, MS (ESI) 407.2 (M + H)⁺; Chiral SFC (Method A): t_(R) 3.92 min, >95% ee and de. 00012

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.05 (d, J = 4.4 Hz, 1H), 9.56 (d, J = 12.9 Hz, 1H), 8.81 (d, J = 2.0 Hz, 2H), 8.76-8.66 (m, 1H), 8.17 (d, J = 16.6 Hz, 1H), 8.11 (s, 1H), 7.66 (d, J = 3.3 Hz, 1H), 4.85-4.73 (m, 1H), 4.23-4.18 (m, 0.5H), 4.10- 4.02 (m, 0.5H), 3.50-3.40 (m, 0.5H), 3.00-2.85 (m, 1H), 2.82-2.70 (m, 0.5H), 2.33 (d, J = 3.8 Hz, 3H), 2.14-1.93 (m, 5H), 1.92-1.78 (m, 0.5H), 1.78- 1.60 (m, 1.5H); LCMS (Method D): t_(R) 3.14 min, MS (ESI) 407.2 (M + H)⁺; Chiral SFC (Method A): t_(R) 4.19 min, >95% ee and de.

Example 2: synthesis of 1-((2S,5R)-5-(4-(imidazo[1,2-a]pyridin-6-ylamino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (00013)

Under argon, 3-(tributylstannyl)pyridine (607 mg, 1.65 mmol), 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 2, 500 mg, 1.74 mmol) and bis(triphenylphosphine)palladium(II) chloride (244 mg, 0.34 mmol) in 1,4-dioxane (20 mL) were heated to 100° C. and stirred for 32 hours. The mixture was diluted with dichloromethane containing 1% triethylamine and coated onto silica. This was purified with silica column chromatography (0% to 40% acetonitrile in dichloromethane containing 1% triethylamine) to afford 1-((2S,5R)-5-(4-chloro-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (134 mg, 18%) as an orange gum. ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.46-9.41 (m, 1H), 8.80-8.76 (m, 1H), 8.65-8.59 (m, 1H), 8.33-8.29 (m, 1H), 7.66-7.59 (m, 1H), 4.86-4.70 (m, 0.5H), 4.27-4.17 (m, 0.5H), 4.09-3.97 (m, 0.5H), 3.55-3.41 (m, 0.5H), 3.06-2.98 (m, 0.5H), 2.88-2.82 (m, 0.5H), 2.10-1.90 (m, 6H), 1.89-1.76 (m, 0.5H), 1.75-1.61 (m, 1.5H), 1.29-1.20 (m, 1.5H), 1.17-1.10 (m, 1.5H); LCMS (Method C): t_(R) 1.81 min, MS (ESI) 331.1 (M+H)⁺. To a solution of 1-((2S,5R)-5-(4-chloro-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (30 mg, 0.09 mmol) in 2-propanol (2 mL), was added imidazo[1,2-a]pyridin-6-amine (36.2 mg, 0.27 mmol) and hydrochloric acid (0.02 mL, 0.27 mmol). The mixture was stirred at 60° C. for 16 hours, poured into saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate twice. The combined organic layers were dried over sodium sulfate and concentrated to afford a yellow oil. The oil was purified with reversed phase chromatography (method B) and lyophilized to afford 1-((2S,5R)-5-(4-(imidazo[1,2-a]pyridin-6-ylamino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one as a blue-ish solid. ¹H-NMR (400 MHz, Chloroform-d) mixture of rotamers δ 9.84 (d, J=6.3 Hz, 1H), 9.36 (d, J=51.8 Hz, 1H), 9.23 (dd, J=4.3, 2.3 Hz, 1H), 8.71 (dd, J=4.8, 1.5 Hz, 1H), 8.44-8.38 (m, 1H), 7.96 (d, J=13.8 Hz, 1H), 7.62-7.53 (m, 3H), 7.30 (td, J=9.6, 2.0 Hz, 1H), 7.18 (d, J=1.8 Hz, 1H), 4.89-4.77 (m, 1H), 4.28-4.16 (m, 0.5H), 4.08-3.96 (m, 0.5H), 3.51-3.41 (m, 0.5H), 2.98-2.86 (m, 1H), 2.82-2.72 (m, 0.5H), 2.14-1.93 (m, 5H), 1.91-1.80 (m, 0.5H), 1.77-1.65 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.18-1.12 (m, 1.5H); LCMS (Method B): t_(R) 2.19 min, MS (ESI) 428.1 (M+H)⁺.

The following compounds were prepared following procedures analogous to Example 2, using the appropriate starting materials, and purified using reversed phase chromatography method A/B and/or prep-SFC.

Compound # Structure and compound name Analytical data 00014

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.08-9.83 (m, 1H), 8.79 (d, J = 1.3 Hz, 1H), 8.42 (s, 1H), 8.13-7.81 (m, 2H), 7.45-7.32 (m, 2H), 7.17 (s, 1H), 6.88- 6.79 (m, 1H), 5.34-5.14 (m, 0.2H), 4.72- 4.40 (m, 1.3H), 4.15-3.88 (m, 3.3H), 3.67-3.41 (m, 1H), 3.22-2.97 (m, 1.2H), 2.44-2.34 (m, 1H), 2.17-2.04 (m, 1H), 2.00-1.75 (m, 4H), 1.48-1.36 (m, 1H), 1.32-1.07 (m, 3H); LCMS (Method D): t_(R) 3.51 min, MS (ESI) 436.2 (M + H)⁺. (+/+)-trans-1-(5-(4-((3- fluorophenyl)amino)-6-(5- methoxypyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1-yl)ethan-1-one 00015

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.96 (s, 1H), 9.22-9.19 (m, 1H), 8.70 (dd, J = 4.8, 1.7 Hz, 1H), 8.38 (d, J = 7.9 Hz, 1H), 7.87 (d, J = 12.1 Hz, 1H), 7.57 (dd, J = 8.1,4.8 Hz, 1H), 7.44-7.32 (m, 2H), 7.16 (s, 1H), 6.88-6.79 (m, 1H), 5.29-5.05 (m, 0.2H), 4.77-4.34 (m, 1.6H), 4.23-3.97 (m, 0.4H), 3.68-3.49 (m, 0.8H), 3.17 (s, 1H), 2.45-2.35 (m, 1H), 2.16-2.03 (m, 1H), 1.96-1.79 (m, 4H), 1.47-1.37 (m, 1H), 1.26-1.07 (m, 3H); LCMS (Method D): t_(R) 3.37 min, MS (ESI) 406.2 (M + H)⁺. (+/+)-trans-1-(5-(4-((3- fluorophenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2-methylpiperidin- 1-yl)ethan-1-one 00016

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.99 (d, J = 5.1 Hz, 1H), 8.80 (dd, J = 7.6, 1.8 Hz, 1H), 8.44 (t, J = 2.7 Hz, 1H), 8.25 (dt, J = 8.4, 2.2 Hz, 1H), 7.93- 7.89 (m, 1H), 7.59-7.46 (m, 1H), 7.37 (td, J = 8.1, 2.0 Hz, 1H), 7.18 (d, J = 3.8 Hz, 1H), 7.11-7.05 (m, 1H), 4.85-4.76 (m, 0.5H), 4.72-4.64 (m, 0.5H), 4.27-4.17 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.93 (s, 3H), 3.48-3.40 (m, 0.5H), 2.99-2.85 (m, 1H), 2.80-2.69 (m, 0.5H), 2.13-1.93 (m, 5H), 1.92-1.77 (m, 0.5H), 1.77-1.61 (m, 1.5H), 1.32-1.28 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method D): t_(R) 3.46 min, MS (ESI) 452.1 (M + H)⁺. (+/−)-cis-1-(5-(4-((3- chlorophenyl)amino)-6-(5- methoxypyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1-yl)ethan-1-one 00017

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.02-9.82 (m, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.42(d, J = 2.9 Hz, 1H), 8.14 (t, J = 2.0 Hz, 1H), 8.04-7.79 (m, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 7.15 (s, 1H), 7.10-7.03 (m, 1H), 5.44- 5.10 (m, 0.3H), 4.75-4.40 (m, 1.4H), 4.07- 3.90 (m, 3.3H), 3.65-3.48 (m, 0.7H), 3.20-2.99 (m, 1.3H), 2.46-2.37 (m, 1H), 2.15-2.05 (m, 1H), 1.93-1.81 (m, 4H), 1.43 (d, J = 13.3 Hz, 1H), 1.26-1.10 (m, 3H); LCMS (Method D): t_(R) 3.57 min, MS (ESI) 452.1 (M + H)⁺. (+/−)-trans-1-(5-(4-((3- chlorophenyl)amino)-6-(5- methoxypyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1-yl)ethan-1-one 00018

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.72 (d, J = 7.1 Hz, 1H), 9.19 (dd, J = 5.5, 2.3 Hz, 1H), 8.70 (dt, J = 4.9, 1.7 Hz, 1H), 8.45-8.31 (m, 1H), 7.74 (d, J = 12.7 Hz, 1H), 7.62-7.52 (m, 1H), 7.52- 7.40 (m, 1H), 7.22 (td, J = 7.8, 2.3 Hz, 1H), 7.14 (d, J = 4.4 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 4.82-4.70 (m, 0.5H), 4.67-4.54 (m, 0.5H), 4.09-3.95 (m, 0.5H), 3.95-3.80 (m, 0.5H), 3.48-3.37 (m, 0.5H), 2.95- 2.78 (m, 1H), 2.78-2.64 (m, 0.5H), 2.32 (d, J = 1.5 Hz, 3H), 2.12-1.44 (m, 9H), 0.92-0.78 (m, 3H); LCMS (Method B): t_(R) 3.12 min, MS (ESI) 416.2 (M + H)⁺. (+/−)-cis-1-(2-ethyl-5-(4-(pyridin-3- yl)-6-(m-tolylamino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00019

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.75-9.51 (m, 1H), 9.19 (s, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.46- 8.28 (m, 1H), 7.71-7.36 (m, 3H), 7.22 (t, J = 7.8 Hz, 1H), 7.12 (s, 1H), 6.85 (d, J = 7.4 Hz, 1H), 4.68-4.24 (m, 1.5H), 3.85-3.42 (m, 1H), 3.20-2.88 (m, 1.5H), 2.51-2.22 (m, 4H), 2.16-1.38 (m, 8H), 0.90-0.73 (m, 3H); LCMS (Method B): t_(R) 3.16 min, MS (ESI) 416.2 (M + H)⁺. (+/−)-frans-1-(2-ethyl-5-(4-(pyridin- 3-yl)-6-(m-tolylamino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00020

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.00 (d, J = 7.4 Hz, 1H), 9.21 (dd, J = 6.2, 2.3 Hz, 1H), 8.71 (dt, J = 4.8, 1.5 Hz, 1H), 8.43-8.35 (m, 1H), 8.03- 7.92 (m, 1H), 7.61-7.54 (m, 1H), 7.42- 7.32 (m, 2H), 7.18 (d, J = 3.8 Hz, 1H), 6.90- 6.80 (m, 1H), 4.80-4.68 (m, 0.5H), 4.68- 4.55 (m, 0.5H), 4.12-3.99 (m, 0.5H), 3.99-3.84 (m, 0.5H), 3.45-3.34 (m, 0.5H), 2.97-2.69 (m, 1.5H), 2.12-1.47 (m, 9H), 0.93-0.77 (m, 3H); LCMS (Method B): t_(R) 3.16 min, MS (ESI) 420.2 (M + H)⁺. (+/−)-c/s-1-(2-ethyl-5-(4-((3- fluorophenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00021

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.98 (s, 1H), 9.21 (s, 1H), 8.70 (dd, J = 4.8, 1.7 Hz, 1H), 8.38 (s, 1H), 7.87 (d, J = 12.4 Hz, 1H), 7.57 (dd, J = 8.0, 4.9 Hz, 1H), 7.48- 7.25 (m, 2H), 7.16 (s, 1H), 6.84 (t, J = 8.1 Hz, 1H), 4.60-4.31 (m, 1.5H), 3.60-3.46 (m, 0.5H), 3.24-2.81 (m, 1.5H), 2.44-2.25 (m, 1.5H), 2.18- 1.38 (m, 8H), 0.97-0.60 (m, 3H); LCMS (Method B): t_(R) 3.20 min, MS (ESI) 420.2 (M + H)⁺. (+/−)-trans-1-(2-ethyl-5-(4-((3- fluorophenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00022

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.73 (d, J = 4.8 Hz, 1H), 9.18 (dd, J = 6.9, 2.2 Hz, 1H), 8.73-8.67 (m, 1H), 8.40-8.32 (m, 1H), 7.75-7.61 (m, 1H), 7.60-7.53 (m, 1H), 7.53-7.42 (m, 1H), 7.22 (td, J = 7.8, 3.7 Hz, 1H), 7.15 (d, J = 4.2 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 5.37-5.24 (m, 0.6H), 4.96-4.82 (m, 0.6H), 4.27-4.19 (m, 0.6H), 3.58-3.46 (m, 0.7H), 3.08-2.97 (m, 0.7H), 2.97- 2.77 (m, 0.7H), 2.32 (d, J = 1.7 Hz, 3H), 2.22-1.82 (m, 7.1 H); LCMS (Method B): t_(R) 3.16 min, MS (ESI) 456.2 (M + H)⁺. (+/−)-c/s-1-(5-(4-(pyridin-3-yl)-6-(m- tolylamino)pyrimidin-2-yl)-2- (trifluoromethyl)piperidin-1- yl)ethan-1-one 00023

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.08-9.95 (m, 1H), 9.20 (dd, J = 8.3, 2.2 Hz, 1H), 8.71 (dd, J = 4.7, 1.9 Hz, 1H), 8.42-8.34 (m, 1H), 7.97-7.88 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.32 (m, 2H), 7.19 (d, J = 4.1 Hz, 1H), 6.90- 6.75 (m, 1H), 5.39-5.23 (m, 0.6H), 4.97- 4.77 (m, 0.6H), 4.32-4.19 (m, 0.6H), 3.58- 3.45 (m, 0.7H), 3.13-2.99 (m, 0.7H), 2.99-2.81 (m, 0.7H), 2.23-1.83 (m, 7.1 H); LCMS (Method B): t_(R) 3.16 min, MS (ESI) 460.2 (M + H)⁺. (+/−)-c/s-1-(5-(4-((3- fluorophenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- (trifluoromethyl)piperidin-1- yl)ethan-1-one 00024

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.07-9.86 (m, 1H), 9.27- 9.16 (m, 1H), 8.77-8.66 (m, 1H), 8.44- 8.31 (m, 1H), 7.93-7.74 (m, 1H), 7.63- 7.51 (m, 1H), 7.48-7.31 (m, 2H), 7.24- 7.11 (m, 1H), 6.94-6.80 (m, 1H), 5.41- 5.10 (m, 0.9H), 4.90-4.63 (m, 0.9H), 3.69- 3.57 (m, 0.7H), 3.30-3.21 (m, 2H), 2.24- 1.79 (m, 6.5H); LCMS (Method B): t_(R) 3.33 min, MS (ESI) 460.2 (M + H)⁺. (+/−)-trans-1-(5-(4-((3- fluorophenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- (trifluoromethyl)piperidin-1- yl)ethan-1-one 00025

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 8.9 Hz, 1H), 9.22 (dd, J = 5.1,2.3 Hz, 1H), 8.72 (dt, J = 4.8, 1.4 Hz, 1H), 8.46-8.33 (m, 1H), 7.96- 7.85 (m, 1H), 7.58 (dd, J = 8.0, 4.7 Hz, 1H), 7.45-7.32 (m, 2H), 7.19 (d, J = 2.9 Hz, 1H), 6.85 (tt, J = 8.9, 2.8 Hz, 1H), 6.65- 6.13 (m, 1H), 4.99-4.75 (m, 1H), 4.40- 4.19 (m, 1H), 3.56-3.44 (m, 0.5H), 3.13- 2.72 (m, 1.5H), 2.25-2.09 (m, 4H), 2.09- 1.89 (m, 2.5H), 1.86-1.66 (m, 0.5H); LCMS (Method D): t_(R) 3.27 min, MS (ESI) 442.1 (M + H)⁺. (+/−)-c/s-1-(2-(difluoromethyl)-5-(4- ((3-fluorophenyl)amino)-6-(pyridin- 3-yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00026

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 8.9 Hz, 1H), 9.22 (dd, J = 5.1,2.3 Hz, 1H), 8.72 (dt, J = 4.8, 1.4 Hz, 1H), 8.44-8.36 (m, 1H), 8.00- 7.80 (m, 1H), 7.58 (dd, J = 8.0, 4.7 Hz, 1H), 7.45-7.32 (m, 2H), 7.19 (d, J = 2.9 Hz, 1H), 6.85 (tt, J = 8.9, 2.8 Hz, 1H), 6.67- 6.10 (m, 1H), 5.00-4.80 (m, 1H), 4.39- 4.21 (m, 1H), 3.55-3.45 (m, 0.5H), 3.06- 2.88 (m, 1H), 2.85-2.74 (m, 0.5H), 2.25- 1.86 (m, 6.5H), 1.86-1.60 (m, 0.5H); LCMS (Method B): t_(R) 3.38 min, MS (ESI) 442.1 (M + H)⁺. (+/−)-frans-1-(2-(difluoromethyl)-5- (4-((3-fluorophenyl)amino)-6- (pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00027

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.69 (d, J = 5.7 Hz, 1H), 9.20 (dd, J = 4.7, 2.3 Hz, 1H), 8.70 (d, J = 4.7 Hz, 1H), 8.42-8.34 (m, 1H), 7.73-7.44 (m, 3H), 7.23 (td, J = 7.8, 3.0 Hz, 1H), 7.15 (d, J = 3.2 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), 5.00-4.81 (m, 1H), 4.40-4.17 (m, 1H), 3.56-3.45 (m, 0.5H), 3.03-2.87 (m, 1H), 2.83-2.73 (m, 0.5H), 2.32 (d, J = 3.5 Hz, 3H), 2.23-1.89 (m, 7.5H), 1.85-1.58 (m, 0.5H); LCMS (Method D): t_(R) 3.33 min, MS (ESI) 438.2 (M + H)⁺. (+/−)-cis-1-(2-(difluoromethyl)-5-(4- (pyridin-3-yl)-6-(m- tolylamino)pyrimidin-2-yl)piperidin- 1-yl)ethan-1-one 00028

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 11.06 (s, 1H), 9.54 (d, J = 8.0 Hz, 1H), 9.20-9.10 (m, 1H), 8.74-8.61 (m, 1H), 8.40-8.28 (m, 1H), 7.98 (s, 1H), 7.62-7.48 (m, 1H), 7.41-7.31 (m, 2H), 7.30-7.18 (m, 1H), 7.04 (m, 1H), 6.42- 6.34 (m, 1H), 4.88-4.77 (m, 0.5H), 4.76- 4.64 (m, 0.5H), 4.27-4.16 (m, 0.5H), 4.08- 3.94 (m, 0.5H), 3.47 (m, 0.5H), 2.92 (m, 0.5H), 2.87-2.77 (m, 0.5H), 2.73-2.63 (m, 0.5H), 2.10-1.93 (m, 5H), 1.90-1.76 (m, 0.5H), 1.75-1.60 (m, 1.5H), 1.31- 1.26 (m, 1.5H), 1.18-1.14 (m, 1.5H); UPLC (Method B): t_(R) 1.05 min, MS (ESI) 427.2 (M + H)⁺. 1-((2S,5R)-5-(4-((1H-indol-5- yl)amino)-6-(pyridin-3-yl)pyrimidin- 2-yl)-2-methylpiperidin-1-yl)ethan- 1-one 00029

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 12.94 (d, J = 6.9 Hz, 1H), 9.91 (d, J = 8.4 Hz, 1H), 9.22 (m 1H), 8.71 (m, 1H), 8.44-8.35 (m, 1H), 8.25 (d, J = 18.9 Hz, 1H), 7.98 (s, 1H), 7.70 (m, 1H), 7.58 (dd, J = 8.1, 4.8 Hz, 1H), 7.31-7.16 (m, 2H), 4.90-4.79 (m, 0.5H), 4.78-4.69 (m, 0.5H), 4.27-4.20 (m, 0.5H), 4.12-4.03 (m, 0.5H), 3.49 (m, 0.5H), 3.00-2.83 (m, 1H), 2.79-2.69 (m, 0.5H), 2.17-1.61 (m, 7H), 1.30-1.24 (m, 1.5H), 1.17-1.10 (m,1.5H); LCMS (Method A): t_(R) 2.71 min, MS (ESI) 428.1 (M + H)⁺. 1-((2S,5R)-5-(4-((1H-indazol-6- yl)amino)-6-(pyridin-3-yl)pyrimidin- 2-yl)-2-methylpiperidin-1-yl)ethan- 1-one 00030

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 13.02 (s, 1H), 9.75 (d, J = 7.5 Hz, 1H), 9.19(dd, J = 5.8, 2.2 Hz, 1H), 8.74- 8.63 (m, 1H), 8.41-8.33 (m, 1H), 8.26 (s, 1H), 8.01 (s, 1H), 7.60-7.45 (m, 3H), 7.11 (d, J = 4.5 Hz, 1H), 4.87-4.79 (m, 0.5H), 4.77-4.68 (m, 0.5H), 4.26-4.18 (m, 0.5H), 4.08-3.99 (m, 0.5H), 3.52- 3.41 (m, 0.5H), 2.98-2.79 (m, 1H), 2.77- 2.62 (m, 0.5H), 2.13-1.93 (m, 5H), 1.88- 1.61 (m, 2H), 1.30-1.26 (m, 1.5H), 1.19- 1.15 (m, 1.5H); LCMS (Method D): t_(R) 3.07 min, MS (ESI) 428.1 (M + H)⁺. 1-((2S,5R)-5-(4-((1H-indazol-5- yl)amino)-6-(pyridin-3-yl)pyrimidin- 2-yl)-2-methylpiperidin-1-yl)ethan- 1-one 00031

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.99 (d, J = 8.9 Hz, 1H), 9.21 (dd, J = 6.2, 2.3 Hz, 1H), 8.71 (d, J = 4.6 Hz, 1H), 8.43-8.36 (m, 1H), 7.58 (m, 1H), 7.45-7.32 (m, 1H), 7.27-7.14 (m, 2H), 6.54-6.46 (m, 1H), 4.88-4.78 (m, 0.5H), 4.77-4.68 (m, 0.5H), 4.25-4.18 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.79 (d, J = 1.4 Hz, 3H), 3.45 (m, 0.5H), 2.96-2.85 (m, 1H), 2.80-2.69 (m, 0.5H), 2.12-1.94 (m, 5H), 1.91-1.60 (m, 2H), 1.29-1.25 (m, 1.5H), 1.17-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.70 min, MS (ESI) 436.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- methoxyphenyl)amino)-6-(pyridin- 3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00032

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 12.41 (s, 1H), 9.75 (d, J = 9.8 Hz, 1H),9.19 (dd, J = 6.5, 2.3 Hz, 1H), 8.77- 8.62 (m, 1H), 8.46-8.29 (m, 1H), 8.27- 7.94 (m, 2H), 7.65-7.47 (m, 2H), 7.44- 7.23 (m, 1H), 7.13 (d, J = 4.4 Hz, 1H), 4.90- 4.62 (m, 1H), 4.26-4.18 (m, 0.5H), 4.11- 3.97 (m, 0.5H), 3.48 (m, 0.5H), 2.99- 2.78 (m, 1H), 2.76-2.61 (m, 0.5H), 2.16- 1.57 (m, 7H), 1.30-1.26 (m, 1.5H), 1.17- 1.12 (m, 1.5H); LCMS (Method D): t_(R) 2.93 min, MS (ESI) 428.2 (M + H)⁺. 1-((2S,5R)-5-(4-((1H- benzo[d]imidazol-6-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00033

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 15.48 (s, 1H), 10.06 (d, J = 8.5 Hz, 1H), 9.30-9.17 (m, 1H), 8.72 (d, J = 4.8 Hz, 1H), 8.57 (d, J = 13.7 Hz, 1H), 8.46- 8.34 (m, 1H), 7.95-7.88 (m, 1H), 7.58 (dd, J = 8.0, 4.9 Hz, 1H), 7.50 (d, J = 8.9 Hz, 1H), 7.23 (d, J = 3.2 Hz, 1H), 4.91- 4.68 (m, 1H), 4.30-4.04 (m, 1H), 3.55- 3.44 (m, 0.5H), 3.00-2.88 (m, 1H), 2.83- 2.71 (m, 0.5H), 2.17-1.94 (m, 5H), 1.93- 1.80 (m, 0.5H), 1.78-1.65 (m, 1.5H), 1.33- 1.28 (m, 1.5H), 1.19-1.15 (m, 1.5H); UPLC (Method B): t_(R) 0.99 min, MS (ESI) 429.4 (M + H)⁺. 1-((2S,5R)-5-(4-((1H- benzo[d][1,2,3]triazol-5-yl)amino)- 6-(pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00034

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.80 (d, J = 7.1 Hz, 1H), 9.32- 9.02 (m, 2H), 8.70 (d, J = 4.7 Hz, 1H), 8.43- 8.33 (m, 1H), 7.99 (dd, J = 10.3, 2.2 Hz, 1H), 7.92-7.83 (m, 1H), 7.62-7.49 (m, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 3.7 Hz, 1H), 4.98 (s, 2H), 4.87-4.75 (m, 0.5H), 4.74-4.61 (m, 0.5H), 4.26-4.13 (m, 0.5H), 4.08-3.93 (m, 0.5H), 3.50- 3.40 (m, 0.5H), 2.96-2.79 (m, 1H), 2.76- 2.63 (m, 0.5H), 2.12-1.57 (m, 7H), 1.30- 1.25 (m, 1.5H), 1.16-1.12 (m, 1.5H); UPLC (Method B): t_(R) 1.05 min, MS (ESI) 444.4 (M + H)⁺. 1-((2S,5R)-5-(4-((1-hydroxy-1,3- dihydrobenzo[c][1,2]oxaborol-6- yl)amino)-6-(pyridin-3-yl)pyrimidin- 2-yl)-2-methylpiperidin-1-yl)ethan- 1-one 00035

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 11.07 (s, 1H), 10.18 (s, 1H), 9.23 (dd, J = 5.3, 2.3 Hz, 1H), 8.76-8.66 (m, 1H), 8.46-8.24 (m, 2H), 8.13 (dd, J = 8.8, 3.4 Hz, 1H), 7.72-7.55 (m, 2H), 7.28 (d, J = 2.7 Hz, 1H), 7.15 (t, J = 6.1 Hz, 1H), 6.47 (dd, J = 23.2, 7.1 Hz, 1H), 4.93-4.79 (m, 1H), 4.31-4.17 (m, 0.5H), 4.11-4.02 (m, 0.5H), 3.55-3.43 (m, 0.5H), 3.00- 2.88 (m, 1H), 2.84-2.74 (m, 0.5H), 2.13- 1.97 (m, 5H), 1.92-1.65 (m, 2H), 1.31- 1.26 (m, 1.5H), 1.20-1.15 (m, 1.5H); LCMS (Method D): t_(R) 3.06 min, MS (ESI) 455.2 (M + H)⁺. 6-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)isoquinolin- 1(2H)-one 00036

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.86 (s, 1H), 9.63 (d, J = 8.0 Hz, 1H), 9.34 (d, J = 4.7 Hz, 1H), 9.19 (dd, J = 5.9, 2.2 Hz, 1H), 8.70 (d, J = 4.7 Hz, 1H), 8.45-8.32 (m, 1H), 7.65-7.48 (m, 2H), 7.32 (d, J = 27.4 Hz, 1H), 7.22-7.06 (m, 2H), 4.87-4.77 (m, 0.5H), 4.68 (m, 0.5H), 4.28-4.16 (m, 0.5H), 4.06-3.98 (m, 0.5H), 3.45 (m, 0.5H), 2.99-2.80 (m, 1H), 2.77-2.64 (m, 0.5H), 2.11-2.04 (m, 6H), 2.04-1.91 (m, 2H), 1.89-1.77 (m, 0.5H), 1.75-1.61 (m, 1.5H), 1.29-1.25 (m, 1.5H), 1.16-1.11 (m, 1.5H); UPLC (Method A): t_(R) 1.17 min, MS (ESI) 461.4 (M + H)⁺. N-(4-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)-2- hydroxyphenyl)acetamide 00037

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.00 (d, J = 7.1 Hz, 1H), 9.25- 9.18 (m, 1H), 8.71 (d, J = 4.7 Hz, 1H), 8.46-8.33 (m, 2H), 7.66-7.53 (m, 2H), 7.47-7.38 (m, 1H), 7.18 (d, J = 2.7 Hz, 1H), 4.89-4.79 (m, 0.5H), 4.77-4.67 (m, 0.5H), 4.29-4.18 (m, 0.5H), 4.13-4.03 (m, 0.5H), 3.54-3.42 (m, 0.5H), 2.97- 2.84 (m, 1H), 2.81-2.70 (m, 0.5H), 2.60 (s, 3H), 2.08 (d, J = 4.0 Hz, 3H), 2.05-1.92 (m, 2H), 1.91-1.77 (m, 0.5H), 1.76-1.62 (m, 1.5H), 1.31-1.26 (m, 1.5H), 1.18- 1.13 (m, 1.5H); UPLC (Method A): t_(R) 1.38 min, MS (ESI) 443.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methylbenzo[d]oxazol-6-yl)amino)- 6-(pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00038

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.16 (d, J = 7.1 Hz, 1H), 9.22 (dd, J = 6.7, 2.3 Hz, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.50-8.34 (m, 1H), 7.95-7.81 (m, 1H), 7.72-7.50 (m, 2H), 7.19 (d, J = 3.9 Hz, 1H), 6.95-6.84 (m, 1H), 4.83 (s, 0.5H), 4.77-4.67 (m, 0.5H), 4.26-4.20 (m, 0.5H), 4.14-3.95 (m, 0.5H), 3.48- 3.39 (m, 0.5H), 3.06-2.85 (m, 7H), 2.81- 2.69 (m, 0.5H), 2.13-1.78 (m, 5.5H), 1.77- 1.61 (m, 1.5H), 1.30-1.24 (m, 1.5H), 1.18-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.21 min, MS (ESI) 477.2 (M + H)⁺. 3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin3- yl)pyrimidin-4-yl)amino)-5-fluoro- N,N-dimethylbenzamide 00039

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.05 (d, J = 5.9 Hz, 1H), 9.24- 9.18 (m, 1H), 8.74-8.67 (m, 1H), 8.44- 8.37 (m, 1H), 8.30 (s, 1H), 7.79-7.72 (m, 1H), 7.61-7.55 (m, 1H), 7.52-7.45 (m, 1H), 7.24-7.17 (m, 2H), 7.05 (t, J = 55.9 Hz, 1H), 4.87-4.77 (m, 0.5H), 4.76-4.68 (m, 0.5H), 4.27-4.17 (m, 0.5H), 4.06- 3.98 (m, 0.5H), 3.52-3.41 (m, 0.5H), 2.95- 2.85 (m, 1H), 2.79-2.69 (m, 0.5H), 2.11- 1.94 (m, 5H), 1.91-1.77 (m, 0.5H), 1.75- 1.61 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.17-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.63 min, MS (ESI) 438.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3- (difluoromethyl)phenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan1-one 00040

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 13.26 (s, 1H), 10.09 (d, J = 11.0 Hz, 1H), 9.23 (dd, J = 6.4, 2.2 Hz, 1H), 8.72 (d, J = 4.8 Hz, 1H), 8.47-8.37 (m, 1H), 8.09 (s, 1H), 7.96 (d, J = 12.0 Hz, 1H), 7.64- 7.54 (m, 1H), 7.36-7.28 (m, 1H), 7.22 (d, J = 3.7 Hz, 1H), 4.89-4.80 (m, 0.5H), 4.77-4.67 (m, 0.5H), 4.28-4.20 (m, 0.5H), 4.18-4.02 (m, 0.5H), 3.48 (m, 0.5H), 3.00-2.86 (m, 1H), 2.85-2.69 (m, 0.5H), 2.18-1.65 (m, 7H), 1.33- 1.25 (m, 1.5H), 1.21-1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.33 min, MS (ESI) 446.1 (M + H)⁺. 1-((2S,5R)-5-(4-((4-fluoro-1H- indazol-6-yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2-methylpiperidin- 1-yl)ethan-1-one 00041

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.22 (d, J = 7.9 Hz, 1H), 9.22 (dd, J = 7.1,2.4 Hz, 1H), 8.72 (dt, J = 4.8, 1.6 Hz, 1H), 8.55-8.47 (m, 1H), 8.44- 8.36 (m, 1H), 8.17-8.04 (m, 1H), 8.00- 7.89 (m, 1H), 7.58 (dd, J = 8.1,4.9 Hz, 1H), 7.31-7.25 (m, 1H), 7.20 (d, J = 4.0 Hz, 1H), 4.90-4.78 (m, 0.5H), 4.75-4.65 (m, 0.5H), 4.31-4.16 (m, 0.5H), 4.14-4.01 (m, 0.5H), 3.52-3.45 (m, 0.5H), 3.00- 2.87 (m, 1H), 2.85-2.72 (m, 3.5H), 2.16- 1.96 (m, 5H), 1.93-1.63 (m, 2H), 1.33- 1.25 (m, 1.5H), 1.18-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.16 min, MS (ESI) 463.2 (M + H)⁺. 3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)-5-fluoro-N- methylbenzamide 00042

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 13.11 (s, 1H), 9.83 (d, J = 10.3 Hz, 1H), 9.23 (dd, J = 6.8, 2.2 Hz, 1H), 8.78- 8.68 (m, 1H), 8.47-8.36 (m, 1H), 8.36- 8.26 (m, 1H), 7.92 (t, J = 8.2 Hz, 1H), 7.66- 7.53 (m, 1H), 7.43-7.37 (m, 1H), 7.37- 7.30 (m, 1H), 7.28-7.21 (m, 1H), 4.90- 4.78 (m, 0.5H), 4.72 (m, 0.5H), 4.25-4.17 (m, 0.5H), 4.03 (m, 0.5H), 3.45 (m, 0.5H), 2.97-2.83 (m, 1H), 2.78-2.65 (m, 0.5H), 2.11-1.77 (m, 5.5H), 1.74-1.62 (m, 1.5H), 1.30-1.22 (m, 1.5H), 1.16-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.33 min, MS (ESI) 428.2 (M + H)⁺. 1-((2S,5R)-5-(4-((1H-indazol-4- yl)amino)-6-(pyridin-3-yl)pyrimidin- 2-yl)-2-methylpiperidin-1-yl)ethan- 1-one 00043

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 12.0 Hz, 1H), 9.26- 9.16 (m, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.48-8.32 (m, 1H), 8.15 (d, J = 6.3 Hz, 1H), 7.85 (d, J = 4.5 Hz, 1H), 7.81-7.51 (m, 3H), 7.19 (d, J = 3.6 Hz, 1H), 7.09 (d, J = 9.8 Hz, 1H), 4.91-4.71 (m, 1H), 4.27- 4.15 (m, 0.5H), 4.13-4.00 (m, 0.5H), 3.88 (d, J = 5.1 Hz, 3H), 3.52-3.40 (m, 0.5H), 3.00-2.85 (m, 1H), 2.82-2.70 (m, 0.5H), 2.12-1.81 (m, 5.5H), 1.77-1.64 (m, 1.5H), 1.28-1.22 (m, 1.5H), 1.14-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.49 min, MS (ESI) 486.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5-(1- methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2-methylpiperidin- 1-yl)ethan-1-one 00044

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.79 (d, J = 7.0 Hz, 1H), 9.28- 9.15 (m, 1H), 8.75-8.67 (m, 1H), 8.44- 8.35 (m, 1H), 8.18-8.00 (m, 2H), 7.80 (d, J = 3.5 Hz, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.45 (dd, J = 29.3, 8.2 Hz, 1H), 7.38- 7.29 (m, 1H), 7.26-7.20 (m, 1H), 7.16 (s, 1H), 4.87-4.75 (m, 1H), 4.26-4.16 (m, 0.5H), 4.04 (m, 0.5H), 3.85-3.80 (m, 3H), 3.46 (m, 0.5H), 2.95-2.81 (m, 1H), 2.79- 2.68 (m, 0.5H), 2.17-1.78 (m, 5.5H), 1.77- 1.59 (m, 1.5H), 1.25-1.20 (m, 1.5H), 1.12-1.07 (m, 1.5H); LCMS (Method D): t_(R) 3.35 min, MS (ESI) 468.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(1- methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00045

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.72 (d, J = 8.0 Hz, 1H), 9.24- 9.17 (m, 1H), 8.71 (d, J = 4.5 Hz, 1H), 8.46 (d, J = 2.9 Hz, 1H), 8.42-8.35 (m, 1H), 7.81-7.72 (m, 1H), 7.58 (t, J = 6.0 Hz, 1H), 7.36-7.28 (m, 2H), 7.26-7.19 (m, 1H), 4.84-4.79 (m, 0.5H), 4.75-4.70 (m, 0.5H), 4.28-3.99 (m, 4H), 3.49-3.39 (m, 0.5H), 2.94-2.81 (m, 1H), 2.77-2.67 (m, 0.5H), 2.11-1.77 (m, 5.5H), 1.74-1.60 (m, 1.5H), 1.30-1.21 (m, 1.5H), 1.17- 1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.13 min, MS (ESI) 442.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methyl-2H-indazol-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00046

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (d, J = 10.4 Hz, 1H), 9.48 (s, 1H), 9.26-9.20 (m, 1H), 9.16-9.11 (m, 1H), 8.72 (d, J = 4.6 Hz, 1H), 8.45-8.37 (m, 1H), 7.80 (d, J = 12.7 Hz, 1H), 7.73 (d, J = 13.5 Hz, 1H), 7.62-7.55 (m, 1H), 7.28 (d, J = 9.5 Hz, 1H), 7.25-7.19 (m, 1H), 4.86-4.71 (m, 1H), 4.27-4.16 (m, 0.5H), 4.08-4.00 (m, 0.5H), 3.51-3.42 (m, 0.5H), 2.96-2.85 (m, 1H), 2.81-2.70 (m, 0.5H), 2.10-1.82 (m, 5.5H), 1.73-1.61 (m, 1.5H), 1.27-1.19 (m, 1.5H), 1.16- 1.06 (m, 1.5H); LCMS (Method D): t_(R) 3.67 min, MS (ESI) 473.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- (isoxazol-4-yl)phenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00047

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (d, J = 7.4 Hz, 1H), 10.03 (d, J = 6.0 Hz, 1H), 9.21 (dd, J = 6.0, 2.3 Hz, 1H), 8.71 (dt, J = 4.7, 1.5 Hz, 1H), 8.42- 8.35 (m, 1H), 7.79-7.65 (m, 2H), 7.58 (dd, J = 8.1, 4.8 Hz, 1H), 7.22 (d, J = 2.7 Hz, 1H), 7.09-6.98 (m, 1H), 4.87-4.77 (m, 0.5H), 4.74-4.68 (m, 0.5H), 4.27- 4.18 (m, 0.5H), 4.07-4.00 (m, 0.5H), 3.50- 3.39 (m, 0.5H), 2.96-2.86 (m, 1H), 2.79- 2.69 (m, 0.5H), 2.11-1.95 (m, 8H), 1.90- 1.78 (m, 0.5H), 1.75-1.62 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.17-1.11 (m, 1.5H); UPLC (Method B): t_(R) 1.07 min, MS (ESI) 463.3 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)-5- fluorophenyl)acetamide 00048

  ¹H-NMR (400 MHz, Chloroform-d) mixture of rotamers δ 9.70-8.50 (m, 2H), 8.46- 8.33 (m, 1H), 8.12 (s, 0.5H), 8.01 (s, 0.5H), 7.65-7.33 (m, 2H), 7.27-7.18 (m, 1.5H), 7.18-7.11 (m, 1.5H), 7.01 (s, 1H), 5.09- 4.99 (m, 0.5H), 4.97-4.85 (m, 0.5H), 4.24- 4.14 (m, 0.5H), 4.03-3.94 (m, 0.5H), 3.90 (t, J = 7.0 Hz, 2H), 3.63-3.52 (m, 0.5H), 3.09 (t, J = 12.7 Hz, 0.5H), 2.96- 2.80 (m, 1H), 2.69-2.60 (m, 2H), 2.25- 1.98 (m, 7H), 1.96-1.67 (m, 2H), 1.37- 1.31 (m, 1.5H), 1.27-1.22 (m, 1.5H); UPLC (Method B): t_(R) 1.11 min, MS (ESI) 471.4 (M + H)⁺. 1-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4- yl)amino)phenyl)pyrrolidin-2-one 00049

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.94 (d, J = 9.6 Hz, 1H), 9.58 (dd, J = 12.9, 1.3 Hz, 1H), 8.85-8.77 (m, 2H), 8.31 (d, J = 4.2 Hz, 1H), 8.02 (t, J = 7.0 Hz, 1H), 7.89 (d, J = 1.7 Hz, 1H), 7.44- 7.30 (m, 2H), 4.90-4.79 (m, 0.5H), 4.78- 4.69 (m, 0.5H), 4.30-4.17 (m, 0.5H), 4.12- 3.99 (m, 3H), 3.55-3.43 (m, 0.5H), 3.00- 2.87 (m, 1H), 2.84-2.71 (m, 0.5H), 2.15- 1.93 (m, 5H), 1.90-1.79 (m, 0.5H), 1.76- 1.63 (m, 1.5H), 1.34-1.25 (m, 1.5H), 1.19-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.35 min, MS (ESI) 443.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((1- methyl-1H-indazol-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00050

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.82 (d, J = 7.1 Hz, 1H), 9.57 (dd, J = 13.0, 1.3 Hz, 1H), 8.83-8.76 (m, 2H), 8.48 (d, J = 2.4 Hz, 1H), 7.81-7.76 (m, 2H), 7.36-7.28 (m, 1H), 7.27-7.19 (m, 1H), 4.89-4.78 (m, 0.5H), 4.78-4.71 (m, 0.5H), 4.28-4.03 (m, 4H), 3.51-3.43 (m, 0.5H), 2.98-2.83 (m, 1H), 2.80-2.70 (m, 0.5H), 2.12-1.93 (m, 5H), 1.92-1.77 (m, 0.5H), 1.74-1.60 (m, 1.5H), 1.29-1.25 (m, 1.5H), 1.17-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.15 min, MS (ESI) 443.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methyl-2/−/−indazol-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00051

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.44 (s, 1H), 9.32-9.10 (m, 2H), 8.85-8.63 (m, 1H), 8.47-8.33 (m, 1H), 7.62-7.44 (m, 2H), 7.29-7.11 (m, 2H), 6.61 (d, J = 7.7 Hz, 1H), 4.93-4.75 (m, 0.5H), 4.73-4.60 (m, 0.5H), 4.28- 4.11 (m, 0.5H), 4.10-3.92 (m, 0.5H), 3.49 (s, 2H), 2.94-2.60 (m, 1.5H), 2.12-1.89 (m, 5.5H), 1.89-1.74 (m, 0.5H), 1.73- 1.57 (m, 1.5H), 1.30-1.18 (m, 1.5H), 1.18- 1.03 (m, 1.5H); LCMS (Method D): t_(R) 2.98 min, MS (ESI) 443.1 (M + H)⁺. 4-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)indolin-2- 00052

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.93243 (d, J = 6.0 Hz, 1H), 9.24- 9.16 (m, 1H), 8.77-8.61 (m, 2H), 8.51 (s, 1H), 8.44-8.35 (m, 1H), 7.81-7.62 (m, 2H), 7.61-7.55 (m, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.18 (d, J = 4.0 Hz, 1H), 4.91-4.77 (m, 0.5H), 4.77-4.65 (m, 0.5H), 4.26- 4.16 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.91 (d, J = 3.7 Hz, 3H), 3.60-3.49 (m, 0.5H), 3.05-2.83 (m, 1H), 2.80-2.65 (m, 0.5H), 2.15-1.95 (m, 5H), 1.90- 1.76 (m, 0.5H), 1.75-1.61 (m, 1.5H), 1.31-1.22 (m, 1.5H), 1.17-1.08 (m, 1.5H); LCMS (Method D): t_(R) 3.13 min, MS (ESI) 469.2 (M + H)⁺ 1-((2S,5R)-2-methyl-5-(4-((3-(1- . methyl-1H-1,2,4-triazol-3- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00053

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.91 (d, J = 6.1 Hz, 1H), 9.26- 9.16 (m, 1H), 8.75-8.65 (m, 1H), 8.49 (d, J = 12.6 Hz, 1H), 8.47-8.42 (m, 1H), 8.42- 8.34 (m, 1H), 7.74-7.55 (m, 2H), 7.52- 7.38 (m, 2H), 7.19 (s, 1H), 4.88-4.72 (m, 1H), 4.30-4.16 (m, 0.5H), 4.16-3.98 (m, 3.5H), 3.56-3.44 (m, 0.5H), 2.99-2.83 (m, 1H), 2.82-2.68 (m, 0.5H), 2.14-1.78 (m, 5.5H), 1.75-1.58 (m, 1.5H), 1.28- 1.21 (m, 1.5H), 1.18-1.07 (m, 1.5H); LCMS (Method D): t_(R) 3.19 min, MS (ESI) 469.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(1- methyl-1H-1,2,3-triazol-4- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00054

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.93 (d, J = 9.1 Hz, 1H), 9.78 (d, J = 3.7 Hz, 1H), 9.24-9.15 (m, 1H), 8.76- 8.64 (m, 1H), 8.44-8.34 (m, 1H), 8.11 (d, J = 30.7 Hz, 1H), 7.63-7.47 (m, 2H), 7.30- 7.03 (m, 3H), 4.88-4.76 (m, 0.5H), 4.76- 4.64 (m, 0.5H), 4.28-4.14 (m, 0.5H), 4.06-3.95 (m, 0.5H), 3.55-3.42 (m, 0.5H), 3.00-2.77 (m, 1H), 2.78-2.65 (m, 0.5H), 2.13-1.75 (m, 8.5H), 1.75-1.58 (m, 1.5H), 1.31-1.23 (m, 1.5), 1.18-1.08 (m, 1.5H); LCMS (Method D): t_(R) 3.05 min, MS (ESI) 445.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4- yl)amino)phenyl)acetamide 00055

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.14 (d, J = 6.1 Hz, 1H), 9.56 (d, J = 12.5 Hz, 1H), 8.81 (d, J = 1.7 Hz, 2H), 8.18 (d, J = 7.0 Hz, 1H), 8.15-8.12 (m, 0.5H), 7.99 (d, J = 25.9 Hz, 1H), 7.89- 7.83 (m, 1.5H), 7.67 (s, 1H), 7.42 (s, 1H), 7.04 (t, J = 56.0 Hz, 1H), 4.87-4.75 (m, 1H), 4.30-4.17 (m, 0.5H), 4.15-4.02 (m, 0.5H), 3.93-3.81 (m, 3H), 3.57-3.42 (m, 0.5H), 3.02-2.87 (m, 1H), 2.85-2.74 (m, 0.5H), 2.15-1.80 (m, 5.5H), 1.76-1.62 (m, 1.5H), 1.28-1.20 (m, 1.5H), 1.15- 1.06 (m, 1.5H); LCMS (Method D): t_(R) 3.54 min, MS (ESI) 519.22 (M + H)⁺. 1-((2S,5R)-5-(4-((3- (difluoromethyl)-5-(1-methyl- 1Hpyrazol-4-yl)phenyl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00056

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.84 (d, J = 10.4 Hz, 1H), 9.22 (dd, J = 6.6, 2.3 Hz, 1H), 8.74-8.68 (m, 1H), 8.44-8.36 (m, 1H), 8.28 (d, J = 4.6 Hz, 1H), 7.97 (dd, J = 9.5, 7.5 Hz, 1H), 7.59 (dd, J = 8.1, 4.8 Hz, 1H), 7.43-7.29 (m, 3H), 4.86-4.77 (m, 0.5H), 4.76-4.69 (m, 0.5H), 4.25-4.17 (m, 0.5H), 4.08-4.00 (m, 3.5H), 3.50-3.40 (m, 0.5H), 2.96- 2.84 (m, 1H), 2.79-2.65 (m, 0.5H), 2.11- 1.96 (m, 5H), 1.90-1.77 (m, 0.5H), 1.74- 1.62 (m, 1.5H), 1.30-1.23 (m, 1.5H), 1.17- 1.10 (m, 1.5H); UPLC (Method B): t_(R) 1.17 min, MS (ESI) 442.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((1- methyl-1H-indazol-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 0057

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.04 (d, J = 6.4 Hz, 1H), 9.22 (dd, J = 5.4, 2.2 Hz, 1H), 8.72 (d, J = 5.0 Hz, 1H), 8.48-8.36 (m, 1H), 8.21-8.17 (m, 1H), 8.17-8.11 (m, 1H), 8.99 (d, J = 22.3 Hz, 1H), 7.90-7.84 (m, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7. 41 (s, 1H), 7.22- 7.16 (m, 1H), 7.04 (t, J = 55.9 Hz, 1H), 4.87- 4.74 (m, 1H), 4.30-4.16 (m, 0.5H), 4.09- 3.99 (m, 0.5H), 3.96-3.84 (m, 3H), 3.54- 3.44 (m, 0.5H), 2.95-2.87 (m, 1H), 2.79- 2.73 (m, 0.5H), 2.13-1.95 (m, 5H), 1.88- 1.81 (m, 0.5H), 1.74-1.62 (m, 1.5H), 1.28-1.18 (m, 1.5H), 1.14-1.06 (m, 1.5H); UPLC (Method B): t_(R) 1.49 min, MS (ESI) 518.4 (M + H)⁺. 1-((2S,5R)-5-(4-((3- (difluoromethyl)-5-(1-methyl-1H- pyrazol-4-yl)phenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00058

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.99 (d, J = 7.1 Hz, 1H), 9.21 (dd, J = 6.3, 2.3 Hz, 1H), 8.74-8.68 (m, 1H), 8.43-8.36 (m, 1H), 8.27 (d, J = 12.0 Hz, 1H), 7.70 (d, J = 6.0 Hz, 1H), 7.58 (dd, J = 7.9, 4.7 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.19 (dd, J = 14.0, 5.7 Hz, 2H), 4.87-4.78 (m, 0.5H), 4.74-4.67 (m, 0.5H), 4.26- 4.17 (m, 0.5H), 4.02 (dd, J = 13.8, 4.1 Hz, 0.5H), 3.51-3.42 (m, 0.5H), 2.95-2.85 (m, 1H), 2.79-2.66 (m, 0.5H), 2.10-1.90 (m, 8H), 1.89-1.76 (m, 0.5H), 1.74-1.61 (m, 1.5H), 1.30-1.23 (m, 1.5H), 1.16- 1.10 (m, 1.5H); UPLC (Method A): t_(R) 1.65 min, MS (ESI) 452.4 (M + H)⁺. 1-((2S,5R)-5-(4-((3-(1,1- difluoroethyl)phenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 0059

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.15 (d, J = 7.4 Hz, 2H), 9.55 (d, J = 13.1 Hz, 1H), 8.81 (d, J = 1.8 Hz, 2H), 8.08 (t, J = 17.9 Hz, 2H), 7.68 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 22.3 Hz, 1H), 7.02 (t, 1H), 4.92-4.77 (m, 0.5H), 4.77-4.66 (m, 0.5H), 4.29-4.16 (m, 0.5H), 4.09- 3.97 (m, 0.5H), 3.53-3.42 (m, 0.5H), 3.00- 2.86 (m, 1H), 2.81-2.69 (m, 0.5H), 2.12- 1.98 (m, 8H), 1.92-1.76 (m, 0.5H), 1.76- 1.60 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.17-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.30 min, MS (ESI) 496.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyrazin-2- yl)pyrimidin-4-yl)amino)-5- (difluoromethyl)phenyl)acetamide 00060

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.14 (d, J = 8.6 Hz, 1H), 10.03 (s, 1H), 9.26-9.15 (m, 1H), 8.76-8.65 (m, 1H), 8.43-8.33 (m, 1H), 8.07 (dd, J = 27.9, 17.7 Hz, 2H), 7.63-7.51 (m, 1H), 7.33 (d, J = 20.8 Hz, 1H), 7.21 (d, J = 2.8 Hz, 1H), 7.02 (t, J = 56.1 Hz, 1H), 4.90-4.75 (m, 0.5H), 4.74-4.67 (m, 0.5H), 4.28-4.12 (m, 0.5H), 4.05-3.91 (m, 0.5H), 3.53- 3.41 (m, 0.5H), 3.36-3.33 (m, 0.5H), 2.99- 2.84 (m, 1H), 2.79-2.68 (m, 0.5H), 2.11- 1.93 (m, 7.5H), 1.90-1.77 (m, 0.5H), 1.74-1.58 (m, 1.5H), 1.32-1.19 (m, 1.5H), 1.18-1.07 (m, 1.5H); LCMS (Method D): t_(R) 3.26 min, MS (ESI) 495.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin-3- yl)pyrimidin-4-yl)amino)-5- (difluoromethyl)phenyl)acetamide 00061

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (d, J = 7.0 Hz, 1H), 9.23 (dd, J = 5.7, 2.3 Hz, 1H), 8.72 (d, J = 4.8 Hz, 1H), 8.49 (d, J = 9.9 Hz, 1H), 8.45- 8.35 (m, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.68- 7.55 (m, 2H), 7.52 (d, J = 7.7 Hz, 1H), 7.22 (d, J = 3.1 Hz, 1H), 4.86-4.75 (m, 0.5H), 4.71-4.61 (m, 0.5H), 4.28-4.09 (m, 3.5H), 4.06-3.95 (m, 0.5), 3.53-3.43 (m, 0.5H), 2.98-2.83 (m, 1H), 2.77-2.68 (m, 0.5H), 2.11-1.96 (m, 5H), 1.89-1.77 (m, 0.5H), 1.75-1.59 (m, 1.5H), 1.29- 1.18 (m, 1.5H), 1.16-1.03 (m, 1.5H); UPLC (Method A): t_(R) 1.36 min, MS (ESI) 470.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(1- methyl-1H-tetrazol-5- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00062

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.06 (d, J = 7.3 Hz, 1H), 9.22 (dd, J = 6.8, 2.3 Hz, 1H), 8.86 (d, J = 31.2 Hz, 1H), 8.71 (dd, J = 4.0, 2.3 Hz, 1H), 8.45- 8.32 (m, 1H), 7.83-7.67 (m, 2H), 7.64- 7.48 (m, 2H), 7.20 (d, J = 4.3 Hz, 1H), 4.90- 4.78 (m, 0.5H), 4.74-4.67 (m, 0.5H), 4.42 (d, J = 2.2 Hz, 3H), 4.27-4.17 (m, 0.5H), 4.07 (m, 0.5H), 3.55 (m, 0.5H), 3.04- 2.85 (m, 1H), 2.74 (m, 0.5H), 2.06 (m, 5H), 1.94-1.79 (m, 0.5H), 1.79-1.62 (m, 1.5H), 1.27 (m, 1.5H), 1.13 (m, 1.5H); UPLC (Method A): t_(R) 1.50 min, MS (ESI) 470.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(2- methyl-2H-tetrazol-5- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00063

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.24 (d, J = 8.5 Hz, 1H), 10.12 (d, J = 4.6 Hz, 1H), 9.29-9.19 (m, 1H), 8.81-8.69 (m, 2H), 8.47-8.36 (m, 1H), 7.71 (t, J = 8.0 Hz, 1H), 7.66-7.50 (m, 3H), 7.25 (d, J = 3.7 Hz, 1H), 4.86-4.79 (m, 0.5H), 4.77-4.65 (m, 0.5H), 4.24-4.16 (m, 0.5H), 4.05-3.94 (m, 0.5H), 3.55- 3.44 (m, 0.5H), 3.00-2.85 (m, 1H), 2.84- 2.69 (m, 0.5H), 2.17-1.93 (m, 5H), 1.94- 1.76 (m, 0.5H), 1.75-1.58 (m, 1.5H), 1.31- 1.18 (m, 1.5H), 1.15-1.03 (m, 1.5H); UPLC (Method A): t_(R) 1.37 min, MS (ESI) 456.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-(1H-tetrazol-1- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2-methylpiperidin- 1-yl)ethan-1-one 00064

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.16 (s, 1H), 9.56 (d, J = 15.0 Hz, 1H), 8.94-8.66 (m, 3H), 7.80 (dd, J = 25.3, 8.2 Hz, 1H), 7.71-7.62 (m, 2H), 7.53 (t, J = 7.8 Hz, 1H), 4.91-4.79 (m, 0.5H), 4.78-4.69 (m, 0.5H), 4.29-4.18 (m, 0.5H), 4.18-4.03 (m, 0.5H), 3.62-3.49 (m, 0.5H), 3.07-2.87 (m, 1H), 2.86-2.71 (m, 0.5H), 2.66 (d, J = 2.5 Hz, 3H), 2.24- 1.95 (m, 5H), 1.94-1.78 (m, 0.5H), 1.78- 1.62 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.19- 1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.67 min, MS (ESI) 471.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(5- methyl-1,2,4-oxadiazol-3- yl)phenyl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00065

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.91 (d, J = 7.3 Hz, 1H), 9.55 (dd, J = 11.8, 1.2 Hz, 1H), 8.80 (d, J = 1.8 Hz, 2H), 8.19-7.98 (m, 2H), 7.81 (d, J = 3.3 Hz, 1H), 7.64 (s, 2H), 7.34 (td, J = 8.1, 4.2 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 4.88- 4.76 (m, 1H), 4.29-4.16 (m, 0.5H), 4.13- 4.01 (m, 0.5H), 3.88 (d, J = 6.5 Hz, 3H), 3.53-3.42 (m, 0.5H), 2.99-2.84 (m, 1H), 2.82-2.69 (m, 0.5H), 2.16-1.95 (m, 5H), 1.92-1.80 (m, 0.5H), 1.78-1.60 (m, 1.5H), 1.28-1.22 (m, 1.5H), 1.15-1.08 (m, 1.5H); LCMS (Method D): t_(R) 3.44 min, MS (ESI) 469.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(1- methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00066

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (d, J = 12.0 Hz, 1H), 9.56 (dd, J = 12.5, 1.1 Hz, 1H), 8.81 (d, J = 1.6 Hz, 2H), 8.15 (d, J = 7.3 Hz, 1H), 7.85 (d, J = 4.6 Hz, 1H), 7.78 (s, 0.5H), 7.71-7.63 (m, 2H), 7.54 (d, J = 11.6 Hz, 0.5H), 7.13- 7.06 (m, 1H), 4.88-4.77 (m, 1H), 4.30- 4.18 (m, 0.5H), 4.15-4.01 (m, 0.5H), 3.92- 3.83 (m, 3H), 3.54-3.41 (m, 0.5H), 3.00- 2.88 (m, 1H), 2.85-2.72 (m, 0.5H), 2.20- 1.93 (m, 5H), 1.93-1.80 (m, 0.5H), 1.79- 1.53 (m, 1.5H), 1.30-1.23 (m, 1.5H), 1.16-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.60 min, MS (ESI) 487.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5-(1- methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)-2-methylpiperidin- 1-yl)ethan-1-one 00067

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.09 (d, J = 6.4 Hz, 1H), 9.64- 9.48 (m, 1H), 8.81 (d, J = 1.9 Hz, 2H), 7.65 (d, J = 2.3 Hz, 1H), 7.37 (dd, J = 20.5, 11.4 Hz, 1H), 7.23 (d, J = 14.8 Hz, 1H), 6.54- 6.47 (m, 1H), 4.90-4.79 (m, 0.5H), 4.78- 4.70 (m, 0.5H), 4.31-4.17 (m, 0.5H), 4.15-4.02 (m, 0.5H), 3.79 (d, J = 1.5 Hz, 3H), 3.53-3.40 (m, 0.5H), 3.01-2.86 (m, 1H), 2.84-2.71 (m, 0.5H), 2.18-1.93 (m, 5H), 1.93-1.79 (m, 0.5H), 1.79-1.62 (m, 1.5H), 1.30-1.25 (m, 1.5H), 1.17-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.81 min, MS (ESI) 437.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- methoxyphenyl)amino)-6-(pyrazin- 2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00068

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 5.6 Hz, 1H), 9.56 (dd, J = 11.0, 1.1 Hz, 1H), 8.80 (d, J = 1.5 Hz, 2H), 8.54-8.42 (m, 2H), 7.72-7.54 (m, 2H), 7.53-7.39 (m, 2H), 4.86-4.76 (m, 1H), 4.27-4.16 (m, 0.5H), 4.15-4.03 (m, 3.5H), 3.58-3.42 (m, 0.5H), 3.00- 2.86 (m, 1H), 2.86-2.68 (m, 0.5H), 2.17- 1.96 (m, 5H), 1.93-1.77 (m, 0.5H), 1.76- 1.64 (m, 1.5H), 1.27 (d, J = 6.8 Hz, 1.5H), 1.13 (d, J = 7.0 Hz, 1.5H); LCMS (Method D): t_(R) 3.31 min, MS (ESI) 470.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(1- m ethyl-1H-1,2,3-triazol-4- yl)phenyl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00069

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.25 (d, J = 9.6 Hz, 1H), 9.56 (d, J = 12.1 Hz, 1H), 8.86-8.76 (m, 2H), 8.57 (d, J = 9.8 Hz, 1H), 8.12 (d, J = 16.7 Hz, 1H), 7.84 (dd, J = 43.2, 11.7 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.29 (t, J = 9.1 Hz, 1H), 4.89-4.73 (m, 1H), 4.28-4.19 (m, 0.5H), 4.15-4.05 (m, 3.5H), 3.56-3.46 (m, 0.5H), 3.02-2.89 (m, 1H), 2.86-2.75 (m, 0.5H), 2.14-1.97 (m, 5H), 1.94-1.82 (m, 0.5H), 1.80-1.64 (m, 1.5H), 1.29 (d, J = 6.8 Hz, 1.5H), 1.15 (d, J = 7.0 Hz, 1.5H); UPLC (Method A): t_(R) 1.49 min, MS (ESI) 488.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5-(1- methyl-1H-1,2,3-triazol-4- yl)phenyl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00070

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.97 (d, J = 11.0 Hz, 1H), 9.55 (dd, J = 14.3, 1.2 Hz, 1H), 8.80 (q, J = 2.0, 1.5 Hz, 2H), 7.63 (d, J = 2.3 Hz, 1H), 7.32- 7.18 (m, 1H), 7.17-7.03 (m, 1H), 6.54- 6.43 (m, 1H), 4.91-4.68 (m, 1H), 4.30- 4.14 (m, 0.5H), 4.15-3.99 (m, 0.5H), 3.81- 3.64 (m, 4H), 3.51-3.41 (m, 0.5H), 3.15 (t, J = 4.9 Hz, 4H), 3.00-2.84 (m, 1H), 2.84- 2.69 (m, 0.5H), 2.16-1.91 (m, 5.5H), 1.91-1.78 (m, 0.5H), 1.77-1.60 (m, 1.5H), 1.31-1.22 (m, 1.5H), 1.19-1.09 (m, 1.5H); UPLC (Method B): t_(R) 1.56 min, MS (ESI) 492.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- morpholinophenyl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one

Example 3: synthesis of 1-((2S,5R)-5-(4-((4-hydroxyphenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (00071)

To a solution of 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 2, 50 mg, 0.17 mmol) in 2-propanol (2 mL) was added 4-aminophenol (19.9 mg, 0.18 mmol) and concentrated hydrochloric acid (0.03 mL, 0.35 mmol). The mixture was stirred at 70° C. for 16 hours and concentrated. The residue was redissolved in water, neutralized with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate three times. The combined organic layers were dried over sodium sulfate and concentrated to afford a solid. The solid was purified with reversed phase chromatography (method A) and lyophilized to afford 1-((2S,5R)-5-(4-chloro-6-((4- hydroxyphenyl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (20 mg, 32%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 9.64-9.53 (m, 1H), 9.34 (s, 1H), 7.34 (s, 2H), 6.79-6.71 (m, 2H), 6.47 (s, 1H), 4.82-4.73 (m, 0.5H), 4.65-4.54 (m, 0.5H), 4.21-4.09 (m, 0.5H), 3.91-3.84 (m, 0.5H), 2.77-2.65 (m, 1H), 2.57-2.53 (m, 0.5H), 2.07-1.98 (m, 3H), 1.97-1.70 (m, 3H), 1.69-1.55 (m, 1.5H), 1.25-1.18 (m, 1.5H), 1.13-1.05 (m, 1.5H); LCMS (Method A): t_(R) 1.81 min, MS (ESI) 361.1 (M+H)⁺. Under nitrogen, 1-((2S,5R)-5-(4-chloro-6-((4-hydroxyphenyl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (18.7 mg, 0.05 mmol), pyridine-3-boronic acid (24 mg, 0.20 mmol), sodium carbonate (22 mg, 0.20 mmol) and PdCl₂(dppf) (8.4 mg, 11 μmol) were dissolved in a mixture of 1,2-dimethoxyethane (3 mL) and water (1 mL). The mixture was stirred at 80° C. for 16 hours. The mixture was filtered through a short C18-column plug, was purified with reversed phase chromatography (method A) and lyophilized to afford a white solid with 82% de. The product was further purified by chiral preparative SFC (Method A) and lyophilized to afford 1-((2S,5R)-5-(4-((4-hydroxyphenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (5.6 mg, 27%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 9.45 (d, J=7.9 Hz, 1H), 9.25 (s, 1H), 9.16 (dd, J=5.9, 2.4 Hz, 1H), 8.68 (d, J=4.7 Hz, 1H), 8.34 (td, J=5.9, 2.9 Hz, 1H), 7.62-7.33 (m, 3H), 7.00 (d, J=4.3 Hz, 1H), 6.84-6.64 (m, 2H), 4.88-4.75 (m, 1H), 4.72-4.64 (m, 0.5H), 4.25-4.15 (m, 0.5H), 4.02-3.95 (m, 0.5H), 3.49-3.37 (m, 0.5H), 2.94-2.74 (m, 1H), 2.70-2.56 (m, 1H), 2.10-1.90 (m, 4H), 1.90-1.74 (m, 0.5H), 1.74-1.56 (m, 1.5H), 1.29-1.20 (m, 1.5H), 1.20-1.05 (m, 1.5H); LCMS (Method B): t_(R) 2.48 min, MS (ESI) 404.1 (M+H)⁺; Chiral SFC (Method C): t_(R) 5.39 min, >95% ee and de.

The following compounds were prepared following procedures analogous to Example 3, using the appropriate starting materials, and purified using reversed phase chromatography method A/B and/or prep-SFC.

Compound # Structure and compound name Analytical data 00072

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.88 (d, J = 7.6 Hz, 1H), 9.38 (d, J = 8.8 Hz, 2H), 9.32 (d, J = 2.1 Hz, 1H), 7.76 (dd, J = 8.3, 2.8 Hz, 2H), 7.36 (td, J = 8.8, 8.0, 2.0 Hz, 2H), 7.21 (d, J = 4.2 Hz, 1H), 7.06 (t, J = 7.3 Hz, 1H), 4.87-4.76 (m, 0.5H), 4.75-4.66 (m, 0.5H), 4.25-4.15 (m, 0.5H), 4.08- 4.00 (m, 0.5H), 3.50-3.40 (m, 0.5H), 2.96-2.81 (m, 1H), 2.77-2.65 (m, 0.5H), 2.10-1.89 (m, 5H), 1.88- 1.76 (m, 0.5H), 1.76-1.60 (m, 1.5H) 1.29-1.26 (m, 1.5H), 1.16-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.37 min, MS (ESI) 389.2 (M + H)⁺. (+/−)-cis-1-(2-methyl-5-(6- (phenylamino)-[4,5′- bipyrimidin]-2-yl)piperidin-1- yl)ethan-1-one 00073

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 11.90 (s, 1H), 9.70 (d, J = 7.2 Hz, 1H), 8.85 (s, 1H), 8.72 (d, J = 3.4 Hz, 1H), 7.79 (dt, J = 6.7, 2.9 Hz, 3H), 7.41-7.31 (m, 2H), 7.27 (d, J = 2.4 Hz, 1H), 7.09- 6.99 (m, 2H), 4.88-4.73 (m, 1H), 4.27-4.17 (m, 0.5H), 4.14-4.05 (m, 0.5H), 3.52-3.42 (m, 0.5H), 2.98-2.86 (m, 1H), 2.79-2.68 (m, 0.5H), 2.17- 1.91 (m, 5H), 1.90-1.79 (m, 0.5H), 1.77-1.64 (m, 1.5H), 1.31-1.22 (m, 1.5H), 1.19-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.47 min, MS (ESI) 427.2 (M + H)⁺. (+/−)-c/s-1-(2-methyl-5-(4- (phenylamino)-6-(1H- pyrrolo[2,3-c]pyridin-4- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00074

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.99 (d, J = 5.1 Hz, 1H), 8.80 (dd, J = 7.6, 1.8 Hz, 1H), 8.44 (t, J = 2.7 Hz, 1H), 8.25 (dt, J = 8.4, 2.2 Hz, 1H), 7.96-7.84 (m, 1H), 7.58-7.46 (m, 1H), 7.37 (td, J = 8.1,2.0 Hz, 1H),7.18(d, J = 3.8 Hz, 1H), 7.12- 7.02 (m, 1H), 4.89-4.78 (m, 0.5H), 4.74-4.64 (m, 0.5H), 4.27-4.16 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.93 (d, J = 1.2 Hz, 3H), 3.52-3.39 (m, 0.5H), 2.99- 2.84 (m, 1H), 2.81-2.70 (m, 0.5H), 2.11-1.92 (m, 5H), 1.92-1.77 (m, 0.5H), 1.77-1.61 (m, 1.5H), 1.34-1.24 (m, 1.5H), 1.20-1.09 (m, 1.5H); LCMS (Method B): t_(R) 3.65 min, MS (ESI) 452.1 (M + H)⁺. 1-((2S,5R)-5-(4-((3- chlorophenyl)amino)-6-(5- methoxypyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00075

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.64 (d, J = 8.3 Hz, 1H), 9.41 (s, 1H), 9.24-9.14 (m, 1H), 8.70 (d, J = 4.7 Hz, 1H), 8.40-8.33 (m, 1H), 7.57 (dd, J = 8.0, 4.7 Hz, 1H), 7.31-7.08 (m, 4H), 6.49-6.42 (m, 1H), 4.87-4.77 (m, 0.5H), 4.73- 4.64 (m, 0.5H), 4.25-4.17 (m, 0.5H), 4.08-3.99 (m, 0.5H), 3.49-3.45 (m, 0.5H), 2.97-2.81 (m, 1H), 2.74-2.63 (m, 0.5H), 2.10-1.93 (m, 5H), 1.87- 1.78 (m, 0.5H), 1.73-1.64 (m, 1.5H), 1.29-1.25 (m, 1.5H), 1.16-1.12 (m, 1.5H); LCMS (Method B): t_(R) 2.65 min, MS (ESI) 404.1 (M + H)⁺. 1-((2S,5R)-5-(4-((3- hydroxyphenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1- yl)ethan-1-one 00076

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.46 (d, J = 17.5 Hz, 1H), 9.74 (d, J = 8.6 Hz, 1H), 9.24-9.15 (m, 1H), 8.70 (d, J = 4.7 Hz, 1H), 8.42- 8.34 (m, 1H), 7.57 (dd, J = 8.1,4.8 Hz, 1H), 7.38 (d, J = 21.6 Hz, 1H), 7.25 (t, J = 7.4 Hz, 1H), 7.19-7.10 (m, 2H), 4.90-4.77 (m, 0.5H), 4.75-4.65 (m, 0.5H), 4.25-4.17 (m, 0.5H), 4.08-3.99 (m, 0.5H), 3.43 (s, 2H), 2.96-2.78 (m, 1H), 2.74-2.62 (m, 0.5H), 2.14- 1.76 (m, 6H), 1.76-1.60 (m, 1.5H), 1.30-1.24 (m, 1.5H), 1.16-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.02 min, MS (ESI) 443.2 (M + H)⁺. 6-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)indolin-2-one 00077

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.98 (d, J = 5.7 Hz, 1H), 9.21 (dd, J = 6.7, 2.3 Hz, 1H), 8.71 (d, J = 4.8 Hz, 1H), 8.52 (d, J = 34.0 Hz, 1H), 8.40 (t, J = 7.6 Hz, 1H), 8.35-8.29 (m, 1H), 7.65- 7.46 (m, 2H), 7.45-7.37 (m, 2H), 7.19 (d, J = 3.1 Hz, 1H), 6.33 (t, J = 2.2 Hz, 1H), 4.87-4.71 (m, 0.5H), 4.27-4.15 (m, 0.5H), 4.13-4.02 (m, 0.5H), 3.56-3.45 (m, 0.5H), 3.00-2.83 (m, 1H), 2.79- 2.68 (m, 0.5H), 2.29-2.23 (m, 3H), 2.19-1.91 (m, 5.5H), 1.90-1.78 (m, 0.5H), 1.76-1.59 (m, 1.5H), 1.27-1.17 (m, 1.5H), 1.13-1.07 (m, 1.5H); UPLC (Method A): t_(R) 1.58 min, MS (ESI) 468.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- ((3-(3-methyl-1H-pyrazol-1- yl)phenyl)amino)-6-(pyridin- 3-yl)pyrimidin-2-yl)piperidin- 1-yl)ethan-1-one 00078

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.09 (d, J = 6.1 Hz, 1H), 9.29 (d, J = 3.8 Hz, 1H), 9.22 (dd, J = 6.8, 2.3 Hz, 1H), 8.74-8.63 (m, 2H), 8.44-8.37 (m, 1H), 8.21 (d, J = 4.8 Hz, 1H), 7.63- 7.47 (m, 4H), 7.21 (d, J = 2.7 Hz, 1H), 4.86-4.76 (m, 0.5H), 4.73-4.65 (m, 0.5H), 4.25-4.17 (m, 0.5H), 4.06-3.97 (m, 0.5H), 3.55-3.43 (m, 0.5H), 2.99- 2.86 (m, 1H), 2.79-2.69 (m, 0.5H), 2.12-1.95 (m, 5H), 1.88-1.77 (m, 0.5H), 1.75-1.60 (m, 1.5H), 1.28-1.22 (m, 1.5H), 1.15-1.08 (m, 1.5H); LCMS (Method B): t_(R) 2.41 min, MS (ESI) 455.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-(1H- 1,2,4-triazol-1- yl)phenyl)amino)-6-(pyridin- 3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00079

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.28 (s, 1H), 9.84 (d, J = 4.7 Hz, 1H), 9.22 (dd, J = 5.2, 2.3 Hz, 1H), 8.73-8.67 (m, 1H), 8.44-8.28 (m, 2H), 7.99-7.91 (m, 2H), 7.64-7.48 (m, 5H), 7.36- 7.26 (m, 2H), 7.22 (s, 1H), 4.83-4.74 (m, 0.5H), 4.72- 4.66 (m, 0.5H), 4.24-4.14 (m, 0.5H), 4.06-3.96 (m, 0.5H), 3.54-3.43 (m, 0.5H), 2.98-2.80 (m, 1H), 2.76-2.64 (m, 0.5H), 2.11-1.97 (m, 5H), 1.88- 1.75 (m, 0.5H), 1.73-1.59 (m, 1.5H), 1.25-1.15 (m, 1.5H), 1.12-1.05 (m, 1.5H); LCMS (Method B): t_(R) 3.05 min, MS (ESI) 507.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)phenyl)benzamide 00080

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.02 (d, J = 9.3 Hz, 1H), 9.21 (dd, J = 6.5, 2.2 Hz, 1H), 8.71 (d, J = 4.8 Hz, 1H), 8.40 (dd, J = 8.3, 6.3 Hz, 1H), 7.96 (t, J = 12.4 Hz, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.43-7.34 (m, 2H), 7.19 (d, J = 3.9 Hz, 1H), 6.88-6.81 (m, 1H), 4.89-4.78 (m, 0.5H), 4.78- 4.66 (m, 0.5H), 4.27-4.19 (m, 0.5H), 4.10-4.00 (m, 0.5H), 3.49-3.47 (m, 0.5H), 2.94-2.86 (m, 1H), 2.81-2.70 (m, 0.5H), 2.09-1.98 (m, 5H), 1.95- 1.82 (m, 0.5H), 1.78-1.64 (m, 1.5H), 1.31-1.26 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.00 min, MS (ESI) 406.22 (M + H)⁺. 1-((2S,5R)-5-(4-((3- fluorophenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1- yl)ethan-1-one 00081

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.80 (d, J = 4.1 Hz, 1H), 9.64 (s, 1H), 9.20 (dd, J = 5.6, 2.2 Hz, 1H), 8.70 (dd, J = 4.1, 2.4 Hz, 1H), 8.43- 8.32 (m, 1H), 8.19 (d, J = 29.0 Hz, 1H), 7.60-7.51 (m, 2H), 7.31-7.17 (m, 3H), 5.73-5.61 (m, 1H), 4.88-4.75 (m, 0.5H), 4.73-4.65 (m, 0.5H), 4.28- 4.11 (m, 0.5H), 4.04-3.97 (m, 2.5H), 3.50-3.41 (m, 0.5H), 2.97-2.80 (m, 1H), 2.78-2.59 (m, 0.5H), 2.14-1.89 (m, 5H), 1.89-1.75 (m, 0.5H), 1.75- 1.59 (m, 1.5H), 1.30-1.24 (m, 1.5H), 1.16-1.10 (m, 1.5H); LCMS (Method D): t_(R) 2.96 min, MS (ESI) 461.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)phenyl)-2- hydroxyacetamide 00082

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.47 (s, 1H), 9.18 (dd, J = 5.0, 2.4 Hz, 1H), 8.69 (d, J = 4.8 Hz, 1H), 8.46-8.26 (m, 1H), 7.56 (dd, J = 8.0,4.7 Hz, 1H), 7.13 (d, J = 2.7 Hz, 1H), 7.05-6.82 (m, 3H), 6.37-6.16 (m, 1H), 5.09 (s, 2H), 4.91-4.62 (m, 1H), 4.25-4.14 (m, 0.5H), 4.06-3.92 (m, 0.5H), 3.51-3.38 (m, 0.5H), 2.95-2.76 (m, 1H), 2.74- 2.56 (m, 0.5H), 2.14-1.90 (m, 5H), 1.90-1.76 (m, 0.5H), 1.74-1.62 (m, 1.5H), 1.29-1.23 (m, 1.5H), 1.16-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.09 min, MS (ESI) 403.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3- aminophenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)- 2-methylpiperidin-1- yl)ethan-1-one 00083

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.14 (d, J = 6.8 Hz, 1H), 9.22 (dd, J = 6.5, 2.3 Hz, 1H), 8.83-8.79 (m, 1H), 8.78-8.66 (m, 2H), 8.41 (ddt, J = 8.3, 6.5, 2.0 Hz, 1H), 7.98 (d, J = 3.0 Hz, 1H), 7.69 (dd, J = 14.8, 8.0 Hz, 1H), 7.62-7.48 (m, 3H), 7.23 (d, J = 2.9 Hz, 1H), 4.87-4.75 (m, 0.5H), 4.75-4.66 (m, 0.5H), 4.25-4.14 (m, 0.5H), 4.11- 3.95 (m, 0.5H), 3.53-3.42 (m, 0.5H), 2.97-2.83 (m, 1H), 2.82-2.70 (m, 0.5H), 2.10-1.95 (m, 5H), 1.92- 1.73 (m, 0.5H), 1.73-1.62 (m, 1.5H), 1.27-1.19 (m, 1.5H), 1.11-1.04 (m, 1.5H); LCMS (Method B): t_(R) 2.79 min, MS (ESI) 455.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-(1H- 1,2,3-triazol-1- yl)phenyl)amino)-6-(pyridin- 3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan1- one 00084

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.84-9.69 (m, 2H), 9.20 (dd, J = 5.6, 2.3 Hz, 1H), 8.76-8.64 (m, 1H), 8.45-8.33 (m, 1H), 8.19 (d, J = 36.9 Hz, 1H), 7.61-7.44 (m, 2H), 7.27 (t, J = 8.1 Hz, 1H), 7.23-7.13 (m, 2H), 4.88-4.75 (m, 0.5H), 4.73- 4.64 (m, 0.5H), 4.28-4.12 (m, 0.5H), 4.06-3.93 (m, 2.5H), 3.53-3.43 (m, 0.5H), 3.38 (s, 3H), 3.00- 2.79 (m, 1H), 2.78-2.62 (m, 0.5H), 2.14-1.89 (m, 5H), 1.89-1.74 (m, 0.5H), 1.74-1.56 (m, 1.5H), 1.32-1.20 (m, 1.5H), 1.20-1.07 (m, 1.5H); LCMS (Method B): t_(R) 2.69 min, MS (ESI) 475.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)phenyl)-2- methoxyacetamide 00085

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.93 (d, J = 10.4 Hz, 1H), 9.71 (d, J = 3.6 Hz, 1H), 8.95 (s, 1H), 8.76 (d, J = 3.2 Hz, 1H), 8.13 (d, J = 30.0 Hz, 1H), 7.75 (t, J = 2.5 Hz, 1H), 7.61 (t, J = 9.3 Hz, 1H), 7.31-7.21 (m, 2H), 7.13-7.00 (m, 2H), 4.91- 4.65 (m, 1H), 4.29-4.16 (m, 0.5H), 4.11-4.03 (m, 0.5H), 3.98 (s, 3H), 3.53-3.47 (m, 0.5H), 2.99-2.84 (m, 1H), 2.79-2.67 (m, 0.5H), 2.10-1.97 (m, 8H), 1.93-1.76 (m, 0.5H), 1.76-1.63 (m, 1.5H), 1.31- 1.25 (m, 1.5H), 1.18-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.20 min, MS (ESI) 498.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6-(1- methyl-1H-pyrrolo[2,3- c]pyridin-4-yl)pyrimidin-4- yl)amino)phenyl)acetamide 00086

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.84 (d, J = 6.3 Hz, 1H), 8.96 (s, 1H), 8.77 (s, 1H), 8.54-8.44 (m, 2H), 7.84-7.57 (m, 2H), 7.54-7.35 (m, 2H), 7.30 (s, 1H), 7.04 (d, J = 3.0 Hz, 1H), 4.91- 4.76 (m, 1H), 4.28-4.18 (m, 0.5H), 4.14-4.06 (m, 3.5H), 3.99 (s, 3H), 3.56-3.47 (m, 0.5H), 3.00-2.88 (m, 1H), 2.83-2.70 (m, 0.5H), 2.15-2.00 (m, 5H), 1.93-1.79 (m, 0.5H), 1.79-1.59 (m, 1.5H), 1.30- 1.24 (m, 1.5H), 1.16-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.34 min, MS (ESI) 522.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- ((3-(1-methyl-1H-1,2,3- triazol-4-yl)phenyl)amino)- 6-(1-methyl-1H-pyrrolo[2,3- c]pyridin-4-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00087

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.89 (d, J = 5.1 Hz, 1H), 9.21 (dd, J = 5.9, 2.3 Hz, 1H), 8.71 (d, J = 4.9 Hz, 1H), 8.44-8.34 (m, 1H), 7.97 (d, 1H), 7.58 (dd, J = 8.0, 4.7 Hz, 1H), 7.49- 7.41 (m, 1H), 7.39-7.28 (m, 1H), 7.19 (d, J = 2.4 Hz, 1H), 6.98 (dd, J = 29.0, 8.2 Hz, 1H), 4.89-4.79 (m, 0.5H), 4.79-4.69 (m, 0.5H), 4.27-4.15 (m, 0.5H), 4.09-3.98 (m, 0.5H), 3.71-3.61 (m, 2H), 3.53- 3.44 (m, 0.5H), 3.15-3.05 (m, 2H), 2.97-2.83 (m, 1H), 2.79-2.70 (m,0.5H), 2.13-1.91 (m, 5H), 1.91- 1.78 (m, 0.5H), 1.76-1.63 (m, 1.5H), 1.29-1.24 (m, 1.5H), 1.17-1.11 (m, 1.5H); UPLC (Method A): t_(R) 1.40 min, MS (ESI) 457.4 (M + H)⁺. 1-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)phenyl)azetidin-2- one 00088

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.87 (d, J = 4.1 Hz, 1H), 9.20 (s, 1H), 8.78-8.66 (m, 1H), 8.49-8.33 (m, 1H), 8.15 (d, J = 21.3 Hz, 1H), 7.66-7.46 (m, 2H), 7.41-7.09 (m, 3H), 4.87- 4.78 (m, 0.5H), 4.76-4.69 (m, 0.5H), 4.44 (t, J = 7.9 Hz, 2H), 4.25-3.96 (m, 3H), 3.49-3.45 (m, 0.5H), 2.94-2.83 (m, 1H), 2.73-2.68 (m, 0.5H), 2.13- 1.94 (m, 5H), 1.87-1.77 (m, 0.5H), 1.73-1.60 (m, 1.5H), 1.28-1.23 (m, 1.5H), 1.20-1.09 (m, 1.5H); UPLC (Method A): t_(R) 1.37 min, MS (ESI) 473.4 (M + H)⁺. 3-(3-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)phenyl)oxazolidin- 2-one 00089

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.17 (d, J = 6.8 Hz, 1H), 9.88-9.65 (m, 1H), 9.27- 9.13 (m, 1H), 8.70 (dd, J = 4.0, 2.5 Hz, 1H), 8.46- 8.34 (m, 1H), 8.16 (d, J = 54.7 Hz, 1H), 7.60-7.52 (m, 1H), 7.46 (dd, J = 26.4, 7.9 Hz, 1H), 7.24 (t, J = 8.1 Hz, 1H), 7.20-7.04 (m, 2H), 4.88-4.77 (m, 0.5H), 4.75-4.63 (m, 0.5H), 4.27-4.14 (m, 0.5H), 4.05-3.95 (m, 0.5H), 3.52-3.43 (m, 0.5H), 2.96- 2.82 (m, 1H), 2.78-2.66 (m, 0.5H), 2.10-1.91 (m, 5H), 1.88-1.74 (m, 1.5H), 1.72-1.58 (m, 1.5H), 1.31-1.21 (m, 1.5H), 1.16-1.06 (m, 1.5H), 0.86- 0.73 (m, 4H); UPLC (Method B): t_(R) 1.14 min, MS (ESI) 471.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6- (pyridin3-yl)pyrimidin-4- yl)amino)phenyl)- cyclopropanecarboxamide 00090

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.94 (d, J = 10.5 Hz, 1H), 8.49 (d, J = 5.2 Hz, 1H), 8.20-8.11 (m, 2H), 7.84 (d, J = 4.4 Hz, 1H), 7.78 (s, 1H), 7.65 (d, J = 11.4 Hz, 1H), 7.57-7.46 (m, 1H), 7.16-7.03 (m, 2H), 4.85-4.72 (m, 2H), 4.68 (s, 1H), 4.29-4.14 (m, 0.5H), 4.13-3.98 (m, 0.5H), 3.87 (dd, J = 4.9, 1.7 Hz, 3H), 3.79 (d, J = 7.6 Hz, 1H), 3.70 (d, J = 7.4 Hz, 1H), 3.60 (d, J = 9.3 Hz, 1H), 3.49- 3.21 (m, 0.5H), 3.09 (d, J = 9.4 Hz, 1H), 2.95-2.84 (m, 1H), 2.81-2.69 (m, 0.5H), 2.16-1.77 (m, 7.5H), 1.77-1.56 (m, 1.5H), 1.27-1.21 (m, 1.5H), 1.14- 1.07 (m, 1.5H); UPLC (Method B): t_(R) 1.14 min, MS (ESI) 583.4 (M + H)⁺. 1-((2S,5R)-5-(4-(5-((1S,4S)- 2-oxa-5-azabicyclo- [2.2.1]heptan-5-yl)pyridin-3- yl)-6-((3-fluoro-5-(1-methyl- 1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-2-methylpiperidin-1- yl)ethan-1-one 00091

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.98 (d, J = 10.9 Hz, 1H), 8.80 (dd, J = 5.4, 1.8 Hz, 1H), 8.45 (t, J = 2.0 Hz, 1H), 8.15 (d, J = 6.4 Hz, 1H), 7.94 (dt, J = 4.8, 2.3 Hz, 1H), 7.85 (d, J = 4.5 Hz, 1H), 7.65 (d, J = 6.1 Hz, 1H), 7.53 (d, J = 11.5 Hz, 1H), 7.19 (d, J = 3.5 Hz, 1H), 7.09 (d, J = 10.0 Hz, 1H), 4.91-4.70 (m, 1H), 4.38-4.13 (m, 2.5H), 4.13- 3.97 (m, 0.5H), 3.88 (d, J = 5.0 Hz, 3H), 3.75-3.69 (m, 2H), 3.52-3.40 (m, 0.5H), 3.34 (s, 3H), 2.97- 2.83 (m, 1H), 2.82-2.70 (m, 0.5H), 2.18-1.92 (m, 5H), 1.92-1.79 (m, 0.5H), 1.79-1.53 (m, 1.5H), 1.28-1.21 (m, 1.5H), 1.14-1.08 (m, 1.5H); UPLC (Method B): t_(R) 1.42 min, MS (ESI) 560.4 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- (1-methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(5-(2- methoxyethoxy)pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00092

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.11 (d, J = 8.4 Hz, 1H), 9.95 (d, J = 6.3 Hz, 1H), 8.95 (s, 1H), 8.77 (d, J = 3.5 Hz, 1H), 7.94-7.62 (m, 3H), 7.32 (d, J = 2.0 Hz, 1H), 7.11-6.90 (m, 2H), 4.93-4.68 (m, 1H), 4.27-4.18 (m, 0.5H), 4.14- 4.03 (m, 0.5H), 3.98 (s, 3H), 3.51-3.40 (m, 0.5H), 3.01-2.86 (m, 1H), 2.84-2.72 (m, 0.5H), 2.18- 1.95 (m, 8H), 1.95-1.79 (m, 0.5H), 1.79-1.59 (m, 1.5H), 1.36-1.23 (m, 1.5H), 1.23-1.10 (m, 1.5H); UPLC (Method B): t_(R) 0.98 min, MS (ESI) 516.2 (M + H)⁺. N-(3-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6-(1- methyl-1H-pyrrolo[2,3- c]pyridin-4-yl)pyrimidin-4- yl)amino)-5- fluorophenyl)acetamide 00093

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 11.9 Hz, 1H), 8.80 (d, J = 5.3, 1.8 Hz, 1H), 8.44 (d, J = 2.7 Hz, 1H), 8.15 (d, J = 6.5 Hz, 1H), 7.99-7.89 (m, 1H), 7.85 (d, J = 4.5 Hz, 1H), 7.81- 7.76 (m, 0.5H), 7.70-7.62 (m, 1H), 7.58-7.49 (m, 0.5H), 7.20 (d, J = 3.7 Hz, 1H), 7.13-7.04 (m, 1H), 4.98 (t, J = 5.5 Hz, 1H), 4.86-4.72 (m, 1H), 4.27- 4.14 (m, 2.5H), 4.11-4.02 (m, 0.5H), 3.88 (d, J = 4.9 Hz, 3H), 3.81-3.74 (m, 2H), 3.54-3.39 (m, 0.5H), 2.98-2.85 (m, 1H), 2.81-2.70 (m, 0.5H), 2.12- 1.92 (m, 5H), 1.91-1.79 (m, 0.5H), 1.76-1.59 (m, 1.5H), 1.25 (d, J = 6.9 Hz, 1.5H), 1.12 (d, J = 7.1 Hz, 1.5H); UPLC (Method A): t_(R) 1.40 min, MS (ESI) 546.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-fluoro-5- (1-methyl-1H-pyrazol-4- yl)phenyl)amino)-6-(5-(2- hydroxyethoxy)pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00094

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.84 (d, J = 6.3 Hz, 1H), 9.00 (s, 1H), 8.73 (s, 1H), 8.50 (d, J = 15.6 Hz, 1H), 8.48-8.42 (m, 1H), 7.77 (d, J = 3.1 Hz, 1H), 7.73-7.61 (m, 1H), 7.52-7.41 (m, 2H), 7.28 (s, 1H), 7.05 (d, J = 2.9 Hz, 1H), 4.87- 4.79 (m, 1H), 4.54 (t, J = 5.1 Hz, 2H), 4.28-4.18 (m, 0.5H), 4.14-4.04 (m, 3.5H), 3.72 (t, J = 5.1 Hz, 2H), 3.56-3.47 (m, 0.5H), 3.23 (s, 3H), 2.99-2.87 (m, 1H), 2.83-2.70 (m, 0.5H), 2.18-1.96 (m, 5H), 1.94- 1.80 (m, 0.5H), 1.77-1.63 (m, 1.5H), 1.27 (d, J = 6.8 Hz, 1.5H), 1.13 (d, J = 7.0 Hz, 1.5H); UPLC (Method B): t_(R) 1.00 min, MS (ESI) 566.4 (M + H)⁺. 1-((2S,5R)-5-(4-(1-(2- methoxyethyl)-1H- pyrrolo[2,3-c]pyridin4-yl)-6- ((3-(1-methyl-1H-1,2,3- triazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-2-methylpiperidin-1- yl)ethan1-one

Example 4: synthesis of 1-((2S,5R)-2-methyl-5-(4-((2-methylpyridin-4-yl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00095)

To a solution of 2-methylpyridin-4-amine (3.19 g, 29.5 mmol) in dry tetrahydrofuran (100 mL) was added 1M lithium bis(trimethylsilyl)amide in tetrahydrofuran (29.5 mL, 29.5 mmol) and the mixture was stirred for 10 minutes. Next, 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 2, 850 mg, 2.95 mmol) in dry tetrahydrofuran (100 mL) was added over 10 minutes and the mixture was stirred at room temperature for 2 hours. The mixture was poured into saturated ammonium chloride solution and was extracted with ethyl acetate twice. The combined organic layers were washed with brine once, dried over sodium sulfate and concentrated to afford a brown oil. The oil was purified with silica column chromatography (80% to 100% ethyl acetate in n-heptane followed by 0% to 10% methanol in dichloromethane) to afford 1-((2S,5R)-5-(4-chloro-6-((2-methylpyridin-4-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (275 mg 25%) as a yellow oil. ¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 10.16 (s, 1H), 8.34-8.26 (m, 1H), 7.73-7.63 (m, 1H), 7.48-7.38 (m, 1H), 6.80 (d, J=4.5 Hz, 1H), 4.86-4.75 (m, 0.5H), 4.75-4.66 (m, 0.5H), 4.25-4.15 (m, 0.5H), 3.96 (m, 0.5H), 2.91-2.73 (m, 1H), 2.72-2.58 (m, 0.5H), 2.43 (d, J=2.5 Hz, 3H), 2.11-1.74 (m, 6H), 1.74-1.58 (m, 1.5H), 1.24 (m, 1.5H), 1.13 (m, 1.5H); LCMS (Method A): t_(R) 1.49 min, MS (ESI) 360.1 (M+H)⁺. Under nitrogen, 1-((2S,5R)-5-(4-chloro-6-((2-methylpyridin-4-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (275 mg, 0.76 mmol), sodium carbonate (162 mg, 1.53 mmol), pyridine-3-boronic acid (188 mg, 1.53 mmol) and PdCl₂(dppf)-CH₂Cl₂ adduct (62.4 mg, 0.08 mmol) were dissolved in a mixture of 1,2-dimethoxyethane (6 mL) and water (2 mL). The mixture was heated to 80° C. for 1 hour, filtered through a C18-plug and concentrated to afford a dark residue. The residue was purified with reversed phase chromatography (method B) and lyophilized to afford a light yellow solid. The product was further purified by chiral preparative SFC (Method B) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-((2-methylpyridin-4-yl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (135 mg, 41%) as beige solid. ¹H-NMR (400 MHz, DMSO-d6) a mixture of rotamers δ 10.12 (d, J=4.7 Hz, 1H), 9.23 (dd, J=5.8, 2.3 Hz, 1H), 8.73 (dd, J=4.1, 2.3 Hz, 1H), 8.45-8.37 (m, 1H), 8.30 (dd, J=5.7, 4.1 Hz, 1H), 7.78 (dd, J=21.4, 2.2 Hz, 1H), 7.62-7.47 (m, 2H), 7.25 (d, J=4.2 Hz, 1H), 4.92-4.72 (m, 1H), 4.30-4.16 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.53-3.41 (m, 0.5H), 3.04-2.85 (m, 1H), 2.85-2.70 (m, 0.5H), 2.47-2.39 (m, 3H), 2.17-1.93 (m, 5H), 1.93-1.79 (m, 0.5H), 1.78-1.65 (m, 1.5H), 1.32-1.25 (m, 1.5H), 1.20-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.06 min, MS (ESI) 403.2 (M+H)⁺; Chiral SFC (Method B): t_(R) 3.60 min, >95% ee and de.

The following compounds were prepared following procedures analogous to Example 4, using the appropriate starting materials, and purified using reversed phase chromatography method A or B and prep-SFC.

Compound # Structure and compound name Analytical data 00096

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.93 (d, J = 5.0 Hz, 1H), 9.22 (dd, J = 5.8, 2.3 Hz, 1H), 8.80-8.63 (m, 2H), 8.40 (tt, J = 5.5, 2.5 Hz, 1H), 8.17 (d, J = 13.7 Hz, 1H), 8.09 (t, J = 2.3 Hz, 1H), 7.58 (dd, J = 8.0, 4.9 Hz, 1H), 7.19 (d, J= 4.5 Hz, 1H), 4.83 (s, 0.5H), 4.75 (dd, J = 13.0, 4.1 Hz, 0.5H), 4.27-4.18 (m, 0.5H), 4.02 (dd, J = 13.7, 4.1 Hz, 0.5H), 3.44 (dd, J = 13.8, 11.7 Hz, 0.5H), 2.89 (td, J = 12.9, 12.2, 8.0 Hz, 1H), 2.82-2.68 (m, 0.5H), 2.33 (d, J = 3.5 Hz, 3H), 2.17-1.59 (m, 7H), 1.29-1.24 (d, J = 6.8 Hz, 1.5H), 1.17-1.12 (d, J = 7.0 Hz, 1.5H); LCMS (Method D): t_(R) 3.14 min, MS (ESI) 403.2 (M + H)⁺. (+/−)-cis-1-(2-methyl-5-(4-((5- methylpyridin-3-yl)amino)-6- (pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00097

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.04 (s, 1H), 9.39 (m, 2H), 9.33 (d, J = 1.9 Hz, 1H), 8.70 (m, 1H), 8.20-8.05 (m, 2H), 7.24 (m, 1H), 4.83 (s, 0.5H), 4.74 (dd, J = 13.2, 4.1 Hz, 0.5H), 4.27-4.15 (m, 0.5H), 4.03 (m, 0.5H), 3.44 (dd, J = 13.7, 11.8 Hz, 0.5H), 2.90 (m, 1H), 2.75 (m, 0.5H), 2.33 (m, 3H), 2.05 (m, 5H), 1.89-1.63 (m, 2H), 1.29-1.24 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 2.99 min, MS (ESI) 404.1 (M + H)⁺. (+/−)-c/s-1-(2-methyl-5-(6-((5- methylpyridin-3-yl)amino)-[4,5′- bipyrimidin]-2-yl)piperidin-1- yl)ethan-1-one 00098

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.91 (s, 1H), 9.00 (m, 1H), 8.69 (m, 1H), 8.55 (s, 1H), 8.24-8.14 (m, 2H), 8.09 (t, J = 2.3 Hz, 1H), 7.18 (d, J = 4.5 Hz, 1H), 4.82 (d, J = 7.3 Hz, 0.5H), 4.74 (m, 0.5H), 4.22 (m, 0.5H), 4.02 (dd, J = 13.4, 4.2 Hz, 0.5H), 3.44 (dd, J = 13.8, 11.9 Hz, 0.5H), 2.94-2.82 (m, 1H), 2.80- 2.65 (m, 0.5H), 2.41 (s, 3H), 2.32 (m, 3H), 2.05 (m, 5H), 1.90-1.60 (m, 2H), 1.32-1.24 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.20 min, MS (ESI) 417.2 (M + H)⁺. (+/−)-c/s-1-(2-methyl-5-(4-(5- methylpyridin-3-yl)-6-((5- methylpyridin-3- yl)amino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00099

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 11.93 (s, 1H), 9.89 (s, 1H), 8.86 (s, 1H), 8.78-8.67 (m, 2H), 8.21 (m, 1H), 8.09 (d, J = 2.7 Hz, 1H), 7.81 (t, J = 2.7 Hz, 1H), 7.30 (d, J = 2.8 Hz, 1H), 7.08 (d, J = 2.8 Hz, 1H), 4.89- 4.76 (m, 1H), 4.29-4.18 (m, 0.5H), 4.08 (m, 0.5H), 3.53-3.48 (m, 0.5H), 3.01-2.87 (m, 1H), 2.84-2.71 (m, 0.5H), 2.34 (m, 3H), 2.18- 1.97 (m, 5H), 1.95-1.64 (m, 2H), 1.32-1.24 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.10 min, MS (ESI) 442.1 (M + H)⁺. (+/−)-cis-1-(2-methyl-5-(4-((5- methylpyridin-3-yl)amino)-6-(1H- pyrrolo[2,3-c]pyridin-4- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00100

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.95 (s, 1H), 9.13 (dd, J = 6.8, 2.1 Hz, 1H), 8.79-8.63 (m, 2H), 8.47 (dt, J = 4.1, 2.1 Hz, 1H), 8.19 (dd, J = 15.1,2.4 Hz, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.25 (d, J = 4.8 Hz, 1H), 5.09- 4.97 (m, 2H), 4.87-4.81 (m, 0.5H), 4.78- 4.64 (m, 2.5H), 4.47-4.36 (m, 1H), 4.29-4.18 (m, 0.5H), 4.13-3.97 (m, 0.5H), 3.55-3.41 (m, 0.5H), 3.01-2.83 (m, 1H), 2.82-2.70 (m, 0.5H), 2.33 (d, J = 3.6 Hz, 3H), 2.05 (m, 5H), 1.93-1.61 (m, 2H), 1.32-1.24 (m, 1.5H), 1.19- 1.12 (m, 1.5H); LCMS (Method D): tR 2.99 min, MS (ESI) 459.4 (M + H)⁺. (+/−)-c/s-1-(2-methyl-5-(4-((5- methylpyridin-3-yl)amino)-6-(5- (oxetan-3-yl)pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00101

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.23 (s, 1H), 9.24 (s, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.50-8.34 (m, 3H), 7.90-7.73 (m, 2H), 7.59 (dd, J= 8.0, 4.7 Hz, 1H), 7.28 (d, J = 3.8 Hz, 1H), 4.84 (s, 0.5H), 4.79-4.70 (m, 0.5H), 4.32-4.15 (m, 0.5H), 4.13-4.02 (m, 0.5H), 3.56-3.43 (m, 0.5H), 3.03-2.86 (m, 1H), 2.85-2.72 (m, 0.5H), 2.17-1.61 (m, 7H), 1.33-1.26 (m, 1.5H), 1.21-1.11 (m, 1.5H); LCMS (Method D): tR 2.98 min, MS (ESI) 389.2 (M + H)⁺. (+/−)-c/s-1-(2-methyl-5-(4- (pyridin-3-yl)-6-(pyridin-4- ylamino)pyrimidin-2-yl)piperidin- 1-yl)ethan-1-one 00102

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.99 (s, 1H), 9.22 (dd, J = 6.4, 2.3 Hz, 1H), 8.94 (d, J = 2.5 Hz, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.46-8.32 (m, 1H), 8.32-8.17 (m, 2H), 7.58 (dd, J = 8.1,4.7 Hz, 1H), 7.45-7.34 (m, 1H), 7.20 (d, J = 4.0 Hz, 1H), 4.82 (s, 0.5H), 4.72 (dd, J = 13.4, 4.2 Hz, 0.5H), 4.27-4.16 (m, 0.5H), 4.04 (dd, J = 13.9, 4.2 Hz, 0.5H), 3.45 (dd, J = 13.6, 11.9 Hz, 0.5H), 2.99-2.84 (m, 1H), 2.79-2.69 (m, 0.5H), 2.10-1.62 (m, 7H), 1.32-1.22 (m, 1.5H), 1.19-1.10 (m, 1.5H); LCMS (Method D): tR 2.99 min, MS (ESI) 389.2 (M + H)⁺. (+/−)-cis-1-(2-methyl-5-(4- (pyridin-3-yl)-6-(pyridin-3- ylamino)pyrimidin-2-yl)piperidin- 1-yl)ethan-1-one 00103

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.11 (d, J = 5.1 Hz, 1H), 9.04-8.96 (m, 1H), 8.56 (d, J = 2.1 Hz, 1H), 8.35-8.25 (m, 1H), 8.25-8.17 (m, 1H), 7.78 (dd, J = 21.3, 2.1 Hz, 1H), 7.57-7.46 (m, 1H), 7.25 (d, J = 4.5 Hz, 1H), 4.89-4.81 (m, 0.5H), 4.80-4.72 (m, 0.5H), 4.28-4.18 (m, 0.5H), 4.08-4.01 (m, 0.5H), 3.54-3.43 (m, 0.5H), 3.02-2.86 (m, 1H), 2.84-2.72 (m, 0.5H), 2.44 (d, J = 3.0 Hz, 3H), 2.42 (s, 3H), 2.12-1.79 (m, 5.5H), 1.77- 1.64 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.20- 1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.21 min, MS (ESI) 417.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-(5- methylpyridin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00104

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.56 (s, 1H), 9.27-9.22 (m, 1H), 8.74 (d, J = 4.7 Hz, 1H), 8.47-8.39 (m, 1H), 8.12-8.06 (m, 1H), 7.85-7.79 (m, 1H), 7.63- 7.57 (m, 1H), 7.47 (d, J = 5.8 Hz, 1H), 7.31 (d, J = 4.1 Hz, 1H), 4.88-4.79 (m, 0.5H), 4.79-4.72 (m, 0.5H), 4.28-4.18 (m, 0.5H), 4.11-4.02 (m, 0.5H), 3.52-3.43 (m, 0.5H), 3.05-2.86 (m, 1H), 2.86-2.75 (m, 0.5H), 2.13-1.93 (m, 5H), 1.93-1.79 (m, 0.5H), 1.79-1.63 (m, 1.5H), 1.30-1.26 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method D): t_(R) 3.20 min, MS (ESI) 407.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoropyridin- 4-yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00105

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.00 (d, J = 4.3 Hz, 1H), 8.30-8.24 (m, 1H), 7.75 (dd, J = 23.0, 2.1 Hz, 1H), 7.66- 7.61 (m, 1H), 7.47 (ddd, J = 14.9, 5.7, 2.1 Hz, 1H), 7.36 (s, 1H), 7.01 (d, J = 3.0 Hz, 1H), 4.87- 4.78 (m, 0.5H), 4.76-4.68 (m, 0.5H), 4.27- 4.17 (m, 0.5H), 4.05-3.97 (m, 0.5H), 3.47- 3.37 (m, 0.5H), 2.91-2.80 (m, 1H), 2.74-2.63 (m, 0.5H), 2.43 (d, J = 3.1 Hz, 3H), 2.28 (s, 3H), 2.07 (d, J = 7.3 Hz, 3H), 2.03-1.78 (m, 2.5H), 1.75-1.61 (m, 1.5H), 1.30-1.25 (m, 1.5H), 1.17-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.78 min, MS (ESI) 422.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methylpyridin-4-yl)amino)-6-(4- methylthiophen-2-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00106

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.60-10.54 (m, 1H), 9.02 (d, J = 8.2 Hz, 1H), 8.94-8.85 (m, 2H), 8.09 (dd, J = 5.8, 3.5 Hz, 1H), 7.83 (dd, J = 8.3, 1.8 Hz, 1H), 7.45 (m, 1H), 7.31 (d, J = 4.6 Hz, 1H), 4.88- 4.80 (m, 0.5H), 4.78-4.71 (m, 0.5H), 4.30- 4.18 (m, 0.5H), 4.14-4.06 (m, 0.5H), 3.97 (t, J = 7.0 Hz, 2H), 3.50-3.41 (m, 0.5H), 3.31 (m, 1H), 3.18-3.15 (m, 0.5H), 3.05-2.75 (m, 1.5H), 2.57 (t, J = 8.0 Hz, 2H), 2.20-1.80 (m, 6H), 1.78-1.65 (m, 1.5H), 1.31-1.26 (m, 1.5H), 1.18-1.12 (m, 1.5H); LCMS (Method B): t_(R) 2.51 min, MS (ESI) 486.3 (M + H)⁺. 1-(5-(2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-((2- fluoropyridin-4- yl)amino)pyrimidin-4-yl)pyridin- 3-yl)pyrrolidin-2-one 00107

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.30 (s, 1H), 9.23 (dd, J = 6.5, 2.3 Hz, 1H), 8.94 (dd, J = 5.6, 2.4 Hz, 1H), 8.77- 8.68 (m, 2H), 8.45-8.37 (m, 2H), 7.59 (dd, J = 8.0, 4.8 Hz, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.19 (t, J = 55.3 Hz, 1H), 4.87-4.77 (m, 0.5H), 4.76- 4.68 (m, 0.5H), 4.24-4.17 (m, 0.5H), 4.07- 3.98 (m, 0.5H), 3.50-3.40 (m, 0.5H), 2.98- 2.85 (m, 1H),2.81-2.70 (m, 0.5H), 2.10-1.95 (m, 5H), 1.90-1.79 (m, 0.5H), 1.74-1.61 (m, 1.5H), 1.30-1.23 (m, 1.5H), 1.17-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.23 min, MS (ESI) 439.2 (M + H)⁺. 1-((2S,5R)-5-(4-((5- (difluoromethyl)pyridin-3- yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00108

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J = 5.5 Hz, 1H), 9.00 (dd, J = 7.2, 1.9 Hz, 1H), 8.93-8.82 (m, 2H), 8.29 (t, J = 5.5 Hz, 1H), 7.79 (dd, J = 25.0, 2.3 Hz, 1H), 7.56-7.47 (m, 1H), 7.28 (d, J = 5.4 Hz, 1H), 4.89-4.72 (m, 1H), 4.29-4.17 (m, 0.5H), 4.13- 4.03 (m, 0.5H), 3.97 (t, J = 7.1 Hz, 2H), 3.52- 3.39 (m, 0.5H), 3.31 (s, 1H), 3.03-2.85 (m, 1H), 2.85-2.72 (m, 0.5H), 2.56 (t, J = 8.0 Hz, 2H), 2.45 (d, J = 3.5 Hz, 3H), 2.20-1.93 (m, 6H), 1.87 (m, 0.5H), 1.78-1.63 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method B): t_(R) 3.14 min, MS (ESI) 490.2 (M + H)⁺. 1-(5-(2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-4-yl)pyridin- 3-yl)pyrrolidin-2-one 00109

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.15 (d, J = 7.0 Hz, 1H), 9.25 (dd, J = 6.2, 2.1 Hz, 1H), 8.77 (t, J = 1.8 Hz, 1H), 8.42 (dt, J = 6.6, 2.1 Hz, 1H), 8.30 (dd, J = 5.7, 4.0 Hz, 1H), 7.83-7.73 (m, 1H), 7.56-7.47 (m, 1H), 7.31 (d, J = 4.8 Hz, 1H), 4.90-4.75 (m, 1H), 4.26-4.18 (m, 0.5H), 4.09-4.01 (m, 0.5H), 3.53-3.42 (m, 0.5H), 3.05 (s, 3H), 3.09- 2.86 (m, 4H), 2.84-2.73 (m, 0.5H), 2.45 (d, J = 3.1 Hz, 3H), 2.08 (d, J = 5.6 Hz, 5H), 1.92- 1.79 (m, 0.5H), 1.77-1.63 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.19-1.13 (m, 1.5H); LCMS (Method B): t_(R) 2.42 min, MS (ESI) 474.3 (M + H)⁺. 5-(2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-4-yl)-N,N- dimethylnicotinamide 00110

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (s, 1H), 8.42 (dd, J = 8.8, 1.9 Hz, 1H), 8.29 (t, J = 5.0 Hz, 1H), 7.88-7.75 (m, 2H), 7.57-7.45 (m, 1H), 7.22-7.16 (m, 1H), 4.89-4.72 (m, 1H), 4.28-4.18 (m, 0.5H), 4.10- 4.02 (m, 0.5H), 3.94 (s, 3H), 3.90 (s, 3H), 3.49- 3.40 (m, 0.5H), 2.98-2.86 (m, 1H), 2.81- 2.72 (m, 0.5H), 2.45 (d, J = 3.7 Hz, 3H), 2.12- 1.95 (m, 5H), 1.90-1.79 (m, 0.5H), 1.76-1.66 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.19-1.13 (m, 1.5H); LCMS (Method B): t_(R) 2.73 min, MS (ESI) 463.2 (M + H)⁺. 1-((2S,5R)-5-(4-(5,6- dimethoxypyridin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00111

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.16 (d, J = 4.8 Hz, 1H), 9.15-9.05 (m, 1H), 8.65 (d, J = 2.5 Hz, 1H), 8.34-8.17 (m, 2H), 7.78 (dd, J = 23.8, 2.0 Hz, 1H), 7.51 (ddd, J = 16.3, 5.8, 2.1 Hz, 1H), 7.45 (t, J = 73.2 Hz, 1H), 7.30 (d, J = 4.5 Hz, 1H), 4.89-4.73 (m, 1H), 4.28-4.19 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.51-3.42 (m, 0.5H), 2.99-2.88 (m, 1H), 2.84-2.75 (m, 0.5H), 2.47-2.42 (m, 3H), 2.12-1.80 (m, 5.5H), 1.77-1.65 (m, 1.5H), 1.32-1.25 (m, 1.5H), 1.19-1.12 (m, 1.5H); LCMS (Method B): t_(R) 2.78 min, MS (ESI) 469.2 (M + H)⁺. 1-((2S,5R)-5-(4-(5- (difluoromethoxy)pyridin3-yl)-6- ((2-methylpyridin4- yl)amino)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00112

¹H-NMR (400 MHz, Methanol-d4) mixture of rotamers δ 9.16 (d, J = 8.8 Hz, 1H), 8.80 (d, J = 5.7 Hz, 1H), 8.69 (s, 1H), 8.26 (t, J = 5.8 Hz, 1H), 7.83 (d, J = 20.6 Hz, 1H), 7.73-7.60 (m, 1H), 7.31 (d, J = 8.7 Hz, 1H), 5.04-4.92 (m, 1H), 4.40-4.32 (m, 0.5H), 4.28-4.15 (m, 3.5H), 3.68-3.58 (m, 0.5H), 3.17-3.06 (m, 1H), 3.02- 2.87 (m, 0.5H), 2.52 (s, 3H), 2.25-2.15 (m, 5H), 2.05-1.92 (m, 0.5H), 1.91-1.77 (m, 1.5H), 1.43-1.36 (m, 1.5H), 1.32-1.25 (m, 1.5H); LCMS (Method B): t_(R) 2.49 min, MS (ESI) 457.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-(1- methyl-1/7-pyrazolo[3,4- c]pyridin-4-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00113

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.09 (d, J = 5.7 Hz, 1H), 8.57 (dd, J = 6.9, 1.8 Hz, 1H), 8.29 (t, J = 4.9 Hz, 1H), 7.99- 7.96 (m, 1H), 7.79 (dd, J = 24.7, 2.2 Hz, 1H), 7.50 (m, 1H), 7.39-7.35 (m, 1H), 7.22 (d, J = 5.4 Hz, 1H), 4.90-4.72 (m, 1H), 4.27-4.15 (m, 2.5H), 4.09-3.97 (m, 2.5H), 3.96-3.85 (m, 1H), 3.46 (m, 1H), 3.00-2.90 (m, 3.5H), 2.86 (s, 3H), 2.84-2.72 (m, 0.5H), 2.44 (d, J = 3.3 Hz, 3H), 2.12-1.93 (m, 5H), 1.91-1.78 (m, 0.5H), 1.77-1.60 (m, 1.5H), 1.31-1.26 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method D): t_(R) 2.98 min, MS (ESI) 529.3 (M + H)⁺. 1-(5-(2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-4-yl)pyridin- 3-yl)-N,N-dimethylazetidine-3- carboxamide 00114

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.11 (d, J = 6.7 Hz, 1H), 8.58-8.53 (m, 1H), 8.31-8.26 (m, 1H), 7.98-7.95 (m, 1H), 7.84-7.75 (m, 1H), 7.55-7.45 (m, 2H), 7.38-7.34 (m, 1H), 7.22 (d, J = 5.9 Hz, 1H), 7.06 (s, 1H), 4.91-4.73 (m, 1H), 4.28-4.18 (m, 0.5H), 4.16-4.01 (m, 2.5H), 3.95 (t, J = 6.7 Hz, 2H), 3.56-3.40 (m, 1.5H), 3.32-3.30 (m, 0.5H), 3.00-2.85 (m, 1H), 2.83-2.72 (m, 0.5H), 2.44 (d, J = 3.4 Hz, 3H), 2.07 (m, 4.5H), 1.92-1.77 (m, 0.5H), 1.77-1.61 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 2.81 min, MS (ESI) 501.3 (M + H)⁺. 1-(5-(2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-4-yl)pyridin- 3-yl)azetidine-3-carboxamide 00115

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.09 (s, 1H), 8.51 (dd, J = 6.9, 1.7 Hz, 1H), 8.28 (t, J = 4.8 Hz, 1H), 8.18 (d, J = 2.7 Hz, 1H), 7.80 (dd, J = 26.3, 2.1 Hz, 1H), 7.55- 7.45 (m, 2H), 7.21 (d, J = 5.8 Hz, 1H), 4.89- 4.80 (m, 0.5H), 4.80-4.72 (m, 1.5H), 4.70- 4.67 (m, 1H), 4.27-4.19 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.79 (d, J = 7.5 Hz, 1H), 3.70 (d, J = 7.5 Hz, 1H), 3.60 (d, J = 9.2 Hz, 1H), 3.50-3.41 (m, 0.5H), 3.09 (d, J = 9.3 Hz, 1H), 3.00-2.85 (m, 1H), 2.82-2.73 (m, 0.5H), 2.44 (d, J = 3.5 Hz, 3H), 2.12-2.04 (m, 4.5H), 2.02-1.77 (m, 3H), 1.76-1.61 (m, 1.5H), 1.31-1.26 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method B): t_(R) 2.20 min, MS (ESI) 500.3 (M + H)⁺. 1-((2S,5R)-5-(4-(5-((1S,4S)-2- oxa-5-azabicyclo[2.2.1]heptan- 5-yl)pyridin-3-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00116

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.05 (s, 1H), 8.97 (s, 1H), 8.78 (d, J = 2.9 Hz, 1H), 8.30 (t, J = 4.8 Hz, 1H), 7.84- 7.75 (m, 2H), 7.57-7.48 (m, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.05 (t, J = 2.5 Hz, 1H), 4.89-4.80 (m, 1H), 4.30-4.20 (m, 0.5H), 4.15-4.07 (m, 0.5H), 3.99 (s, 3H), 3.52-3.44 (m, 0.5H), 3.04- 2.88 (m, 1H), 2.87-2.76 (m, 0.5H), 2.45 (d, J = 3.6 Hz, 3H), 2.17-2.01 (m, 5H), 1.93-1.80 (m, 0.5H), 1.78-1.65 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.20-1.14 (m, 1.5H); LCMS (Method B): t_(R) 2.06 min, MS (ESI) 456.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-(1- methyl-1/7-pyrrolo[2,3- c]pyridin4-yl)-6-((2- methylpyridin-4- yl)amino)pyrimidin-2- yl)piperidin1-yl)ethan-1-one 00117

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.49 (broad s, 1H), 10.33 (broad s, 1H), 8.68-8.64 (m, 1H), 8.25 (d, J = 2.7 Hz, 1H), 8.09 (dd, J = 5.7, 3.1 Hz, 1H), 7.84-7.77 (m, 2H), 7.45 (d, J = 5.8 Hz, 1H), 7.23 (d, J = 2.4 Hz, 1H), 4.88-4.80 (m, 0.5H), 4.79-4.74 (m, 0.5H), 4.27-4.19 (m, 0.5H), 4.10-4.03 (m, 0.5H), 3.49-3.40 (m, 0.5H), 3.03-2.83 (m, 1H), 2.82-2.74 (m, 0.5H), 2.13-1.95 (m, 5H), 1.95-1.79 (m, 0.5H), 1.78-1.60 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.17-1.10 (m, 1.5H); LCMS (Method D): t_(R) 2.72 min, MS (ESI) 423.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoropyridin- 4-yl)amino)-6-(5-hydroxypyridin- 3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00118

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.47 (d, J = 8.0 Hz, 1H), 8.98 (s, 1H), 8.79 (d, J = 3.5 Hz, 1H), 8.09 (dd, J = 5.7, 3.4 Hz, 1H), 7.85 (dd, J = 11.2, 1.8 Hz, 1H), 7.78 (dd, J = 2.9, 1.6 Hz, 1H), 7.45 (d, J = 5.8 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.06 (t, J = 3.4 Hz, 1H), 4.91-4.73 (m, 1H), 4.30-4.20 (m, 0.5H), 4.19-4.06 (m, 0.5H), 3.99 (s, 3H), 3.52-3.43 (m, 0.5H), 3.12-2.73 (m, 1.5H), 2.22-1.94 (m, 5H), 1.94-1.81 (m, 0.5H), 1.78-1.66 (m, 1.5H), 1.31-1.27 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method B): t_(R) 2.44 min, MS (ESI) 494.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoropyridin- 4-yl)amino)-6-(1-methyl-1H- pyrrolo[2,3-c]pyridin-4- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00119

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.51 (d, J = 5.5 Hz, 1H), 8.83 (dd, J = 6.8, 1.9 Hz, 1H), 8.46 (dd, J = 2.9, 1.4 Hz, 1H), 8.09 (dd, J = 5.8, 3.2 Hz, 1H), 7.97 (dt, J = 6.8, 2.2 Hz, 1H), 7.82 (dd, J = 8.8, 1.7 Hz, 1H), 7.49- 7.43 (m, 1H), 7.30 (d, J = 4.0 Hz, 1H), 4.88- 4.68 (m, 1H), 4.30 (dt, J = 4.6, 2.8 Hz, 2H), 4.26- 4.18 (m, 0.5H), 4.14-3.99 (m, 0.5H), 3.75- 3.69 (m, 2H), 3.51-3.39 (m, 0.5H), 3.33 (s, 3H), 3.06-2.72 (m, 1.5H), 2.18-1.94 (m, 5H), 1.94- 1.78 (m, 0.5H), 1.78-1.59 (m, 1.5H), 1.31- 1.25 (m, 1.5H), 1.18-1.12 (m, 1.5H); LCMS (Method B): t_(R) 3.16 min, MS (ESI) 481.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoropyridin- 4-yl)amino)-6-(5-(2- methoxyethoxy)pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one

Example 5: synthesis of 1-((2S,5R)-2-methyl-5-(4-(pyridin-3-yl)-6-(quinoxalin-6-ylamino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00120)

To a solution of quinoxalin-6-amine (26.3 mg, 0.18 mmol) in tetrahydrofuran (2 mL) was added 1M lithium bis(trimethylsilyl)amide in tetrahydrofuran (0.18 ml, 0.18 mmol). Next, 1-((2S,5R)-5-(4-chloro-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (30 mg, 0.09 mmol, prepared under Example 2) was added and the mixture was stirred at room temperature for 3 hours. The mixture was diluted with water (2 mL) and concentrated to afford a dark brown residue. The residue was purified with reversed phase chromatography (method B) followed by reversed phase chromatography (method A) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-(pyridin-3-yl)-6-(quinoxalin-6-ylamino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (5 mg, 12%) as a yellow solid. ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.38 (d, J=9.3 Hz, 1H), 9.28-9.22 (m, 1H), 8.96-8.82 (m, 2H), 8.79 (d, J=1.9 Hz, 1H), 8.73 (d, J=4.7 Hz, 1H), 8.49-8.34 (m, 1H), 8.09-7.97 (m, 2H), 7.60 (dd, J=8.1, 4.7 Hz, 1H), 7.36-7.25 (m, 1H), 4.94-4.80 (m, 0.5H), 4.79-4.70 (m, 0.5H), 4.31-4.20 (m, 0.5H), 4.20-4.09 (m, 0.5H), 3.74-3.43 (m, 0.5H), 3.04-2.95 (m, 1H), 2.88-2.74 (m, 0.5H), 2.24-1.96 (m, 5H), 1.96-1.80 (m, 0.5H), 1.80-1.58 (m, 1.5H), 1.35-1.29 (m, 1.5H), 1.21-1.12 (m, 1.5H); LCMS (Method B): t_(R) 2.79 min, MS (ESI) 440.1 (M+H)⁺.

The following compounds were prepared following procedures analogous to Example 5, using the appropriate starting materials, and purified using reversed phase chromatography method A or B and prep-SFC.

Compound # Structure and compound name Analytical data 00121

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.40 (s, 1H), 9.53 (d, J = 17.1 Hz, 1H), 9.30-9.22 (m, 1H), 9.18 (s, 1H), 8.86 (dd, J = 67.5, 2.5 Hz, 1H), 8.76-8.67 (m, 1H), 8.48-8.38 (m, 1H), 8.22-8.08 (m, 1H), 8.06-7.96 (m, 1H), 7.60 (dd, J = 7.9, 4.8 Hz, 1H), 7.33 (d, J = 4.3 Hz, 1H), 4.99-4.79 (m, 1H), 4.30-4.21 (m, 0.5H), 4.13-4.02 (m, 0.5H), 3.52 (dd, J = 13.7, 11.8 Hz, 0.5H), 3.06-2.77 (m, 1.5H), 2.22-1.97 (m, 5H), 1.93-1.65 (m, 2H), 1.33-1.28 (m, 1.5H), 1.21-1.17 (m, 1.5H); LCMS (Method D): t_(R) 3.09 min, MS (ESI) 440.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- (pyridin-3-yl)-6-(quinazolin- 6-ylamino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00122

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.81 (d, J = 7.7 Hz, 1H), 9.83 (d, J = 2.8 Hz, 1H), 9.27 (d, J = 7.3 Hz, 1H), 8.96 (dd, J = 14.4, 2.3 Hz, 1H), 8.75 (d, J = 4.8 Hz, 1H), 8.50-8.42 (m, 2H), 8.05 (d, J = 9.3 Hz, 1H), 7.62 (dd, J = 8.0, 4.8 Hz, 1H), 7.42 (d, J = 3.2 Hz, 1H), 4.93-4.73 (m, 1H), 4.31-4.23 (m, 0.5H), 4.21-4.12 (m, 0.5H), 3.59- 3.49 (m, 0.5H), 3.10-2.94 (m, 1H), 2.93-2.82 (m, 0.5H), 2.24-1.97 (m, 5H), 1.96-1.82 (m, 0.5H), 1.81-1.68 (m, 1.5H), 1.36-1.31 (m, 1.5H), 1.21- 1.17 (m, 1.5H); LCMS (Method D): t_(R) 3.14 min, MS (ESI) 441.2 (M + H)⁺. 1-((2S,5R)-5-(4- (benzo[e][1,2,4]triazin-6- ylamino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00123

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.70 (s, 1H), 9.25 (dd, J = 7.6, 2.2 Hz, 1H), 8.74 (d, J = 4.8 Hz, 1H), 8.66-8.56 (m, 2H), 8.44 (tt, J = 7.8, 2.0 Hz, 1H), 7.78 (d, J = 5.6 Hz, 1H), 7.60 (dd, J = 8.0, 4.8 Hz, 1H), 7.32 (d, J = 5.2 Hz, 1H), 4.89-4.79 (m, 0.5H), 4.78-4.71 (m, 0.5H), 4.28-4.18 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.51-3.42 (m, 0.5H), 3.07-2.72 (m, 1.5H), 2.17-1.94 (m, 5H), 1.93- 1.80 (m, 0.5H), 1.79-1.61 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.18-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.43 min, MS (ESI) 457.1 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- (pyridin-3-yl)-6-((2- (trifluoromethyl)pyridin-4- yl)amino)pyrimidin-2- yl)piperidin 1-yl)ethan-1-one 00124

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.43 (s, 1H), 9.24 (dd, J = 7.6, 2.3 Hz, 1H), 8.98 (dd, J = 8.0, 2.3 Hz, 2H), 8.73 (d, J = 4.7 Hz, 1H), 8.60 (d, J = 3.1 Hz, 1H), 8.43 (tt, J = 7.7, 2.0 Hz, 1H), 7.59 (dd, J = 8.1, 4.8 Hz, 1H), 7.26 (d, J = 5.1 Hz, 1H), 4.88-4.77 (m, 0.5H), 4.75-4.67 (m, 0.5H), 4.27- 4.17 (m, 0.5H), 4.08-3.98 (m, 0.5H), 3.51-3.36 (m, 0.5H), 2.99-2.83 (m, 1H), 2.83-2.72 (m, 0.5H), 2.12-1.91 (m, 5H), 1.91-1.76 (m, 0.5H), 1.75- 1.64 (m, 1.5H), 1.28-1.24 (m, 1.5H), 1.15-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.47 min, MS (ESI) 457.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- (pyridin-3-yl)-6-((5- (trifluoromethyl)pyridin-3- yl)amino)pyrimidin-2- yl)piperidin 1-yl)ethan-1-one 00125

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J = 8.8 Hz, 1H), 10.00 (d, J = 5.5 Hz, 1H), 9.21 (dd, J = 6.4, 2.3 Hz, 1H), 8.78-8.58 (m, 3H), 8.44-8.36 (m 1H), 8.32-8.21 (m, 1H), 7.58 (dd, J = 7.7, 5.2 Hz, 1H), 7.21 (d, J = 3.1 Hz, 1H), 4.86- 4.76 (m, 0.5H), 4.71-4.64 (m, 0.5H), 4.25-4.18 (m, 0.5H), 4.04-3.95 (m, 0.5H), 3.51-3.42 (m, 0.5H), 3.00-2.81 (m, 1H), 2.80-2.65 (m, 0.5H), 2.13- 1.92 (m, 8H), 1.91-1.75 (m, 0.5H), 1.75-1.60 (m, 1.5H), 1.29-1.24 (m, 1.5H), 1.16-1.10 (m, 1.5H); LCMS (Method D): t_(R) 2.82 min, MS (ESI) 446.2 (M + H)⁺. N-(5-((2-((3R,6S)-1-acetyl- 6-methylpiperidin-3-yl)-6- (pyridin-3-yl)pyrimidin-4- yl)amino)pyridin-3- yl)acetamide

Example 6: synthesis of 1-((2S,5R)-2-methyl-5-(4-((2-methylpyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00126)

Under nitrogen, 1-((2S,5R)-5-(4-chloro-6-((2-methylpyridin-4-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (75 mg, 0.21 mmol, prepared under Example 4), 2-tributylstannylpyrazine (154 mg, 0.42 mmol) and bis(triphenylphosphine)palladium(II) chloride (14.63 mg, 0.02 mmol) in N,N-dimethylacetamide (3 mL) were heated to 80° C. for 16 hours. The mixture was cooled to room temperature and eluted through a C18-plug with acetonitrile. The filtrate was purified with reversed phase chromatography (method B) and preparative SFC (method B) to afford 1-((2S,5R)-2-methyl-5-(4-((2-methylpyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (24 mg, 28%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.23 (d, J=4.5 Hz, 1H), 9.60-9.53 (m, 1H), 8.85-8.78 (m, 2H), 8.31 (t, J=5.1 Hz, 1H), 7.83-7.71 (m, 2H), 7.57-7.49 (m, 1H), 4.90-4.76 (m, 1H), 4.28-4.20 (m, 0.5H), 4.13-4.05 (m, 0.5H), 3.54-3.44 (m, 0.5H), 3.04-2.89 (m, 1H), 2.87-2.77 (m, 0.5H), 2.45 (m, 3H), 2.16-1.98 (m, 5H), 1.94-1.81 (m, 0.5H), 1.78-1.64 (m, 1.5H), 1.32-1.28 (m, 1.5H), 1.19-1.15 (m, 1.5H); LCMS (Method D): t_(R) 3.08 min, MS (ESI) 404.2 (M+H)⁺; Chiral SFC (Method B): t_(R) 3.77 min, >95% ee and de.

The following compounds were prepared following procedures analogous to Example 6, using the appropriate starting materials, and purified using reversed phase chromatography method A or B and prep-SFC.

Compound # Structure and compound name Analytical data 00127

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.29 (s, 1H), 9.17-9.12 (m, 1H), 8.74-8.70 (m, 1H), 8.50-8.46 (m, 1H), 8.38-8.30 (m, 1H), 7.86 (d, J = 30.7 Hz, 1H), 7.62-7.53 (m, 1H), 7.36-7.31 (m, 1H), 5.06-4.98 (m, 2H), 4.89-4.75 (m, 1H), 4.70 (m, 2H), 4.47-4.36 (m, 1H), 4.29-4.19 (m, 0.5H), 4.11-4.03 (m, 0.5H), 3.52-3.43 (m, 0.5H), 3.05-2.87 (m, 1H), 2.86-2.77 (m, 0.5H), 2.49- 2.46 (m, 3H), 2.13-1.96 (m, 5H), 1.91-1.82 (m, 0.5H), 1.77-1.66 (m, 1.5H), 1.31-1.27 (m, 1.5H), 1.19-1.14(m, 1.5H); LCMS (Method B): t_(R) 2.92 min, MS (ESI) 459.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4- ((2-methylpyridin-4- yl)amino)-6-(5-(oxetan-3- yl)pyridin-3-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00128

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.66 (s, 1H), 9.59 (dd, J = 14.6, 1.3 Hz, 1H), 8.85- 8.81 (m, 2H), 8.10 (dd, J = 5.7, 3.1 Hz, 1H), 7.83 (dd, J = 8.1, 1.8 Hz, 1H), 7.76 (d, J = 2.5 Hz, 1H), 7.45 (dt, J = 5.8, 1.7 Hz, 1H), 4.92-4.65 (m, 1H), 4.30- 4.20 (m, 0.5H), 4.16-4.07 (m, 0.5H), 3.54-3.42 (m, 0.5H), 3.08-2.76 (m, 1.5H), 2.18-1.95 (m, 5H), 1.95-1.80 (m, 0.5H), 1.79-1.63 (m, 1.5H), 1.32- 1.27 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method D): t_(R) 3.25 min, MS (ESI) 408.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2- fluoropyridin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)- 2-methylpiperidin-1- yl)ethan-1-one 00129

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.39 (s, 1H), 9.56 (d, J = 15.1 Hz, 1H), 8.93 (t, J = 3.6 Hz, 1H), 8.82 (s, 2H), 8.74 (s, 1H), 8.44 (s, 1H), 7.71 (d, J = 3.4 Hz, 1H), 7.20 (t, J = 55.4 Hz, 1H), 4.85-4.78 (m, 0.5H), 4.77-4.70 (m, 0.5H), 4.28- 4.17 (m,0.5H), 4.10-4.01 (m, 0.5H), 3.52-3.41 (m, 0.5H), 3.01-2.87 (m, 1H), 2.85-2.74 (m, 0.5H), 2.14-1.94 (m, 5H), 1.93-1.79 (m, 0.5H), 1.77- 1.62 (m, 1.5H), 1.32-1.25 (m, 1.5H), 1.18-1.11 (m, 1.5H); UPLC (Method A): t_(R) 1.24 min, MS (ESI) 440.2 (M + H)⁺. 1-((2S,5R)-5-(4-((5- (difluoromethyl)pyridin-3- yl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one 00130

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.61 (s, 1H), 9.58 (dd, J = 15.8, 1.2 Hz, 1H), 8.83 (d, J = 2.3 Hz, 2H), 8.48 (ddd, J = 41.1, 5.9, 2.1 Hz, 2H), 7.80-7.66 (m, 2H), 6.92 (t, J = 55.2 Hz, 1H), 4.89-4.80 (m, 0.5H), 4.78-4.72 (m, 0.5H), 4.29- 4.19 (m, 0.5H), 4.15-4.05 (m, 0.5H), 3.53-3.42 (m, 0.5H), 3.06-2.90 (m, 1H), 2.89-2.76 (m, 0.5H), 2.13-1.82 (m, 5.5H), 1.78-1.65 (m, 1.5H), 1.36- 1.25 (m, 1.5H), 1.22-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.27 min, MS (ESI) 440.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2- (difluoromethyl)pyridin-4- yl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan- 1-one

Example 7: synthesis of 1-((2S,5R)-2-methyl-5-(4-(6-methyl pyrazin-2-yl)-6-((2-methyl pyridin-4-yl)amino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00131)

Under argon, 2-methylpyridin-4-amine (188 mg, 1.74 mmol), 1-((2S,5R)-5-(4-chloro-6-(6-methylpyrazin-2-yl)pyrimidin-2-yl)-2-methylpiperidin1-yl)ethan-1-one (200 mg, 0.58 mmol, prepared analogous to Example 2), Pd₂(dba)₃ (26.5 mg, 0.03 mmol), XPhos (27.6 mg, 0.06 mmol) and cesium carbonate (659 mg, 2.02 mmol) in 1,4-dioxane (15 mL) was heated to 80° C. for 16 hours. The mixture was poured into water and extracted with ethyl acetate twice. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated to afford a gum. The gum was purified with reversed phase chromatography (method A) followed by reversed phase chromatography (method B) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-(6-methylpyrazin-2-yl)-6-((2-methylpyridin-4-yl)amino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (20 mg, 16%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.24 (d, J=4.4 Hz, 1H), 9.37 (d, J=13.0 Hz, 1H), 8.72 (d, J=1.9 Hz, 1H), 8.34-8.23 (m, 1H), 7.86-7.68 (m, 2H), 7.60-7.46 (m, 1H), 4.91-4.68 (m, 1H), 4.29-4.16 (m, 0.5H), 4.13-4.03 (m, 0.5H), 3.54-3.40 (m, 0.5H), 3.06-2.87 (m, 1H), 2.87-2.74 (m, 0.5H), 2.62 (s, 3H), 2.45 (d, J=3.7 Hz, 3H), 2.21-1.95 (m, 5H), 1.95-1.79 (m, 0.5H), 1.79-1.63 (m, 1.5H), 1.33-1.25 (m, 1.5H), 1.20-1.14 (m, 1.5H); LCMS (Method D): t_(R) 3.19 min, MS (ESI) 418.2 (M+H)⁺.

The following compounds were prepared following procedures analogous to Example 7 using the appropriate starting materials, and purified using reversed phase chromatography method A/B and/or prep-SFC.

Compound # Structure and compound name Analytical data 00132

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.92 (s, 1H), 8.81 (dd, J = 6.6, 1.8 Hz, 1H), 8.69 (dd, J = 10.8, 2.6 Hz, 1H), 8.44 (t, J = 2.5 Hz, 1H), 8.18 (d, J = 16.3 Hz, 1H), 8.09 (d, J = 2.2 Hz, 1H), 7.92 (dt, J = 4.7, 2.2 Hz, 1H), 7.20 (d, J = 4.6 Hz, 1H), 4.88-4.79 (m, 0.5H), 4.78-4.68 (m, 0.5H), 4.31-4.15 (m, 0.5H), 4.08-3.97 (m, 0.5H), 3.93 (s, 3H), 3.51-3.38 (m, 0.5H), 3.00-2.83 (m, 1H), 2.81-2.63 (m, 0.5H), 2.33 (d, J = 3.6 Hz, 3H), 2.11-1.90 (m, 5H), 1.90-1.77 (m, 0.5H), 1.77-1.60 (m, 1.5H), 1.32-1.23 (m, 1.5H), 1.20-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.27 min, MS (ESI) 433.2 (M + H)⁺. 1-((2S,5R)-5-(4-(5- methoxypyridin-3-yl)-6-((5- methylpyridin-3- yl)amino)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00133

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.88 (s, 1H), 8.79 (d, J = 1.7 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.42 (d, J = 2.9 Hz, 1H), 8.15-7.85 (m, 3H), 7.17 (s, 1H), 5.27 (s, 0.2H), 4.73-4.40 (m, 1H), 4.14-4.03 (m, 0.2H), 3.94 (s, 3H), 3.57 (s, 0.6H), 3.27-2.97 (m, 2H), 2.40 (d, J = 13.2 Hz, 1H), 2.32 (s, 3H), 2.14-2.00 (m, 1H), 1.86 (s, 4H), 1.42 (d, J = 13.3 Hz, 1H), 1.28-1.09 (m, 3H); LCMS (Method D): t_(R) 3.33 min, 97%, MS (ESI) 433.2 (M + H)⁺. 1-((2S,5S)-5-(4-(5- methoxypyridin-3-yl)-6-((5- methylpyridin-3- yl)amino)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00134

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.53 (s, 1H), 9.24 (dd, J = 6.3, 2.3 Hz, 1H), 8.72 (dd, J = 4.8, 1.6 Hz, 1H), 8.47- 8.38 (m, 1H), 7.62-7.57 (m, 1H), 7.57-7.49 (m, 1H), 7.46-7.35 (m, 1H), 7.33-7.28 (m, 1H), 4.89-4.81 (m, 0.5H), 4.81-4.73 (m, 0.5H), 4.28-4.18 (m, 0.5H), 4.10-4.03 (m, 0.5H), 3.50-3.42 (m, 0.5H), 3.02-2.85 (m, 1H), 2.84-2.73 (m, 0.5H), 2.42-2.36 (m, 3H), 2.11-1.95 (m, 5H), 1.92-1.66 (m, 2H), 1.31- 1.25 (m, 1.5H), 1.18-1.13 (m, 1.5H); LCMS (Method D): t_(R) 3.29 min, MS (ESI) 421.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoro-6- methylpyridin-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan1-one 00135

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.28-9.19 (m, 1H), 8.85 (t, J = 2.4 Hz, 0.5H), 8.74-8.67 (m, 1.5H), 8.60 (dd, J = 11.9, 2.3 Hz, 1H), 8.44-8.36 (m, 1.5H), 8.33- 8.28 (m, 0.5H), 7.47-7.38 (m, 1H), 7.16-6.97 (m, 2H), 5.10-4.99 (m, 0.5H), 4.98-4.89 (m, 0.5H), 4.28-4.13 (m, 0.5H), 4.06-3.89 (m, 2.5H), 3.65-3.50 (m, 0.5H), 3.13-3.03 (m, 0.5H), 3.00-2.84 (m, 1H), 2.68-2.63 (m, 2H), 2.30-2.20 (m, 2H), 2.20-1.98 (m, 5H), 1.96- 1.66 (m, 2H), 1.36-1.32 (m, 1.5H), 1.26-1.22 (m, 1.5H); UPLC (Method A): t_(R) 1.09 min, MS (ESI) 472.2 (M + H)⁺. 1-(5-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin- 3-yl)pyrimidin-4- yl)amino)pyridin-3-yl)pyrrolidin- 2-one 00136

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.38 (s, 1H), 10.25 (s, 1H), 9.22 (dd, J = 6.5, 2.2 Hz, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.56-8.36 (m, 2H), 8.16 (d, J = 5.7 Hz, 1H), 7.70 (ddd, J = 37.6, 5.7, 2.0 Hz, 1H), 7.59 (dd, J = 8.0, 4.9 Hz, 1H), 7.29 (s, 1H), 4.87-4.77 (m, 0.5H), 4.75-4.66 (m, 0.5H), 4.26-4.16 (m, 0.5H), 4.06-3.99 (m, 0.5H), 3.55-3.46 (m, 0.5H), 3.00-2.89 (m, 1H), 2.82-2.71 (m, 0.5H), 2.12-1.94 (m, 8H), 1.91-1.78 (m, 0.5H), 1.76-1.60 (m, 1.5H), 1.32-1.25 (m, 1.5H), 1.18-1.11 (m, 1.5H); LCMS (Method B): t_(R) 2.61 min, MS (ESI) 446.2 (M + H)⁺. N-(4-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin- 3-yl)pyrimidin-4- yl)amino)pyridin-2-yl)acetamide 00137

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.37 (d, J = 11.0 Hz, 2H), 9.57 (d, J = 15.1 Hz, 1H), 8.82 (d, J = 1.6 Hz, 2H), 8.49 (dd, J = 43.7, 2.1 Hz, 1H), 8.17 (dd, J = 5.6, 1.6 Hz, 1H), 7.78-7.63 (m, 2H), 4.87-4.79 (m, 0.5H), 4.78-4.67 (m, 0.5H), 4.27-4.17 (m, 0.5H), 4.10-4.02 (m, 0.5H), 3.56-3.46 (m, 0.5H), 3.03-2.91 (m, 1H), 2.86-2.74 (m, 0.5H), 2.16-1.94 (m, 8H), 1.94-1.78 (m, 0.5H), 1.77-1.64 (m, 1.5H), 1.34-1.27 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method B): t_(R) 2.70 min, MS (ESI) 447.2 (M + H)⁺. N-(4-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyrazin- 2-yl)pyrimidin-4- yl)amino)pyridin-2-yl)acetamide 00138

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.03 (d, J = 4.2 Hz, 1H), 9.22 (dd, J = 5.3, 2.3 Hz, 1H), 8.78-8.66 (m, 1H), 8.47- 8.33 (m, 1H), 7.58 (dd, J = 8.1,4.9 Hz, 1H), 7.50 (d, J = 7.0 Hz, 2H), 7.24 (d, J = 4.9 Hz, 1H), 4.90- 4.72 (m, 1H), 4.32-4.15 (m, 0.5H), 4.10- 4.00 (m, 0.5H), 3.51-3.42 (m, 0.5H), 3.03- 2.85 (m, 1H), 2.84-2.73 (m, 0.5H), 2.40 (d, J = 2.1 Hz, 6H), 2.14-1.95 (m, 5H), 1.91-1.65 (m, 2H), 1.31-1.27 (m, 1.5H), 1.19-1.15 (m, 1.5H); LCMS (Method B): t_(R) 2.37 min, MS (ESI) 417.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2,6- dimethylpyridin-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00139

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.16 (d, J = 7.5 Hz, 1H), 9.22 (dd, J = 6.3, 2.3 Hz, 1H), 8.72 (d, J = 4.8 Hz, 1H), 8.41 (ddt, J = 8.4, 6.5, 2.0 Hz, 1H), 8.03 (dd, J = 5.8, 2.3 Hz, 1H), 7.59 (dd, J = 8.0, 4.8 Hz, 1H), 7.51 (dd, J = 19.3, 1.8 Hz, 1H), 7.25 (d, J = 3.2 Hz, 1H), 7.22-7.15 (m, 1H), 4.90-4.77 (m, 0.5H), 4.78-4.68 (m, 0.5H), 4.28-4.17 (m, 0.5H), 4.12-4.04 (m, 0.5H), 3.84 (s, 3H), 3.51-3.41 (m, 0.5H), 2.99-2.85 (m, 1H), 2.83-2.72 (m, 0.5H), 2.15-1.92 (m, 5H), 1.92-1.78 (m, 0.5H), 1.77-1.60 (m, 1.5H), 1.31-1.24 (m, 1.5H), 1.19-1.11 (m, 1.5H); LCMS (Method B): t_(R) 2.53 min, MS (ESI) 419.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2- methoxypyridin-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan1-one 00140

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.07 (d, J = 6.7 Hz, 1H), 9.21 (dd, J = 6.0, 2.3 Hz, 1H), 8.72 (d, J = 4.8 Hz, 1H), 8.40 (t, J = 7.1 Hz, 1H), 7.69-7.48 (m, 1H), 7.30- 7.07 (m, 3H), 4.91-4.80 (m, 0.5H), 4.80-4.71 (m, 0.5H), 4.30-4.16 (m, 0.5H), 4.12-3.98 (m, 0.5H), 3.82 (s, 3H), 3.51-3.39 (m, 0.5H), 3.01- 2.85 (m, 1H), 2.83-2.70 (m, 0.5H), 2.36 (s, 3H), 2.17-1.96 (m, 5H), 1.92-1.80 (m, 0.5H), 1.77-1.64 (m, 1.5H), 1.36-1.23 (m, 1.5H), 1.23-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.37 min, MS (ESI) 433.3 (M + H)⁺. 1-((2S,5R)-5-(4-((2-methoxy-6- methylpyridin-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00141

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.12 (d, J = 4.1 Hz, 1H), 9.35 (d, J = 9.7 Hz, 1H), 9.29-9.11 (m, 1H), 8.83 (d, J = 6.1 Hz, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.49-8.37 (m, 1H), 7.92-7.81 (m, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.64-7.49 (m, 2H), 7.21 (d, J = 3.4 Hz, 1H), 4.88-4.78 (m, 0.5H), 4.77-4.64 (m, 0.5H), 4.29-4.17 (m, 0.5H), 4.13-4.00 (m, 0.5H), 3.54-3.42 (m, 0.5H), 3.02-2.86 (m, 1H), 2.83-2.71 (m, 0.5H), 2.21-1.96 (m, 5H), 1.95-1.79 (m, 0.5H), 1.79-1.64 (m, 1.5H), 1.35-1.22 (m, 1.5H), 1.21-1.09 (m, 1.5H); LCMS (Method B): t_(R) 3.25 min, MS (ESI) 456.2 (M + H)⁺. 1-((2S,5R)-5-(4-((3-(1,3,4- oxadiazol-2-yl)phenyl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00142

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 1H NMR (400 MHz, DMSO) 6 10.10 (d, J = 5.8 Hz, 1H),9.22(dd,J = 6.5, 2.2 Hz, 1H), 8.80-8.68 (m, 2H), 8.45-8.35 (m, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.68-7.50 (m, 3H), 7.20 (d, J = 4.1 Hz, 1H), 4.92-4.69 (m, 1H), 4.28-4.18 (m, 0.5H), 4.10-4.03 (m, 0.5H), 3.54-3.46 (m, 0.5H), 3.00-2.85 (m, 1H), 2.80 -2.70 (m, 0.5H), 2.58 (s, 3H), 2.19-1.95 (m, 5H), 1.95-1.80 (m, 0.5H), 1.77-1.63 (m, 1.5H), 1.31-1.21 (m, 1.5H), 1.17-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.28 min, MS (ESI) 470.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((3-(5- methyl-1,3,4-oxadiazol-2- yl)phenyl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00143

  ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J = 7.3 Hz, 1H), 9.24 (dd, J = 5.9, 2.3 Hz, 1H), 8.76-8.70 (m, 1H), 8.42 (ddt, J = 8.0, 5.9, 2.0 Hz, 1H), 8.37 (t, J = 6.2 Hz, 1H), 8.24 (s, 1H), 8.17 (s, 0.5H), 8.09 (s, 0.5H), 7.89 (d, J = 5.0 Hz, 1H), 7.60 (dd, J = 8.0, 4.7 Hz, 1H), 7.49 (dd, 0.5H), 7.35 (dd, J = 5.7, 2.1 Hz, 0.5H), 7.27 (d, J = 1.8 Hz, 1H), 4.94-4.78 (m, 1H), 4.30-4.19 (m, 0.5H), 4.10 (m, 0.5H), 3.90 (d, J = 7.8 Hz, 3H), 3.49 (m, 0.5H), 3.03-2.87 (m, 1H), 2.87-2.76 (m, 0.5H), 2.08 (m, 5H), 1.94-1.61 (m, 2H), 1.28-1.24 (m, 1.5H), 1.15- 1.12 (m, 1.5H); UPLC (Method A): t_(R) 1.26 min, MS (ESI) 469.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2-(1- methyl-1H-pyrazol-4-yl)pyridin- 4-yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00144

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.40 (s, 1H), 9.24 (dd, J = 6.3, 2.3 Hz, 1H), 8.73 (d, J = 4.8 Hz, 1H), 8.42 (ddd, J = 8.3, 5.2, 1.9 Hz, 1H), 8.13 (d, J = 27.7 Hz, 1H), 7.77-7.50 (m, 2H), 7.27 (d, J = 4.8 Hz, 1H), 6.86 (t, J = 55.3 Hz, 1H), 4.86-4.74 (m, 1H), 4.25-4.21 (m, 0.5H), 4.07-4.03 (m, 0.5H), 3.51-3.44 (m, 0.5H), 3.04-2.86 (m, 1H), 2.86- 2.74 (m, 0.5H), 2.12-1.95 (m, 5H), 1.95- 1.78 (m, 0.5H), 1.78-1.62 (m, 1.5H), 1.32- 1.27 (m, 1.5H), 1.17-1.12 (m, 1.5H), one CH3 signal coincides with solvent signal; UPLC (Method A): t_(R) 1.43 min, MS (ESI) 453.4 (M + H)⁺. 1-((2S,5R)-5-(4-((2- (difluoromethyl)-6-methylpyridin- 4-yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00145

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.49 (d, J = 4.6 Hz, 1H), 9.57 (dd, J = 14.6, 1.3 Hz, 1H), 8.83 (d, J = 2.6 Hz, 2H), 8.14 (dd, J = 30.1,2.0 Hz, 1H), 7.76-7.64 (m, 2H), 6.87 (t, J = 55.3 Hz, 1H), 4.91-4.70 (m, 1H), 4.30-4.18 (m, 0.5H), 4.08 (m, 0.5H), 3.55- 3.43 (m, 0.5H), 3.07-2.89 (m, 1H), 2.84 (m, 0.5H), 2.50 (s, 3H), 2.08 (m, 5H), 1.97-1.80 (m, 0.5H), 1.79-1.64 (m, 1.5H), 1.32-1.28 (m, 1.5H), 1.18-1.15 (m, 1.5H), one CH3 signal coincides with solvent signal; UPLC (Method A): t_(R) 1.48 min, MS (ESI) 454.4 (M + H)⁺. 1-((2S,5R)-5-(4-((2- (difluoromethyl)-6-methylpyridin- 4-yl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00146

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.46 (s, 1H), 9.24 (dd, J = 7.1,2.3 Hz, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.50 (dd, J = 5.5, 2.4 Hz, 1H), 8.47-8.34 (m, 2H), 7.70 (ddd, J = 12.6, 5.6, 2.1 Hz, 1H), 7.60 (dd, J = 8.0, 4.9 Hz, 1H), 7.28 (d, J = 3.9 Hz, 1H), 4.89-4.79 (m, 0.5H), 4.77-4.66 (m, 0.5H), 4.28-4.17 (m, 0.5H), 4.10-4.01 (m, 0.5H), 3.53-3.43 (m, 0.5H), 3.02-2.88 (m, 1H), 2.85-2.74 (m, 0.5H), 2.14-1.93 (m, 8H), 1.91-1.80 (m, 0.5H), 1.77-1.62 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.18-1.12 (m, 1.5H); UPLC (Method A): t_(R) 1.44 min, MS (ESI) 453.4 (M + H)⁺. 1-((2S,5R)-5-(4-((2-(1,1- difluoroethyl)pyridin-4-yl)amino)- 6-(pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00147

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 9.88 (d, J = 8.8 Hz, 1H), 9.20 (dd, J = 6.4, 2.3 Hz, 1H), 8.70 (dd, J = 4.8, 1.5 Hz, 1H), 8.38 (ddt, J = 8.3, 6.5, 2.0 Hz, 1H), 8.26 (d, J = 6.3 Hz, 1H), 7.65-7.47 (m, 3H), 7.15 (d, J = 4.0 Hz, 1H), 4.90-4.77 (m, 0.5H), 4.77-4.67 (m, 0.5H), 4.30-4.14 (m, 0.5H), 4.11-4.02 (m, 0.5H), 3.52-3.40 (m, 0.5H), 2.95-2.82 (m, 1H), 2.80-2.64 (m, 0.5H), 2.60 (s, 3H), 2.12- 1.96 (m, 5H), 1.92-1.76 (m, 0.5H), 1.76-1.64 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.18-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.30 min, MS (ESI) 443.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methylbenzo[d]oxazol-5- yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00148

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.32 (s, 1H), 10.13 (d, J = 2.5 Hz, 1H), 9.35 (dd, J = 4.7, 2.3 Hz, 1H), 8.72 (dd, J = 4.7, 1.7 Hz, 1H), 8.57-8.50 (m, 1H), 8.42 (s, 1H), 7.71 (td, J = 8.0, 3.0 Hz, 1H), 7.59 (dd, J = 13.6, 8.0 Hz, 2H), 7.26 (d, J = 8.5 Hz, 1H), 4.88- 4.77 (m, 0.5H), 4.77-4.67 (m, 0.5H), 4.28- 4.12 (m, 0.5H), 4.08-3.93 (m, 0.5H), 3.58- 3.42 (m, 0.5H), 2.95-2.82 (m, 1H), 2.80-2.61 (m, 0.5H), 2.14 (s, 3H), 2.10-1.97 (m, 5H), 1.91- 1.75 (m, 0.5H), 1.75-1.63 (m, 1.5H), 1.30- 1.24 (m, 1.5H), 1.18-1.12 (m, 1.5H); LCMS (Method D): t_(R) 3.19 min, MS (ESI) 446.2 (M + H)⁺. N-(6-((2-((3R,6S)-1-acetyl-6- methylpiperidin-3-yl)-6-(pyridin- 3-yl)pyrimidin-4- yl)amino)pyridin-2-yl)acetamide 00149

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.52 (d, J = 6.1 Hz, 1H), 9.57 (dd, J = 13.8, 1.3 Hz, 1H), 8.85-8.79 (m, 2H), 7.75 (d, J = 3.8 Hz, 1H), 7.65-7.29 (m, 2H), 4.94-4.70 (m, 1H), 4.31-4.17 (m, 0.5H), 4.15-4.05 (m, 0.5H), 3.53-3.38 (m, 0.5H), 3.10-2.74 (m, 1.5H), 2.40 (d, J = 2.8 Hz, 3H), 2.19-1.94 (m, 5H), 1.94-1.79 (m, 0.5H), 1.79-1.65 (m, 1.5H), 1.33-1.26 (m, 1.5H), 1.20-1.13 (m, 1.5H); UPLC (Method A): t_(R) 1.47 min, MS (ESI) 422.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-fluoro-6- methylpyridin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan1-one 00150

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.16 (d, J = 5.9 Hz, 1H), 9.56 (dd, J = 13.3, 1.3 Hz, 1H), 8.84-8.79 (m, 2H), 7.71 (d, J = 3.2 Hz, 1H), 7.36-7.03 (m, 2H), 4.91-4.71 (m, 1H), 4.29-4.18 (m, 0.5H), 4.15-4.04 (m, 0.5H), 3.82 (s, 3H), 3.52-3.42 (m, 0.5H), 3.05- 2.89 (m, 1H), 2.88-2.72 (m, 0.5H), 2.37 (d, J = 2.5 Hz, 3H), 2.18-1.94 (m, 5H), 1.94-1.79 (m, 0.5H), 1.79-1.61 (m, 1.5H), 1.33-1.27 (m, 1.5H), 1.19-1.13 (m, 1.5H); UPLC (Method B): t_(R) 0.97 min, MS (ESI) 434.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-methoxy-6- methylpyridin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00151

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.81 (d, J = 3.0 Hz, 1H), 9.60 (d, J = 12.8 Hz, 1H), 8.84 (d, J = 2.7 Hz, 2H), 8.75 (s, 1H), 8.48 (d, J = 9.3 Hz, 1H), 7.87 (d, J = 18.0 Hz, 1H), 4.88-4.78 (m, 1H), 4.33-4.15 (m, 0.5H), 4.11-4.00 (m, 0.5H), 3.59-3.43 (m, 0.5H), 3.09-2.70 (m, 1.5H), 2.43 (d, J = 4.6 Hz, 3H), 2.20-1.96 (m, 5H), 1.96-1.78 (m, 0.5H), 1.78-1.66 (m, 1.5H), 1.32-1.26 (m, 1.5H), 1.21-1.14 (m, 1.5H); UPLC (Method B): t_(R) 1.06 min, MS (ESI) 405.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((6- methylpyrimidin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00152

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.01 (d, J = 8.9 Hz, 1H), 9.55 (dd, J = 14.7, 1.3 Hz, 1H), 8.81 (q, J = 2.0 Hz, 2H), 7.70 (d, J = 1.5 Hz, 1H), 7.27 (d, J = 48.1 Hz, 1H), 6.99-6.78 (m, 1H), 4.87-4.79 (m, 1H), 4.28-4.18 (m, 1H), 4.12-4.00 (m, 1H), 3.70 (t, J = 4.9 Hz, 5H), 3.53-3.38 (m, 6H), 3.03-2.84 (m, 1H), 2.83-2.75 (m, 1H), 2.30 (s, 3H), 2.20- 1.93 (m, 6H), 1.93-1.78 (m, 1H), 1.77-1.55 (m, 2H), 1.29-1.23 (m, 2H), 1.17-1.12 (m, 1H); UPLC (Method B): t_(R) 0.95 min, MS (ESI) 489.4 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methyl-6-morpholinopyridin-4- yl)amino)-6-(pyrazin-2- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one 00153

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.33-10.14 (m, 1H), 9.66- 9.46 (m, 1H), 8.82 (d, J = 2.4 Hz, 2H), 8.35 (dd, J = 5.6, 3.6 Hz, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.72 (d, J = 2.9 Hz, 1H), 7.48 (dt, J = 5.2, 2.5 Hz, 1H), 4.94-4.68 (m, 1H), 4.32- 4.17 (m, 0.5H), 4.14-4.03 (m, 0.5H), 3.56- 3.44 (m, 0.5H), 3.04-2.89 (m, 2H), 2.87- 2.73 (m, 0.5H), 2.17-1.94 (m, 5H), 1.94- 1.79 (m,0.5H), 1.79-1.63 (m, 1.5H), 1.33- 1.20 (m, 7.5H), 1.20-1.12 (m, 1.5H); UPLC (Method B): t_(R) 1.33 min, MS (ESI) 484.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2- isopropylpyridin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00154

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.22 (d, J = 10.0 Hz, 1H), 9.57 (d, J = 12.1 Hz, 1H), 8.82 (d, J = 2.0 Hz, 2H), 8.19 (d, J = 25.4 Hz, 1H), 8.01-7.82 (m, 2H), 7.74 (s, 1H), 7.40 (dd, J = 39.1, 1.9 Hz, 1H), 4.96-4.75 (m, 1H), 4.32-4.19 (m, 0.5H), 4.14-4.04 (m, 0.5H), 3.89 (d, J = 7.1 Hz, 3H), 3.57-3.44 (m, 0.5H), 3.10-2.76 (m, 1.5H), 2.45 (s, 3H), 2.27- 1.98 (m, 5H), 1.98-1.82 (m, 0.5H), 1.82- 1.62 (m, 1.5H), 1.31-1.25 (m, 1.5H), 1.18- 1.12 (m, 1.5H); UPLC (Method B): t_(R) 1.33 min, MS (ESI) 484.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methyl-6-(1-methyl-1H-pyrazol- 4-yl)pyridin-4-yl)amino)-6- (pyrazin2-yl)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00155

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.23 (d, J = 7.3 Hz, 1H), 9.56 (d, J = 11.8 Hz, 1H), 8.81 (q, J = 3.0 Hz, 2H), 8.01 (d, J = 5.7 Hz, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 42.3 Hz, 1H), 7.10 (dd, J = 31.8, 6.0 Hz, 1H), 5.30-5.12 (m, 1H), 4.89-4.79 (m, 0.5H), 4.75-4.62 (m, 0.5H), 4.30-4.20 (m, 0.5H), 4.19-4.01 (m, 0.5H), 3.52-3.42 (m, 0.5H), 3.03-2.90 (m, 1H), 2.87-2.74 (m, 0.5H), 2.17- 1.94 (m, 5H), 1.93-1.76 (m, 0.5H), 1.78- 1.64 (m, 1.5H), 1.37-1.23 (m, 7.5H), 1.22- 1.13 (m, 1.5H); UPLC (Method B): t_(R) 1.14 min, MS (ESI) 448.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2- isopropoxypyridin-4-yl)amino)-6- (pyrazin-2-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one 00156

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.71 (s, 1H), 9.58 (dd, J = 11.8, 1.1 Hz, 1H), 8.82 (d, J = 1.6 Hz, 2H), 8.43-8.27 (m, 2H), 7.94 (t, J = 15.8 Hz, 1H), 7.03-6.95 (m, 1H), 4.89-4.72 (m, 1H), 4.32-4.13 (m, 0.5H), 4.13-3.91 (m, 0.5H), 3.54-3.38 (m, 0.5H), 3.02-2.88 (m, 1H), 2.86-2.70 (m, 0.5H), 2.14- 1.94 (m, 5H), 1.92-1.77 (m, 0.5H), 1.78- 1.66 (m, 1.5H), 1.33-1.25 (m, 1.5H), 1.20- 1.11 (m, 1.5H); UPLC (Method B): t_(R) 1.42 min, MS (ESI) 408.2 (M + H)⁺. 1-((2S,5R)-5-(4-((4-fluoropyridin- 2-yl)amino)-6-(pyrazin2- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1-one

Example 8: synthesis of 1-((2S,5R)-5-(4-((2-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-4-yl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (00157)

Under argon, 2-chloro-4-nitropyridine (150 mg, 0.95 mmol), 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (244 mg, 1.04 mmol), tetrakis(triphenylphosphine)palladium(0) (54.7 mg, 0.05 mmol) and sodium carbonate (201 mg, 1.89 mmol) in 1,2-dimethoxyethane (6.5 mL) and water (1.63 mL) was heated to 100° C. for 3 hours. The mixture was diluted with ethyl acetate and water. The layers were separated and the aqueous layer was extracted with ethyl acetate twice. The combined organic layers were washed with water followed by brine, dried over sodium sulfate and concentrated to afford a brown solid. The solid was purified by column chromatography (5% to 40% ethyl acetate in n-heptane) to afford 2-(1-cyclopropyl-1H-pyrazol-4-yl)-4-nitropyridine (190 mg, 0.83 mmol, 87%) as a yellow solid. LCMS (Method C): t_(R) 1.79 min, MS (ESI) 231.1 (M+H)⁺. To a suspension of 2-(1-cyclopropyl-1H-pyrazol-4-yl)-4-nitropyridine (190 mg, 0.83 mmol) in methanol (4 mL), was added iron (230 mg, 4.13 mmol) and ammonium chloride (221 mg, 4.13 mmol) followed by water (12 mL). The mixture was heated to 70° C. for 2 hours. The mixture was cooled to room temperature and partitioned between ethyl acetate and a mixture of water and brine (1:1). The layers were separated and the aqueous layer was extracted with ethyl acetate three times. The combined organic layers were dried over sodium sulfate and concentrated to afford 2-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-4-amine (148 mg, 0.74 mmol, 90%) as a light yellow oil. LCMS (Method C): t_(R) 1.44 min, MS (ESI) 201.1 (M+H)⁺. A solution of 1-((2S,5R)-5-(4-chloro-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (75 mg, 0.23 mmol, prepared under Example 2), 2-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-4-amine (55 mg, 0.27 mmol), Pd₂(dba)₃ (10 mg, 0.01 mmol), XPhos (11 mg, 0.02 mmol) and cesium carbonate (148 mg, 0.45 mmol) in 1,4-dioxane (3 mL) was heated to 90° C. and stirred for 16 hours. The mixture was filtered through Celite and rinsed with ethyl acetate and methanol (1:1). The filtrate was concentrated, purified with reversed phase chromatography (method B) followed by prep-SFC (method B) to afford 1-((2S,5R)-5-(4-((2-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-4-yl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (13 mg, 0.03 mmol, 12%) as a white solid. ¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J=6.1 Hz, 1H), 9.24 (dd, J=6.3, 2.3 Hz, 1H), 8.75-8.70 (m, 1H), 8.42 (m, 1H), 8.37 (t, J=5.3 Hz, 1H), 8.25 (d, J=10.2 Hz, 1H), 8.17 (dd, J=26.2, 2.1 Hz, 1H), 7.89 (d, J=1.4 Hz, 1H), 7.60 (dd, J=8.0, 4.8 Hz, 1H), 7.42 (m, 1H), 7.28 (d, J=1.9 Hz, 1H), 4.90-4.80 (m, 1H), 4.29-4.20 (m, 0.5H), 4.13-4.07 (m, 0.5H), 3.85-3.74 (m, 1H), 3.55-3.44 (m, 0.5H), 3.04-2.87 (m, 1H), 2.87-2.75 (m, 0.5H), 2.20-1.96 (m, 5H), 1.96-1.82 (m, 0.5H), 1.80-1.61 (m, 1.5H), 1.29-1.22 (m, 1.5H), 1.17-1.02 (m, 3.5H), 1.02-0.95 (m, 2H); LCMS (Method D): t_(R) 3.17 min, MS (ESI) 495.2 (M+H)⁺.

The following compounds were prepared following procedures analogous to Example 8 using the appropriate starting materials, and purified using reversed phase chromatography method A/B and/or prep-SFC.

Compound Structure and compound # name Analytical data 00158

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J = 7.1 Hz, 1H), 9.24 (dd, J = 6.2, 2.2 Hz, 1H), 8.73 (dd, J = 4.8, 1.5 Hz, 1H), 8.46-8.33 (m, 2H), 8.29-8.08 (m, 2H), 7.91 (d, J = 4.7 Hz, 1H), 7.60 (dd, J = 8.0, 4.7 Hz, 1H), 7.42 (m, 1H), 7.27 (d, J = 1.9 Hz, 1H), 4.94-4.78 (m, 1H), 4.30- 4.05 (m, 3H), 3.54-3.45 (m, 0.5H), 3.05-2.87 (m, 1H), 2.86-2.76 (m, 0.5H), 2.20-1.96 (m, 5H), 1.97-1.81 (m, 0.5H), 1.80-1.65 (m, 1.5H), 1.41 (t, J = 7.3 Hz, 3H), 1.29-1.20 (m, 1.5H), 1.15- 1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.13 min, MS (ESI) 483.2 (M + H)⁺. 1-((2S-5R)-5-(4-((2-(1-ethyl- 1H-pyrazol-4-yl)pyridin-4- yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1- one 00159

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.18 (d, J = 7.9 Hz, 1H), 9.24 (dd, J = 5.9, 2.2 Hz, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.45-8.34 (m, 2H), 8.28 (d, J = 11.4 Hz, 1H), 8.17 (dd, J = 43.3, 2.0 Hz, 1H), 7.94 (d, J = 4.8 Hz, 1H), 7.60 (dd, J = 8.1, 4.7 Hz, 1H), 7.43 (m, 1H), 7.28 (s, 1H), 4.94- 4.78 (m, 1H), 4.55-4.38 (m, 1H), 4.30-4.20 (m, 0.5H), 4.14-4.06 (m, 0.5H), 4.03-3.94 (m, 2H), 3.55-3.43 (m, 2.5H), 3.04-2.87 (m, 1H), 2.87- 2.76 (m, 0.5H), 2.21-1.80 (m, 9.5H), 1.78-1.62 (m, 1.5H), 1.29-1.21 (m, 1.5H), 1.14-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.11 min, MS (ESI) 539.2 (M + H)⁺. 1-((2S-5R)-2-methyl-5-(4- (pyridin-3-yl)-6-((2-(1- (tetrahydro-2H-pyran-4-yl)- 1H-pyrazol-4-yl)pyridin-4- yl)amino)pyrimidin-2- yl)piperidin-1-yl)ethan-1-one 00160

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.19 (d, J = 7.3 Hz, 1H), 9.24 (dd, J = 6.3, 2.3 Hz, 1H), 8.73 (d, J = 4.7 Hz, 1H), 8.42 (m, 1H), 8.37 (t, J = 5.9 Hz, 1H), 8.27-8.04 (m, 2H), 7.92 (d, J = 4.7 Hz, 1H), 7.60 (dd, J = 8.0, 4.8 Hz, 1H), 7.45 (m, 1H), 7.28 (d, J = 2.0 Hz, 1H), 4.91-4.80 (m, 1H), 4.38-4.19 (m, 2.5H), 4.13-4.50 (m, 0.5H), 3.72 (t, J = 5.2 Hz, 2H), 3.54-3.44 (m, 0.5H), 3.25 (s, 3H), 3.05-2.88 (m, 1H), 2.87-2.76 (m, 0.5H), 2.20-1.81 (m, 5.5H), 1.79-1.62 (m, 1.5H), 1.28- 1.22 (m, 1.5H), 1.15-1.10 (m, 1.5H); LCMS (Method D): t_(R) 3.07 min, MS (ESI) 513.2 (M + H)⁺. 1-((2S,5R)-5-(4-((2-(1-(2- methoxyethyl)-1H-pyrazol-4- yl)pyridin-4-yl)amino)-6- (pyridin-3-yl)pyrimidin-2-yl)-2- methylpiperidin-1-yl)ethan-1- one 00161

¹H-NMR (400 MHz, DMSO-d6) mixture of rotamers δ 10.10 (d, J = 8.2 Hz, 1H), 9.23 (dd, J = 5.1, 2.3 Hz, 1H), 8.73 (dd, J = 4.8, 1.6 Hz, 1H), 8.45-8.38 (m, 1H), 8.18 (d, J = 23.2 Hz, 1H), 8.06-7.80 (m, 2H), 7.59 (dd, J = 8.0, 4.9 Hz, 1H), 7.40 (dd, J = 40.1, 1.9 Hz, 1H), 7.26 (d, J = 2.5 Hz, 1H), 4.92- 4.81 (m, 1H), 4.32-4.15 (m, 0.5H), 4.13-3.98 (m, 0.5H), 3.89 (d, J = 6.8 Hz, 3H), 3.59-3.38 (m, 0.5H), 3.09-2.72 (m, 1.5H), 2.45 (s, 3H), 2.22- 1.96 (m, 5H), 1.95-1.81 (m, 0.5H), 1.79-1.61 (m, 1.5H), 1.30-1.24 (m, 1.5H), 1.17-1.11 (m, 1.5H); LCMS (Method D): t_(R) 3.17 min, MS (ESI) 483.2 (M + H)⁺. 1-((2S,5R)-2-methyl-5-(4-((2- methyl-6-(1-methyl-1H- pyrazol-4-yl)pyridin-4- yl)amino)-6-(pyridin-3- yl)pyrimidin-2-yl)piperidin-1- yl)ethan-1-one

Example 9: Synthesis of (+/−)-cis-1-(2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(1H-pyrazolo[3,4-c]pyridin-4-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00162)

A solution of 50% sodium hydroxide in water (1.0 mL, 38 mmol) was added to a suspension of (4-methoxybenzyl)hydrazine dihydrochloride (4.3 g, 19 mmol) in methanol (50 mL) and the mixture was stirred at room temperature for 1 hour. The salts were filtrated off over a glass filter and washed with methanol. The filtrate was concentrated to afford a sticky white solid.

The solid was suspended in 2-propanol (50 mL) and 3,5-dibromoisonicotinaldehyde (5.0 g, 19 mmol) was added. The mixture was stirred at reflux for 16 hours resulting in an orange suspension. The suspension was allowed to cool to room temperature and water (25 mL) was added. The mixture was stirred at room temperature for 1 hour and the resulting precipitate was filtrated off and washed with 2-propanol/water (4/1, v/v, 50 mL). The solid was transferred to a flask and co-evaporated twice with ethyl acetate. The residue was suspended in tetrahydrofuran (100 mL) at room temperature and sodium hydride (0.38 g, 9.5 mmol) was added. The mixture was stirred for 10 minutes at room temperature and was then stirred at reflux for 16 hours. The mixture was cooled to room temperature, poured into water (300 mL) and extracted with ethyl acetate twice. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated to afford 4-bromo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-c]pyridine (515 mg, 18%) that was used as such in the next step. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 9.28 (s, 1H), 8.39 (s, 1H), 8.25 (s, 1H), 7.37-7.24 (m, 2H), 6.96-6.84 (m, 2H), 5.74 (s, 2H), 3.71 (s, 3H); LCMS (Method A): t_(R) 2.00 min, MS (ESI) 318.0/320.0 (M+H)⁺. A nitrogen flushed mixture of 4-bromo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-c]pyridine (177 mg, 0.56 mmol), bis(pinacolato)diboron (155 mg, 0.61 mmol), potassium acetate (82 mg, 0.83 mmol) and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (23 mg, 0.028 mmol) in 1,4-dioxane (3 mL) was stirred at 80° C. for 2 hours. Additional bis(pinacolato)diboron (155 mg, 0.61 mmol), potassium acetate (82 mg, 0.83 mmol) and 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride (23 mg, 0.028 mmol) were added and the reaction was stirred at 90° C. for 16 hours. The mixture was cooled to room temperature and 1-(5-(4-chloro-6-((5-methylpyridin-3-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (100 mg, 0.28 mmol, prepared analogous to Example 4), sodium carbonate (59 mg, 0.56 mmol), tri-tert-butylphosphonium tetrafluoroborate (8.1 mg, 30 μmol), tris(dibenzylideneacetone)dipalladium(0) (13 mg, 10 μmol), 1,4-dioxane (3 mL) and water (1 mL) were added. The mixture was stirred at 80° C. for 30 hours. The reaction mixture was allowed to cool to room temperature and stirred overnight. Solids were removed by filtration and the reaction mixture was filtered over a small C₁₈-plug using acetonitrile as eluent. The product was purified by reversed phase chromatography (Method A) followed by a second purification using reversed phase chromatography (Method B) to afford 1-(5-(4-(1-(4-methoxybenzyl)-1H-pyrazolo[3,4-c]pyridin-4-yl)-6-((5-methylpyridin-3-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (13 mg, 8%) as a light brown solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 9.91 (d, J=4.8 Hz, 1H), 9.39 (d, J=2.3 Hz, 1H), 8.83 (d, J=1.6 Hz, 1H), 8.76-8.63 (m, 2H), 8.19 (d, J=14.2 Hz, 1H), 8.10 (s, 1H), 7.36-7.27 (m, 3H), 6.92-6.86 (m, 2H), 5.79 (s, 2H), 4.91-4.77 (m, 1H), 4.30-4.16 (m, 0.5H), 4.14-4.02 (m, 0.5H), 3.71 (s, 3H), 3.52-3.39 (m, 0.5H), 3.04-2.71 (m, 1.5H), 2.33 (d, J=4.4 Hz, 3H), 2.15-1.98 (m, 5H), 1.90-1.66 (m, 2H), 1.30-126 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method C): t_(R) 2.01 min, MS (ESI) 563.2 (M+H)⁺. A solution of 1-(5-(4-(1-(4-methoxybenzyl)-1H-pyrazolo[3,4-c]pyridin-4-yl)-6-((5-methylpyridin-3-yl)amino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (13 mg, 23 μmol) in trifluoroacetic acid (1 mL) was stirred at room temperature for 3 hours, heated to 50° C. and stirred for 3 days. The reaction mixture was concentrated and purified using reversed phase chromatography (Method B) to afford (+/−)-cis-1-(2-methyl-5-(4-((5-methylpyridin-3-yl)amino)-6-(1H-pyrazolo[3,4-c]pyridin-4-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (9 mg, 88%) as a white solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 13.93 (s, 1H), 9.90 (d, J=4.6 Hz, 1H), 9.18 (s, 1H), 8.84 (s, 1H), 8.77-8.65 (m, 2H), 8.20 (d, J=14.8 Hz, 1H), 8.10 (s, 1H), 7.37 (d, J=1.7 Hz, 1H), 4.91-4.77 (m, 1H), 4.29-4.18 (m, 0.5H), 4.15-4.01 (m, 0.5H), 3.53-3.41 (m, 0.5H), 3.04-2.74 (m, 1.5H), 2.34 (d, J=4.5 Hz, 3H), 2.17-1.97 (m, 5H), 1.94-1.64 (m, 2H), 1.31-1.27 (m, 1.5H), 1.18-1.14 (m, 1.5H); LCMS (Method D): t_(R) 3.02 min, MS (ESI) 443.2 (M+H)⁺.

Example 10: Synthesis of 1-((2S,5R)-2-methyl-5-(4-(4-methyl-1H-imidazol-1-yl)-6-(phenylamino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00163)

To a mixture of 4-methylimidazole (8 mg, 0.10 mmol) and cesium carbonate (34 mg, 0.10 mmol) in acetonitrile (2 mL) was added 1-((2S,5R)-5-(4,6-dichloropyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (Intermediate 2, 30 mg, 0.1 mmol) in acetonitrile (1 mL). The mixture was stirred at 80° C. for 16 hours. The mixture was diluted with water (0.5 mL) and DMSO (1 mL), purified using by reverse phase chromatography (Method A) and lyophilized to afford 1-((2S,5R)-5-(4-chloro-6-(4-methyl-1H-imidazol-1-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (16 mg, 0.05 mmol, 43%) as a white solid. LCMS (Method A): t_(R) 1.55 min, 98%, MS (ESI) 334.1 (M+H)⁺. A solution of 1-((2S,5R)-5-(4-chloro-6-(4-methyl-1H-imidazol-1-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (15 mg, 0.05 mmol), aniline (0.01 mL, 0.14 mmol) and hydrochloric acid (0.01 mL, 0.14 mmol) in 2-propanol (2 mL) was stirred at 50° C. for 16 hours. The mixture was diluted with DMSO, purified by reverse phase chromatography (Method A and B) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-(4-methyl-1H-imidazol-1-yl)-6-(phenylamino)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (9 mg, 0.02 mmol, 46%) as a white solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 9.84 (d, J=6.8 Hz, 1H), 8.40 (dd, J=12.6, 1.4 Hz, 1H), 7.68 (dd, J=8.1, 3.6 Hz, 2H), 7.56 (d, J=6.4 Hz, 1H), 7.40-7.31 (m, 2H), 7.06 (t, J=7.3 Hz, 1H), 6.69 (d, J=1.6 Hz, 1H), 4.89-4.73 (m, 0.5H), 4.72-4.60 (m, 0.5H), 4.25-4.14 (m, 0.5H), 4.11-3.92 (m, 0.5H), 3.44-3.37 (m, 0.5H), 2.91-2.73 (m, 1H), 2.67-2.57 (m, 0.5H), 2.18 (s, 3H), 2.09-1.57 (m, 7H), 1.28-1.23 (m 1.5H), 1.15-1.10 (m, 1.5H); LCMS (Method B): t_(R) 2.72 min, MS (ESI) 391.1 (M+H)⁺.

Example 11: Synthesis of 1-((2S,5R)-5-(4-(1H-imidazol-1-yl)-6-(phenylamino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (00164)

A solution of 1-((2S,5R)-5-(4-chloro-6-(phenylamino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (37 mg, 0.10 mmol, prepared analogous to Example 3), imidazole (149 mg, 0.20 mmol) and cesium carbonate (65 mg, 0.20 mmol) in N,N-dimethylacetamide (1 mL) was stirred at 130° C. for 4 hours. The mixture was cooled to room temperature and diluted with methanol (1 mL). The solution was purified by reverse phase chromatography (Method B) followed by preparative SFC (Method A) and lyophilized to afford 1-((2S,5R)-5-(4-(1H-imidazol-1-yl)-6-(phenylamino)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (8 mg, 0.01 mmol, 21%). ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 9.87 (d, J=6.1 Hz, 1H), 8.52 (d, J=12.9 Hz, 1H), 7.93-7.82 (m, 1H), 7.74-7.66 (m, 2H), 7.40-7.31 (m, 2H), 7.20-7.12 (m, 1H), 7.06 (t, J=7.5 Hz, 1H), 6.77 (d, J=2.0 Hz, 1H), 4.85-4.75 (m, 0.5H), 4.71-4.64 (m, 0.5H), 4.23-4.17 (m, 0.5H), 4.04-3.98 (m, 0.5H), 3.45-3.37 (m, 0.5H), 2.90-2.76 (m, 1H), 2.69-2.59 (m, 0.5H), 2.09-1.75 (m, 5.5H), 1.73-1.61 (m, 1.5H), 1.29-1.21 (m, 1.5H), 1.16-1.09 (m, 1.5H); LCMS (Method D): t_(R) 3.39 min, MS (ESI) 377.2 (M+H)⁺.

Example 12: Synthesis of (2S,5R)-5-(4-((3-fluorophenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidine-1-carboxamide (00165)

A solution of 1-((2S,5R)-5-(4-((3-fluorophenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (26 mg, 0.06 mmol, prepared analogous to Example 3) and 6M hydrochloric acid (6 mL, 36.0 mmol) was stirred at 80° C. for 48 hours. The mixture was concentrated and purified with SCX (ion exchange) chromatography (washed with methanol and eluted with 3.5M ammonia in methanol) to afford N-(3-fluorophenyl)-2-((3R,6S)-6-methylpiperidin-3-yl)-6-(pyridin3-yl)pyrimidin-4-amine (26 mg, 93%) as a beige solid. LCMS (Method C): t_(R) 1.87 min, MS (ESI) 364.2 (M+H)⁺. To a solution of N-(3-fluorophenyl)-2-((3R,6S)-6-methylpiperidin-3-yl)-6-(pyridin-3-yl)pyrimidin-4-amine (26 mg, 0.06 mmol) in dichloromethane (3 mL) was added triethylamine (0.03 mL, 0.18 mmol) and trimethylsilyl isocyanate (8.04 μl, 0.06 mmol). The mixture was stirred at room temperature for 3 hours and concentrated. The residue was purified with reverse phase chromatography (method B) and lyophilized to afford (2S,5R)-5-(4-((3-fluorophenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidine-1-carboxamide (7 mg, 27%) as a white solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 10.05 (s, 1H), 9.25-9.18 (m, 1H), 8.71 (dd, J=4.7, 1.6 Hz, 1H), 8.41 (dt, J=8.0, 2.0 Hz, 1H), 7.98 (dt, J=12.4, 2.4 Hz, 1H), 7.57 (dd, J=8.0, 4.8 Hz, 1H), 7.44-7.32 (m, 2H), 7.21 (s, 1H), 6.88-6.79 (m, 1H), 5.93 (s, 2H), 4.43-4.28 (m, 1H), 4.26-4.09 (m, 1H), 3.19-3.03 (m, 1H), 2.84-2.72 (m, 1H), 2.04-1.91 (m, 2H), 1.80-1.58 (m, 2H), 1.16 (d, J=6.8 Hz, 3H); LCMS (Method D): t_(R) 3.38 min, MS (ESI) 407.2 (M+H)⁺.

Example 13: Synthesis of 1-((2S,5R)-5-(4-((3-fluoro-5-(1,3,4-oxadiazol-2-yl)phenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (00166)

To a suspension of 3-((2-((3R,6S)-1-acetyl-6-methylpiperidin-3-yl)-6-(pyridin-3-yl)pyrimidin-4-yl)amino)-5-fluorobenzoic acid (46 mg, 0.10 mmol, prepared analogous to Example 2) in dichloromethane (5 mL) was added a solution of (isocyanoimino)triphenylphosphorane (62 mg, 0.20 mmol) in dichloromethane (1 mL). The mixture was stirred at 35° C. for 72 hours and concentrated. The residue was purified with reverse phase chromatography (Method B) and lyophilized to afford 1-((2S,5R)-5-(4-((3-fluoro-5-(1,3,4-oxadiazol-2-yl)phenyl)amino)-6-(pyridin-3-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (129 mg, 24%) as a white solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 10.40 (d, J=8.2 Hz, 1H), 9.40 (d, J=7.8 Hz, 1H), 9.24 (dd, J=7.3, 2.3 Hz, 1H), 8.73 (dt, J=4.8, 1.6 Hz, 1H), 8.46-8.38 (m, 2H), 8.14-7.99 (m, 1H), 7.59 (dd, J=8.1, 4.8 Hz, 1H), 7.46 (dt, J=8.7, 2.0 Hz, 1H), 7.24 (d, J=5.0 Hz, 1H), 4.92-4.78 (m, 0.5H), 4.76-4.67 (m, 0.5H), 4.28-4.17 (m, 0.5H), 4.11-4.00 (m, 0.5H), 3.53-3.43 (m, 0.5H), 3.04-2.87 (m, 1H), 2.87-2.71 (m, 0.5H), 2.19-1.95 (m, 5H), 1.95-1.79 (m, 0.5H), 1.79-1.61 (m, 1.5H), 1.33-1.26 (m, 1.5H), 1.22-1.11 (m, 1.5H); LCMS (Method B): t_(R) 3.03 min, MS (ESI) 474.2 (M+H)⁺.

Example 14: Synthesis of 1-((2S,5R)-2-methyl-5-(4-(methyl(2-methylpyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00167)

To a solution of 1-((2S,5R)-2-methyl-5-(4-((2-methylpyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (50 mg, 0.12 mmol) in N,N-dimethylformamide (2 mL) was added sodium hydride (9.9 mg, 0.25 mmol) and the mixture was stirred for 10 minutes. Iodomethane (12 μL, 0.18 mmol) was added and the solution was stirred at room temperature for 2 hours. The mixture was quenched with water, purified with reverse phase chromatography (Method B) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-(methyl(2-methylpyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (20 mg, 37%) as a pale yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 9.55 (dd, J=13.2, 1.5 Hz, 1H), 8.81-8.71 (m, 2H), 8.49 (dd, J=5.3, 1.7 Hz, 1H), 7.52 (d, J=4.0 Hz, 1H), 7.38 (d, J=2.1 Hz, 1H), 7.30 (dt, J=5.0, 2.2 Hz, 1H), 4.87-4.75 (m, 0.5H), 4.75-4.58 (m, 0.5H), 4.29-4.11 (m, 0.5H), 4.11-3.91 (m, 0.5H), 3.56 (d, J=3.0 Hz, 3H), 3.49-3.38 (m, 0.5H), 3.33 (s, 3H), 2.96-2.82 (m, 1H), 2.80-2.60 (m, 0.5H), 2.14-1.75 (m, 5.5H), 1.74-1.57 (m, 1.5H), 1.30-1.22 (m, 1.5H), 1.16-1.10 (m, 1.5H); UPLC (Method B): t_(R) 0.84 min, MS (ESI) 418.2 (M+H)⁺.

Example 15: Synthesis of 1-((2S,5R)-2-methyl-5-(4-((2-(1-methyl-1H-1,2,3-triazol-4-yl)pyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (00168)

To a suspension of 2-ethynylpyridin-4-amine (200 mg, 1.69 mmol), L-ascorbic acid sodium salt (168 mg, 0.85 mmol) and copper(II) sulfate, anhydrous (67.5 mg, 0.42 mmol) in ^(t)butanol (4 mL and water (4 mL) was added trimethylsilylmethyl azide (0.25 mL, 1.69 mmol) and the mixture was stirred room temperature for 16 hours. The mixture was filtered through celite, washed with methanol and the filtrate was concentrated to afford a colorless oil. The oil was purified by column chromatography (0% to 5% methanol in dichloromathane) and concentrated to afford 2-(1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)pyridin-4-amine (204 mg, 49%) as a white solid. LCMS (Method C): t_(R) 1.76 min, MS (ESI) 248.1 (M+H)⁺. Under argon, 1-((2S,5R)-5-(4-chloro-6-(pyrazin-2-yl)pyrimidin-2-yl)-2-methylpiperidin-1-yl)ethan-1-one (100 mg, 0.30 mmol), 2-(1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)pyridin-4-amine (111 mg, 0.45 mmol) and cesium carbonate (196 mg, 0.60 mmol) were suspended in 1,4-dioxane (4 mL). XPhos (29 mg, 0.06 mmol) and Pd₂(dba)₃ (28 mg, 0.06 mmol) were added and the mixture was heated to 90° C. for 16 hours. The mixture was filtered through celite, washed with methanol and the filtrate was concentrated to afford an oil. The crude oil was purified with reverse phase chromatography (method: B) and lyophilized to afford 1-((2S,5R)-2-methyl-5-(4-((2-(1-methyl-1H-1,2,3-triazol-4-yl)pyridin-4-yl)amino)-6-(pyrazin-2-yl)pyrimidin-2-yl)piperidin-1-yl)ethan-1-one (37 mg, 0.08 mmol, 26%) as a light yellow solid. ¹H-NMR (400 MHz, DMSO-d₆) mixture of rotamers δ 10.43 (d, J=3.8 Hz, 1H), 9.63-9.52 (m, 1H), 8.83 (d, J=1.6 Hz, 2H), 8.71 (dd, J=42.1, 2.1 Hz, 1H), 8.52 (d, J=3.3 Hz, 1H), 8.45 (d, J=5.7 Hz, 1H), 7.76 (d, J=2.1 Hz, 1H), 7.74-7.60 (m, 1H), 4.92-4.79 (m, 0.5H), 4.79-4.68 (m, 0.5H), 4.30-4.19 (m, 0.5H), 4.18-4.01 (m, 3.5H), 3.64-3.51 (m, 0.5H), 3.08-2.93 (m, 1H), 2.90-2.77 (m, 0.5H), 2.24-1.96 (m, 5H), 1.96-1.81 (m, 0.5H), 1.81-1.64 (m, 1.5H), 1.39-1.27 (m, 1.5H), 1.23-1.13 (m, 1.5H); UPLC (Method A): t_(R) 1.27 min, MS (ESI) 471.2 (M+H)⁺.

Assay Data

Assay 1

One thousand four hundred A375 cells were seeded in each well of a 384 well microplate. One day later they were treated with 1 μM S1152 (Selleckchem) in dimethyl sulfoxide, 0.5 μM S1008 (Selleckchem) and dose ranges of invention compounds for one day in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum and 2 mM (2S)-2-amino-4-carbamoylbutanoic acid. Wells were incubated with 4% polyoxymethylene (Sigma Aldrich 158127) at ambient temperature. After ten minutes, polyoxymethylene was replaced with 0.025% Polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline for three times. After one minute phosphate-buffered saline was replaced with 0.2% polyethylene glycol octylphenyl ether in phosphate-buffered saline. After ten minutes at ambient temperature 0.2% polyethylene glycol octylphenyl ether in phosphate-buffered saline was replaced with 0.025% Polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline three times. 1% aminoethanoic acid in phosphate-buffered saline was added for ten minutes at ambient temperature. 1% aminoethanoic acid in phosphate-buffered saline was replaced with 0.025% Polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline. 0.8 μg/ml sc-365823 (clone E-4, Santa Cruz Biotechnologies) in 0.025% Polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline was added to the wells. After one hour at 37° C., the solution was replaced with 0.025% Polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline three times. Phosphate-buffered saline was replaced with 2 μg/ml A-11029 (Invitrogen) in 0.025% polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline. After one hour at ambient temperature in the dark, 12 μM 3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide in phosphate-buffered saline containing 0.2 mg/ml ribonuclease A was added. After one hour at ambient temperature in the dark, signal in wells was measured with a Acumen Cellista. 3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide-positive objects were defined in FL3 (565-600 nm) with a perimeter between 50-800 μm and a total intensity of 10000-1000000 FLU. Signal in FL2 (500-530 nm) was measured in defined objects. A normalized ratio of total In FL2 over total In FL3 staining was log transformed. A non-linear regression (variable slope, 4 parameters) was used to calculate EC₅₀ values using GraphPad Prism (Version 7.0d).

In an alternative procedure, assay 1 has been affected by changing the counteratain. More precicely, after one hour of incubation with A-11029 cells were washed with 0.05% polyoxyethylene (20) sorbitan monolaurate in phosphate-buffered saline for three times. Cells were incubated with 0.5 μg/ml 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride, 4′,6-Diamidino-2-phenylindole dihydrochloride (Sigma D9542) in phosphate-buffered saline for at least 30 minutes at ambient temperature in the dark. A Celigo Imager (Nexcelom) was used to acquire images in the blue and green channel. The blue channel was used as a mask to define the area for the green signal. The average integrated intensity of the green signal was normalized and a non-linear regression (variable slope, 4 parameter) was used to calculate the EC50 values using GraphPad Prism (Version 8.4)

Assay 2 Multiple Myeloma Cellular Efficacy:

10000 OPM-2 (ACC50; DSMZ) were plated into wells of a 384 well plate (Greiner 781090). Cells were treated for 4 days with a dose range of compound or vehicle. At the end of the experiment cells were stained directly with PrestoBlue (ThermoFisher Scietific; A13262) for 2 hours at 37° C. in a humidified incubator according to manufactor's instruction. To assess the relative cell number the PrestoBlue signal was measured using either a TecanM1000Pro reader or a Tecan Sparks reader following the manufactor's instructions. Background (no cells) values were subtracted and set in relation to the vehicle control. To assess the EC₅₀ of each compound the relative fluorescence value was plotted against the compound concentration after log transformation. Data were fitted in a nonlinear manner with a variable slope (four parameters) using graphpad prism software. Cellular efficacy of compounds was evaluated in the multiple myeloma cell line OPM-2 using the cell proliferation/survival assay PrestoBlue. EC₅₀ values are classified as indicated below.

Assay Assay Compound # 1 2

A* — 00001

C — 00002

C C 00003

A* A* 00004

A* — 00005

A — 00006

C — 00007

C — 00008

A* A 00009

A* — 00010

C — 00011

A* — 000012

B — 00013

C — 00014

C — 00015

A* — 00016

B — 00017

B — 00018

C — 00019

B — 00020

C — 00021

A — 00022

A — 00023

C — 00024

B — 00025

C — 00026

B — 00027

A* — 00028

A — 00029

A* — 00030

A* — 00031

A — 00032

A — 00033

A — 00034

A* — 00035

B — 00036

A — 00037

A — 00038

A* A* 00039

A* — 00040

A* A* 00041

A* — 00042

A* — 00043

A* A* 00044

A* A 00045

A* — 00046

A* A* 00047

A* — 00048

A* A* 00049

A* A 00050

A B 00051

A* A* 00052

A* A* 00053

A* A* 00054

A* A* 00055

A* A* 00056

A* A* 00057

A* A 00058

A* A* 00059

A A* 00060

A* A 00061

A* A* 00062

A* A 00063

A* A* 00064

A* A* 00065

A* A* 00066

A* A* 00067

A* A* 00068

A* A* 00069

A* A* 00070

A — 00071

A A 00072

A* A* 00073

A* — 00074

A* — 00075

A — 00076

A* A 00077

A* A* 00078

A* A* 00079

A* A 00080

A A 00081

A A 00082

A* A 00083

A* A 00084

A* A* 00085

A* A* 00086

A* A 00087

A* A 00088

A* A* 00089

— A* 00090

A* A* 00091

A* A* 00092

A* A* 00093

A* A* 00094

A* A* 00095

A* A 00096

B — 00097

A* — 00098

A — 00099

A — 00100

A — 00101

A — 00102

A* A* 00103

A* A* 00104

A* A 00105

A* — 00106

A A 00107

A — 00108

C — 00109

C — 00110

A* A 00111

A* A* 00112

B B 00113

C — 00114

A* A 00115

A* A* 00116

B B 00117

A* A* 00118

A* A* 00119

A* — 00120

A* — 00121

A — 00122

A* A* 00123

A* A 00124

B — 00125

A* A* 000126

A* — 00127

A* A* 00128

A* — 00129

A* A* 00130

A* A* 00131

A* A* 00132

C — 00133

A* A* 00134

B — 00135

B B 00136

A B 00137

A* A 00138

A* A* 00139

A* A* 00140

A* A* 00141

A* A* 00142

A* A* 00143

A* A* 00144

A* A* 00145

A* A 00146

A* A* 00147

A* A* 00148

A* A* 00149

A* A* 00150

A A 00151

A* A 00152

A* A 00153

A* A 00154

A A 00155

A A 00156

A* A* 00157

A* A* 00158

A* A* 00159

A A 00160

A* A* 00161

B — 00162

B — 00163

B — 00164

B — 00165

A* — 00166

A B 00167

A* A* 00168 Legend EC₅₀: A* < 0.2 μM < A < 1 μM < B < 10 μM < C

Assay 3 CBP Bromodomain Binding Assay (TR-FRET)

Compounds solutions of 10 mM in DMSO were pre-diluted in DSMO to 25× stock solutions in DMSO. These were then diluted down to 4× in assay buffer. A dilution series in assay buffer was performed keeping the DMSO concentration stable. 5 μl compound in assay buffer was transferred into the assay plate (provided by assay kit) and the TR-FRET assay Cayman chemicals; 600850) was performed using the manufactor's instructions. After 1 hour incubation at room temperature in the darks, assay plates were read in a Tecan M1000 plate reader or a Tecan Spaks reader using the TR-FRET mode (top read; excitation 340 nM bandwidth 20 nM; emission 620 nM bandwidth 7 nM; gain optimal determined for the first well, number of flashes: 5; flash frequency 100 Hz; integration time: 500 μs, lag time: 100 μs, room temperature). The TR-FRET ratio was calculated by deviding 670 nm emission by 620 nm emission. Values were log transformed and non-linear regression with variable slope (4 parameters) was used to fit values to a dose-response curve to evaluate EC50 values.

Legend EC₅₀: A*<0.2 μM<A<1 μM<B<10 μM<C

Compound # Assay 3 00001 A* 00003 C 00004 A* 00009 A* 00013 A 00030 A 00038 A 00039 A 00040 A* 00041 A* 00042 A 00043 A* 00044 A* 00045 A* 00046 A* 00053 B 00065 A* 00066 B 00068 A* 00069 A* 00072 A 00073 A* 00086 A* 00092 A* 00095 A* 00101 A 00103 A* 00104 A* 00126 A* 00128 A* 00149 A* 00152 A* 00153 A* 00163 B 00165 B 00168 A* Crystal Structure of the Bromodomain of Human CREBBP in Complex with Compound 00004

Crystallization Experimental Setup

The construct used for crystallization comprised residues 1081 to 1197. Crystals of CREBBP in complex with compound 00004 were obtained using hanging-drop vapour-diffusion set-ups. CREBBP at a concentration of 20.3 mg/ml (10 mM Hepes, 500 mM NaCl, 5% Glycerol, 0.5 mM TCEP, pH 7.4) was pre-incubated with 4.3 mM (3.0-fold molar excess) of 00004 (150 mM in DMSO) for 1 h. 1 μl of the protein solution was then mixed with 1 μl of reservoir solution (0.1 M MgCl₂, 0.1 M MES/NaOH pH 6.3, 18% (w/v) PEG 6000 and 10% (v/v) ethylene glycol) and equilibrated at 4° C. over 0.4 ml of reservoir solution. Well diffracting crystals appeared and grew to full size over 4 days.

Data Collection

Crystals were cryo-protected by addition of 10% glycerol (final concentration) to the crystallization drop before mounting. A complete 1.6 Å data set of a CREBBP/00004 crystal was collected at Diamond Light Source (Didcot, UK, beamline i03) and the data were integrated, analyzed and scaled by XDS, Pointless and Aimless within the autoPROC pipeline (Table 1).

TABLE 1 Data collection statistics Space group P2₁ Unit cell parameters [Å] a = 70.4, b = 58.6, c = 73.2 α = 90.0, β = 115.4, γ = 90.0 Resolution [Å] 66.14-1.60 (1.63-1.60) # Unique reflections 68872 (2664) I/σ(I) 14.9 (2.2) Completeness [%] 97.2 (75.5) Multiplicity 3.3 (2.1) R_(meas) 0.050 (0.460)

Structure Determination and Refinement

Molecular replacement was done using a previously determined structure of CREBBP as a starting model. Several rounds of alternating manual re-building and refinement with REFMAC5 resulted in the final model (Table 2). Atomic displacement factors were modelled with a single isotropic B-factor per atom.

TABLE 2 Refinement statistics Resolution 35.00-1.60 (1.64-1.60) R_(work) 0.151 (0.305) R_(free) 0.190 (0.351) Completeness [%] 97.2 (77.6)

Results

We have produced crystals of CREBBP/00004 that diffracted to 1.6 Å resolution and determined the 3-dimensional structure of the protein-ligand complex. Clear electron density in the F_(o)-F_(c) omit map of the initial model at the compound binding site in each chain of CREBBP revealed the binding of the entire compound (FIG. 3 ) and allowed its unambiguous placement. Additionally, the structure also confirms the absolute stereochemistry of compound 00004 (2S, 5R on the piperidine moiety).

BromoKdMAX-Assay

A BromoKdMAX was performed at DiscoverX. This assay may be used for determining whether the compounds of the present invention bind to the bromodomain of p300 and/or the bromodomain of CBP with a particular K_(d) (e.g. 100 nM or less).

The assay principle is the following:

BROMOscan™ is a novel industry leading platform for identifying small molecule bromodomain inhibitors. Based on proven KINOMEscan™ technology, BROMOscan™ employs a proprietary ligand binding site-directed competition assay to quantitatively measure interactions between test compounds and bromodomains. This robust and reliable assay panel is suitable for high throughput screening and delivers quantitative ligand binding data to facilitate the identification and optimization of potent and selective small molecule bromodomain inhibitors. BROMOscan™ assays include trace bromodomain concentrations (<0.1 nM) and thereby report true thermodynamic inhibitor Kd values over a broad range of affinities (<0.1 nM to >10 uM).

The assay was conducted as follows:

For the Bromodomain assays, T7 phage strains displaying bromodomains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection=0.4) and incubated with shaking at 32° C. until lysis (90-150 minutes). The lysates were centrifuged (5,000×g) and filtered (0.2 μm) to remove cell debris. Streptavidin-coated magnetic beads were treated with biotinylated small molecule or acetylated peptide ligands for 30 minutes at room temperature to generate affinity resins for bromodomain assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific phage binding. Binding reactions were assembled by combining bromodomains, liganded affinity beads, and test compounds in 1× binding buffer (17% SeaBlock, 0.33×PBS, 0.04% Tween 20, 0.02% BSA, 0.004% Sodium azide, 7.4 mM DTT). Test compounds were prepared as 1000× stocks in 100% DMSO. Kds were determined using an 11-point 3-fold compound dilution series with one DMSO control point. All compounds for Kd measurements are distributed by acoustic transfer (non-contact dispensing) in 100% DMSO. The compounds were then diluted directly into the assays such that the final concentration of DMSO was 0.09%. All reactions performed in polypropylene 384-well plates. Each was a final volume of 0.02 ml. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1×PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1×PBS, 0.05% Tween 20, 2 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The bromodomain concentration in the eluates was measured by qPCR.

The results were as follows:

Compound DiscoveRx Entrez Mod- Kd Name Gene Symbol Gene Symbol ifier (nM) 00004 ATAD2A ATAD2 > 10000 00004 ATAD2B ATAD2B > 10000 00004 BAZ2A BAZ2A > 10000 00004 BAZ2B BAZ2B > 10000 00004 BRD1 BRD1 > 10000 00004 BRD2(1) BRD2 > 10000 00004 BRD2(1, 2) BRD2 = 7600 00004 BRD2(2) BRD2 > 10000 00004 BRD3(1) BRD3 > 10000 00004 BRD3(1, 2) BRD3 > 10000 00004 BRD3(2) BRD3 > 10000 00004 BRD4(1) BRD4 > 10000 00004 BRD4(1, 2) BRD4 > 10000 00004 BRD4(2) BRD4 > 10000 00004 BRD4(full-length, BRD4 = 7100 short-iso.) 00004 BRD7 BRD7 > 10000 00004 BRD8(1) BRD8 > 10000 00004 BRD8(2) BRD8 > 10000 00004 BRD9 BRD9 > 10000 00004 BRDT(1) BRDT > 10000 00004 BRDT(1, 2) BRDT > 10000 00004 BRDT(2) BRDT > 10000 00004 BRPF1 BRPF1 > 10000 00004 BRPF3 BRPF3 > 10000 00004 CECR2 CECR2 > 10000 00004 CREBBP CREBBP = 29 00004 EP300 EP300 = 12 00004 FALZ BPTF > 10000 00004 GCN5L2 KAT2A > 10000 00004 PBRM1(2) PBRM1 > 10000 00004 PBRM1(5) PBRM1 > 10000 00004 PCAF KAT2B > 10000 00004 SMARCA2 SMARCA2 > 10000 00004 SMARCA4 SMARCA4 > 10000 00004 TAF1(2) TAF1 > 10000 00004 TAF1L(2) TAF1L > 10000 00004 TRIM24(Bromo.) TRIM24 > 10000 00004 TRIM24(PHD, Bromo.) TRIM24 > 10000 00004 TRIM33(PHD, Bromo.) TRIM33 > 10000 00004 WDR9(2) BRWD1 > 10000 

1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof

wherein R¹ is selected from halogen, unsubstituted or substituted hydrocarbon group which contains from 1 to 20 carbon atoms and unsubstituted or substituted hydrocarbon group which contains from 1 to 20 carbon atoms and 1 to 15 heteroatoms selected from O, N and S; R²¹ is selected from hydrogen, unsubstituted or substituted C₁₋₆ alkyl, unsubstituted or substituted C₁₋₆ alkyl which contains one to three oxygen atoms between carbon atoms, and unsubstituted or substituted C₃₋₆ cycloalkyl); R³ is selected from unsubstituted or substituted heterocyclyl, -unsubstituted or substituted carbocyclyl, unsubstituted or substituted C₁₋₆ alkylene-(heterocycyl), unsubstituted or substituted C₁₋₆ alkylene-(substituted heterocyclyl), unsubstituted or substituted C₁₋₆ alkylene (carbocyclyl), and unsubstituted or substituted C₁₋₆ alkylene-(substituted carbocyclyl); each of X¹, X² and X³ is independently selected from N, CH and CR^(x), wherein at least one of said X¹, X² and X³ is N; R³¹ is selected from -hydrogen, —C₁₋₆-alkyl, and —C₁₋₆-alkyl substituted with one or more F; wherein R³ and any R³¹ are separate substituents or linked with each other; and E is either absent or is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)—, —O—, -L¹-L²- and -L²-L¹-, wherein L¹ is selected from —CH₂—, —CHR^(x)—, —CR^(x) ₂—, —NH—, —NR^(x)— and —O— and L² is selected from —CH₂—, —CHR^(x)— and —CR^(x) ₂—; R^(6x) is -halogen, —OH, ═O, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkyl substituted with one or more OH, monocyclic aryl unsubstituted or substituted with one or more R^(xb), monocyclic heteroaryl unsubstituted or substituted with one or more R^(xb), monocyclic cycloalkyl unsubstituted or substituted with one or more R^(xb), monocyclic heterocycloalkyl unsubstituted or substituted with one or more R^(xb), monocyclic cycloalkenyl unsubstituted or substituted with one or more R^(xb) monocyclic heterocycloalkenyl unsubstituted or substituted with one or more R^(xb), wherein said R^(xb) is independently selected from -halogen, —OH, ═O, C₁₋₄ alkyl, C₁₋₂ haloalkyl, C₁₋₂ alkyl substituted with one or two OH; wherein Ring A is further unsubstituted or substituted with one or more groups R^(x), wherein any two R^(x) groups at ring A are separate substituents or linked with each other, or any R^(x) group at ring A is a separate substituent or linked with R²¹; or wherein Ring A is further substituted with one group R^(x) so as to form together with R^(6x) a bicyclic moiety having the following partial structure:

wherein Ring B is an unsubstituted or substituted heterocycle or unsubstituted or substituted carbocycle; each R^(x) is independently selected from -halogen, —OH, unsubstituted or substituted —O—C₁₋₆ alkyl, unsubstituted or substituted —NHC₁₋₆ alkyl, unsubstituted or substituted —N(C₁₋₆ alkyl)₂, ═O, unsubstituted or substituted C₁₋₆ alkyl, unsubstituted or substituted carbocyclyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted C₁₋₆ alkylene (carbocyclyl), unsubstituted or substituted —C₁₋₆ alkylene-(substituted carbocyclyl), unsubstituted or substituted C₁₋₆ alkylene-(heterocyclyl), unsubstituted or substituted —C₁₋₆ alkylene-(substituted heterocyclyl), unsubstituted or substituted —O—(C₁₋₆ alkylene)-(carbocyclyl), unsubstituted or substituted —O—(C₁₋₆ alkylene)-(substituted carbocyclyl), unsubstituted or substituted —O—(C₁₋₆ alkylene)-(heterocyclyl), and unsubstituted or substituted —O—(C₁₋₆ alkylene)-(substituted heterocyclyl), and wherein the substituent of the substituted hydrocarbon group, substituted C₃₋₆ cycloalkyl, substituted heterocyclyl, substituted heterocycle, substituted carbocyclyl, substituted carbocycle and substituted C₁₋₆ alkylene is independently selected from —C₁₋₆ alkyl, —C₁₋₆ alkyl substituted with one or more halogen, -halogen, —CN, —NO₂, oxo, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —N(R*)—S(O)₂R*, —OR*, —O—C(O)R*, —O—C(O)—NR*R*, —SR*, —S(O)R*, —S(O)₂R*, —S(O)₂—NR*R*, —N(R*)—S(O)₂—NR*R*, heterocyclyl, heterocyclyl substituted with halogen or C₁₋₆ alkyl, carbocyclyl, and carbocyclyl substituted with halogen or C₁₋₆ alkyl; wherein each R* is independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with halogen, heterocyclyl, heterocyclyl substituted with halogen or C₁₋₆ alkyl, carbocyclyl, and carbocyclyl substituted with halogen or C₁₋₆ alkyl; wherein any two R* connected to the same nitrogen atom are either separate substituents or linked with each other, and wherein the substituent of the substituted C₁₋₆ alkyl and of the substituted C₁₋₆ alkylene is independently selected from -halogen, —CN, —NO₂, oxo, —C(O)R**, —COOR**, —C(O)NR**R**, —NR**R**, —N(R**)—C(O)R**, —N(R**)—C(O)—OR**, —N(R**)—C(O)—NR**R**, —N(R**)—S(O)₂R**, —OR**, —O—C(O)R**, —O—C(O)—NR**R**, —SR**, —S(O)R**, —S(O)₂R**, —S(O)₂—NR**R**, and —N(R**)—S(O)₂—NR**R**; wherein R** is independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkyl substituted with halogen, heterocyclyl, heterocyclyl substituted with halogen or C₁₋₆ alkyl, carbocyclyl and carbocyclyl substituted with halogen or C₁₋₆ alkyl; wherein any two R** connected to the same nitrogen atom are either separate substituents or linked with each other.
 2. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (V)


3. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (VI)


4. The compound according to claim 1, wherein X² and X³ are N.
 5. The compound according to claim 1, wherein R²¹ is —CH₃ or —CH₂CH₃.
 6. The compound according to claim 1, wherein R³¹ is selected from -hydrogen and —C₁₋₂-alkyl.
 7. The compound according to claim 1, wherein E is selected from —CH₂—, —O—, —CH₂—O— and —CH₂—CH₂—.
 8. The compound according to claim 1, wherein the number of groups R^(x) in Ring A is 0, 1, or
 2. 9. The compound according to claim 1, wherein each R^(x) is independently selected from -halogen, —OH, —O—C₁₋₂ alkyl, —O—C₁₋₂ alkyl substituted with one or more R^(xa), —NH—C₁₋₂ alkyl, —NH—C₁₋₂ alkyl substituted with one or more R^(xa), —N(C₁₋₂ alkyl)₂, —N(C₁₋₂ alkyl substituted with one or more R^(xa))₂, ═O, C₁₋₃ alkyl, C₁₋₃ alkyl substituted with one or more R^(xa), C₁₋₂ haloalkyl, —W-(monocyclic carbocyclyl), —W-(monocyclic carbocyclyl substituted with one or more R^(xa)), —W-(monocyclic heterocyclyl), —W-(monocyclic heterocyclyl substituted with one or more R^(xa)), and wherein —W— is absent, —(C₁₋₂ alkylene)- or —O—(C₁₋₂ alkylene)-, and wherein monocyclic carbocyclyl is selected from phenyl and C₃₋₆ cycloalkyl, and wherein monocyclic heterocyclyl is selected from thiophenyl, pyridyl, pyrazinyl and pyrimidinyl, and wherein said R^(xa) is independently selected from —Cl, —F, and —OH.
 10. The compound according to claim 1, wherein R¹ is selected from unsubstituted or substituted heterocyclyl and unsubstituted or unsubstituted or substituted carbocyclyl, and wherein R¹ is selected from phenyl, a 5- or 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more ring heteroatoms independently selected from O, S and N, and wherein said phenyl, said 5- or 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently unsubstituted or substituted with one or more substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-OR*, —O—(C₁₋₄alkylene)-OR*, —(C₁₋₂alkylene)-O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-N(R^(oo))₂, —O—(C₁₋₄alkylene)-C(O)N(R^(oo))₂, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R*)—C(O)R*, —N(R*)—C(O)—OR*, —N(R*)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, S and N, each monocyclic carbocyclyl and heterocyclyl independently unsubstituted or substituted with one or more substituents independently selected from halogen, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl and/or wherein each monocyclic heterocyclyl is independently unsubstituted or substituted with one bivalent substituent selected from C₁₋₃ alkylene, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—; and wherein each R^(oo) is independently selected from H, C₁₋₄ alkyl, or together with the nitrogen atom to which they are attached form a six-membered monocyclic heterocyclyl.
 11. The compound according to claim 1, wherein R³ is selected from phenyl, a 6-membered monocyclic heteroaryl and a 8-10 membered bicyclic heteroaryl, each independently comprising one or more ring heteroatoms independently selected from O, B, S and N, and wherein said phenyl, said 6-membered monocyclic heteroaryl and said 8-10 membered bicyclic heteroaryl is independently unsubstituted or substituted with one or more substituents selected from halogen, —C₁₋₆ alkyl, C₁₋₆ haloalkyl, —O—(C₁₋₆ alkyl), —O—(C₁₋₆ haloalkyl), —OH, —CN, ═O, —C(O)R*, —COOR*, —C(O)NR*R*, —NR*R*, —N(R**)—C(O)R*, —N(R**)—C(O)—OR*, —N(R**)—C(O)—NR*R*, —O—C(O)R*, —O—C(O)—NR*R*, and 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from O, B, S and N, each monocyclic carbocyclyl and heterocyclyl independently unsubstituted or substituted with one or more substituents independently selected from halogen, cyclopropyl, —C₁₋₄ alkyl, C₁₋₄ haloalkyl, —O—(C₁₋₄ alkyl), —O—(C₁₋₄ haloalkyl), —OH, ═O, —C₁₋₃alkylene-OR*, —C(O)R* and —C(O)NR*R*; wherein each R* is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, cyclopropyl, cyclobutyl, oxetanyl, —C₁₋₂alkylene-OH, —C₁₋₂alkylene-O(C₁₋₂alkyl), phenyl, and wherein each R** is independently selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and/or wherein each monocyclic heterocyclyl is independently unsubstituted or substituted with one bivalent substituent selected from C₁₋₃ alkylene such as —CH₂—CH₂— and —CH₂—CH₂—CH₂—, C₁₋₃ alkylene substituted with 1 to 4 F, —CH₂—O—CH₂— and —CH₂—NH—CH₂—.
 12. The compound according to claim 1, wherein the compound of formula (I) is active on the bromodomain of p300 and/or the bromodomain of CBP with an EC50 of 10000 nM or less.
 13. A pharmaceutical composition comprising: a compound having the formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, and no, one, or more pharmaceutically acceptable excipient(s) or carrier(s).
 14. A method of treating or ameliorating a cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof.
 15. The method of claim 14, wherein said compound is used in combination with a second therapeutic agent, wherein said second therapeutic agent is an anti-cancer agent.
 16. The compound according to claim 1, wherein X² and X³ are N, and wherein X¹ is OH.
 17. The compound according to claim 1, wherein R²¹ is —CH₃.
 18. The compound according to claim 1, wherein R³¹ is -hydrogen.
 19. The compound according to claim 1, wherein E is —CH₂—.
 20. The method of claim 14, wherein the cancer is selected from melanoma, non-small cell lung cancer, prostate cancer, bile duct cancer, bladder cancer, pancreatic cancer, thyroid cancer, ovarian cancer, colorectal tumor, hairy cell leukemia, acute myeloid leukemia, multiple myeloma, liver cancer, breast cancer, esophageal cancer, head and neck cancer and glioma.
 21. A method of treating or ameliorating a cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim
 13. 22. The method of claim 21, wherein the cancer is selected from melanoma, non-small cell lung cancer, prostate cancer, bile duct cancer, bladder cancer, pancreatic cancer, thyroid cancer, ovarian cancer, colorectal tumor, hairy cell leukemia, acute myeloid leukemia, multiple myeloma, liver cancer, breast cancer, esophageal cancer, head and neck cancer and glioma.
 23. The method of claim 21, wherein said pharmaceutical composition is used in combination with a second therapeutic agent, wherein said second therapeutic agent is an anti-cancer agent. 